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CHAPTER I 
INTRODUCTION 
1.1 DENTAL ANATOMY 
In order to design and to develop biomaterials substitutes for the replacement of dental and bone 
tissues, it is mandatory to understand how the tooth and the surrounding tissue, which supports and 
stabilizes it, are composed. Craniofacial and, in particular, dental and mandibular tissues are very 
interesting and complicate to replicate, since they are a combination of hard and soft tissues that 
have to communicate and work together.  
1.1.1 Tooth development 
 
Tooth development, namely odontogenesis, is a complex process that occurs in the 6
th
 week of 
embryonic life and continues to 15
th
 year of birth, when the roots of the permanent 3
rd
 molars reach 
their completion
1
.Tooth development involves a series of interactions, and differentiations of 
epithelial cells, from the mucosal lining of the oral cavity, and ectomesenchimal cells, which 
originate at the ectodermal junction of the developing brain
2–4
. These cells instruct the overlying 
ectoderm to start tooth development, which begins in the anterior portion of the future maxilla and 
proceeds posteriorly
2,5,6
. The early stage of tooth formation involves three sequential phases: bud 
stage, cap stage and bell stage
5,7
. Briefly, in the cap stage, tooth formation starts with formation of 
the dental lamina. The localized proliferation of cells in dental lamina forms oval swellings, the 
tooth bud which grows into the mesenchyme, the focal bud-like thickenings determine the site of 
the future teeth (20 for the deciduous teeth and 32 for the permanent one)
1,6
. The deep surface of 
each ectodermal tooth bud becomes invaginated and the ectomesenchymal cells which are within 
this concavity form the dental papilla that will become the soft tissue core of the tooth, the dental 
pulp. The ectodermal, cap-shaped covering over the papilla is called enamel organ since it will 
produce the future enamel of the teeth. The outer cellular layer of the ectodermal enamel organ is 
named outer enamel epithelium, the inner layer coating the cap is the inner enamel epithelium, and 
the cell region between the above layers forms the bulk of the cap and is called the stellate 
reticulum
3,8,9
. As the enamel organ and the dental papilla form, the surrounding condenses to 
become the dental sac, which lathers forms the cementum and periodontal ligament
5
. The formation 
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of a concavity along the inner surface and the continuous growth of the tissue of the cap leads to 
bell stage. In this phase the inner enamel epithelium develops into enamel-forming ameloblasts, 
while dental papilla cells differentiate into odontoblasts, which produce predentin and deposit it 
adjacent to the inner enamel epithelium. The predentin is a matrix of collagen fibers, that 
subsequently calcifies to become dentin. Dentin has a tubular structure, due to cytoplasmic 
processes of single odontoblasts, which recede from the dentine-enamel junction and leave behind a 
cytoplasmatic extension in the deposited dentinal matrix. Whereas the development of dental pulp 
cells occurs after a stimulus of the inner enamel epithelium, differentiation of the inner enamel 
epithelium in ameloblasts occurs only after dentin deposition
7,9,10
. After  a tiny layer of dentin is 
formed, ameloblasts produce enamel in form of prisms or rods over the dentin layer, thus helping to 
form the outer layer of the tooth, namely the crown. The enamel matrix is a high mineralized tissue 
that, approximately, consists of 95% of minerals. Meanwhile odontoblasts form dentin and 
ameloblasts form enamel, inner and outer enamel epithelia cells proliferate together in the neck 
region to surround the dental papillary part, forming the so called epithelial root sheath, or Hertwig 
epithelial root sheath
11
. In this region, the inner enamel epithelium stimulates dental pulp cells to 
differentiate into odontoblasts instead of ameloblasts, in order to generate the dentin of the 
root
3,4,7,12
. As the dentin increases, the pulp cavity becomes smaller and a tight canal for vessels and 
nerves is formed at the bottom of the root. 
After formation of dentin in the root region, root sheath undergoes disintegration, allowing 
ectomesenchymal cell penetration from the dental sac to the root surface, which will differentiate 
into cementoid-depositing cementoblasts over the root dentin, converting it into calcified 
cementum
2,13,14
. As the teeth develop, jaws ossify and ectomesenchymal cells from dental follicle 
become active in bone and in other periodontal tissues formation. Some cells from dental follicle 
differentiate into periodontal fibroblasts, which will form the periodontal ligament, while others 
become osteoblasts involved in alveolar bone development in which fibers of the periodontal 
ligament, will get anchored ensuring tooth stability
15,16
. It has been hypothesized, even if not yet 
proved, that ectomesenchymal cells remain in the mature periodontium and take part in the tissue 
turnover 
17
.  
The subsequent crucial event is represented by the completed tooth crown eruption into the oral 
cavity; as the tooth erupts and passes through the oral epithelium, the incisal part of the reduced 
dental epithelium is destroyed, but the present epithelium interacts with oral epithelium to become 
the junctional epithelium, and the tooth reach the final position
10
. Deciduous teeth usually erupt 
between the 6
th
 and 24
th
 months after birth, indeed permanent teeth develop later, but in a similar 
manner to the deciduous one and, as they grow, the root of the corresponding deciduous tooth is 
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resorbed by osteoclasts
10
. Permanent teeth eruption usually starts during the sixth year of life and 
keeps going on until early adulthood. 
1.1.2 The components of tooth   
 
The tooth is divided in two zones, the crown and the root. The upper part, exposed to the mouth 
environment, is the crown, while the root is usually embedded within the bone.  
There are four tissues that make up a tooth: enamel, dentin, cementum (hard tissue) and pulp (soft 
tissue).  
The Enamel constitutes the outer surface of crown, it is formed by ameloblast and its structure is the 
hardest in the body
18
. Thus, it makes the tooth able to withstand cyclic and high stresses, the 
chewing process and changes in pressure and temperature. The enamel does not have the ability to 
regenerate itself, or to further grow after it is completely formed; however, it does have the ability 
to re-mineralize, allowing the tooth structure to be protected, to regain minerals and to stop caries, if  
proper nutrition and oral cares are followed
18–20
.  Furthermore, the enamel covers the second tissue 
that makes teeth, the dentin, which is the most abundant component of the tooth
5,21,22
. The dentin is 
softer than the enamel, but harder than bone, because it is composed by microscopic canals named 
dentinal tubules, which contain dentinal fibers. These fibers, confer mechanical strength and 
transmit stimuli and nutrition throughout the tissues
23
. The dentin is formed by odontoblast cells 
and, unlike enamel, it has the ability to grow during life. For this reason, three types of dentin exist: 
primary dentin is the tissue that forms when a tooth erupts, secondary dentin is the result of primary 
dentin growth and the third type, named reparative dentin, is formed as a response to irritation and 
trauma (erosion or caries)
21,22,24,25
. The root of tooth is covered by a tissue that is not as hard as 
enamel or dentin, but it is still harder than bone: it is the Cementum. It contains attachment fibers 
that anchor the tooth at the bone, so its role at the interface with alveolar bone is crucial in order to 
give stability to the tooth
26,27
. The cementum could be divided in primary cementum, which covers 
the entire length of the root and does have the ability to grow and cellular cementum, which 
continues to form on the apical half of the root. The inner tooth tissue is the pulp, a soft tissue 
located in the center of tooth, surrounded by dentin. The pulp composition includes connective 
tissue, blood vessels, lymph vessels and nerve tissue; which are responsible for signal transmission 
of pain and sensitivity; and dentin-producing cells, having a role in repairing structural 
damages
10,28
. The pulp tissue is retained in two zones in the pulp chamber, which are the crown and 
the pulp canals located in the root; the amount of pulp tissue decreases with the growth of dentin
1
.  
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Figure 1. Dental anatomy
29
. 
1.1.3 The components of periodontium  
  
The Periodontium is a combination of hard and soft tissue and its principle function is to anchor the 
tooth to the jaw bone tissue. It is formed by two units, the gingival and the attachment unit
8,30
. 
Gingival unit is formed by two different tissues, gingiva which is a soft tissue that surrounds the 
teeth and the alveolar mucosa, which consists of the soft tissue that constitutes cheeks, lips, soft 
palate and the underside of tongue. The gingiva is steadily bound to the underlying bone and it is 
connected with the alveolar mucosa by the mucogingival junction. The gingiva consists of a free 
gingiva that is unattached to the underlying bone and an attached gingiva, that extends from the 
base of the free gingiva to the mucogingival junction
30–33
. A crucial role is played by the cemento-
enamel junction, also called epithelium junction, since it seals off the periodontal tissue from the 
oral cavity. A healthy periodontium depends on the integrity of this junction, in fact a failure of the 
epithelium junction is the starting point of many periodontal pathologies 
30,34,35
. 
 
 
 
Figure 2. Periodontium structure
36
. 
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The attachment unit is composed by the cementum, the periodontal ligament and the alveolar 
process. Cementum is a biphasic material, composed of about 50% mineral substituted apatite and 
50% organic matrix, which contains around 90% collagen type I, and trace of other collagens (III, 
V, VI,XII,  XIV) and non-collagenous proteins (such as bone sialoprotein, dentin matrix protein 1, 
dentin sialoprotein, fibronectin, osteocalcin, osteonectin, osteopontin, tenascin)
30,37
. This hard, 
avascular connective tissue that covers roots of teeth, serves primarily to attach the periodontal 
ligament fibers, and could be divided in two different types: the acellular extrinsic fiber cementum, 
also named primary cementum
8
, and  the cellular intrinsic fiber cementum. Most of the periodontal 
ligament fibers are inserted in the primary cementum, which is highly mineralized and develops 
very slowly, because it is considered acellular since cells that form it remain on the surface
30,33
. The 
cellular intrinsic fiber cementum is less mineralized and with cementoblast cells entrapped in the 
lacunae within the matrix that they produce
30
. The cellular intrinsic fiber cementum is produced as a 
repair tissue for root fractures and to fill resorptive defects. 
Concerning periodontal ligament, it is a soft tissue consisting of specialized connective tissue, 
which ranges in width between 0.15 and 0.38 mm, with a decrease of thickness with aging
8,30,38
. Its 
principal function is to support teeth in their socket and, at the same time, to permit them to 
withstand the considerable forces of mastication
30,33,39
. Furthermore, the periodontal ligament could 
act as a sensor for the positioning of jaws and, most important function, is that it is a reservoir of 
cells for tissue regeneration
30
.  
The alveolar process is the portion of the maxilla and mandible that forms and supports the tooth 
socket (alveoli). It forms when the tooth erupts to provide the osseous attachment to the forming 
periodontal ligament. It consist of an external plate of cortical bone formed by Haversian bone and 
compacted bone lamellae. The inner socket wall of thin, compact bone called the alveolar bone, 
contains a series of openings through which neurovascular boundless link the periodontal ligament 
with the central component of the alveolar bone and the cancellous bone and trabeculae, between 
these two compact layers, which acts as supporting alveolar bone
30,40
.  
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1.2  TISSUE ENGINEERING CONCEPT 
 
1.2.1 The History of Tissue Engineering 
 
Tissue engineering can be defined as the use of a combination of cells, engineering materials, and 
suitable biochemical factors to improve or replace biological functions in an effort to improve 
clinical procedures for the repair of damaged tissues and organs. The first definition of tissue 
engineering is attributed to Drs. Langer and Vacanti who stated it to be "an interdisciplinary field 
that applies the principles of engineering and life sciences toward the development of biological 
substitutes that restore, maintain, or improve tissue function or a whole organ" in the 1993
41
.  
The ambitious objective of tissue engineering is to create functional constructs able to restore, 
maintain and improve the damaged tissues or whole organs. Since ancient times, artificial creation 
of tissues and organs was a dream and a desire of human mankind. The first historical reference to 
tissue engineering, is usually referred to the famous painting “Healing of Justinian” by Fra 
Angelico, which depicts the brothers Saints Damien and Cosmos transplanting a homograft limb 
onto a wounded soldier (278 AD). Many others examples that could be referred to the field of 
earlier tissue engineering could be find in history, from both literature and arts, which reveal the 
desire of human to create by himself living individuals or, at least, parts of them. In the early 1500, 
Paracelsus, a Swiss physician, alchemist and astrologer, tried to find a formula to create life starting 
from a mixture of chemical substances closed in a defined environment. Two hundred years later, 
Johann Wolfang von Goethe, in his literature’s work “Faust”, posed as central theme the desire to 
create life as a mean to be powerful. The creation of the Homunculus in Faust drama, could be 
considered a precursor of the modern technology, such as cloning, genetic or stem cell technique. 
Besides literature, art and mythological reports, various people performed pioneering works to 
replace body parts combining materials, usually metallic, and the first knowledge in clinical 
medicine and biology. The first example of tissue substitution, was in dentistry
42
. Since the Galileo-
Roman period, it was quite usual to substitute lost teeth or parts of skull with metallic implants or 
with homologous transplantation, as it is detailed in Ambroise Parè’s work published in the 1564 
“Dix livres de la chirurgie”, where he provided information about instrumentations, measures and 
materials needed to reconstruct teeth and maxillofacial parts
43
. It was in the middle of 18
th
 Century 
that, in parallel with clinical studies animal experiments began. The first to perform studies on the 
fate of transplantation using animals was John Hunter, posing the basis for the future transplantation 
medicine
44
. But hundred years had to be passed for the first successful transplantation, performed 
by Heinrich Christian Bünger, who transplanted the first skin graft within 1817
45
. He used the 
method to restore the nose of a woman who had suffered for fifteen years from a skin eruption that 
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caused the loss of her nose and affected other areas of the face so that a forehead or cheek graft was 
inadvisable. Christian Heinrich Bünger chose as a donor site the superior lateral surface of the upper 
thigh, taking an oval piece of skin which he trimmed to shape and applied to the freshened nasal 
region one and a half hour after removal, a delay caused by attempts to stanch excessive bleeding in 
the freshened area. The graft was partially successful and an year later other procedures were 
carried out on the upper lip and nose with a flap from the arm. A new era was being born, more 
related to science and experimental proofs, even more the link between medicine and engineering 
technique became strong, in particular between dental technique and clinical medicine which led the 
formation of a Maxillofacial and Plastic Facial Surgery discipline at the Westdeutsche Kieferklinik 
in Düsseldorf. Furthermore, the darkness time during the First and Second War was, from the side 
of the early tissue engineering, a huge field for generate knowledge and experience.  
The milestone breakthrough was reached when scientists understood that the tissue regeneration is 
dependent on the cell proliferation, in particular the first reference could be attributed to Rudolf 
Virchow, in his publication “Zellularpathologie”. But the art became science, in 1950s when R.G. 
Harrison first, maintained frog neural tissue outside of the body for weeks, and it was in those years 
that investigators understood the requirements of cells in order to maintain the viability, avoiding 
particular bacterial contamination with the addition of antibiotics
46
.  
This long history, started thousand years ago, brought to the recent and first definition of tissue 
engineering that, in 1987, set as fundamental the relationship between tissue and substitute, a 
cooperation between biology and engineering to create or restore human tissues
47
. The concept of 
“scaffold” as a substrate to culture and grow cells, started to be the basis concept of this new agreed 
multidisciplinary science. Key point in tissue engineering was given by a co-working between 
Boston Children’s Hospital and MIT, in particular between Dr. Joseph Vacanti and Prof. Robert 
Langer, who generated skin grafts from a culture of dermal fibroblasts and keratinocytes grown on 
protein scaffolds, and used it for regeneration of burn wounds 
48
. Their article in Science
41
 (1993), 
could be considered as the beginning of a new biomedical discipline and they could be considered 
as the founders of modern Tissue engineering, which is supported on three pillars, the three 
paradigms of tissue engineering: cells, matrix(scaffold materials) and regulators 
41,49,50
.  
Cells are the building blocks of tissues, and tissues are the basic units of function in the body. 
Generally, groups of cells make and secrete their own support structure, the so called extra-cellular 
matrix (ECM). This matrix, acts as a support for cells, furthermore it receives messages in form of 
signaling molecules from many sources that constitute the local environment (ECM). Each signal 
can start a chain of responses that determine what happens to the cell. By understanding how 
individual cells respond to signals, interact with the ECM, and organize into tissues and organs, 
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researchers have been able to manipulate these processes to restore damaged tissues or even create 
new ones.  
The process often begins with building a from a wide set of possible sources, from naturals (e.g. 
proteins) to synthetics (e.g. polymers, ceramics). Once scaffolds are created, cells with or without 
regulators, called growth factors, can be introduced. If the environment is right, a tissue develops.  
1.2.2 The Three Paradigms of the Tissue Engineering 
 
Tissue engineering is an interdisciplinary field where biology and engineering are combined 
together to develop substitutes that could replace, maintain and eventually improve the damaged 
functions of human tissues. Unlike drug therapy or organ transplantation therapy, tissue engineering 
approach provides implants specifically designed to treat the disease state, trying to avoid 
complications due to rejection, immune response or systemic drug therapy issues. Tissue 
engineering, is based on the use of a combination of cells, engineered materials and methods, as 
well as suitable biochemical and physio-chemical factors to improve or replace biological function 
of the tissue
41,50,51
. There are two approaches in order to generate a substrate that allows the tissue 
regeneration: 
- Development and growth of human tissues in vitro, for future implantation in the body to 
replace tissue loss; 
- In vivo implantation of cell-free devices or three dimensional constructs with cells, in order 
to induce regeneration of tissue loss directly in the site of implantation. 
The ideal approach of tissue engineering is to first isolate cell samples through a biopsy in the 
patient, to subsequently seed and culture them on a 3D scaffold under specific and controlled 
accompanied conditions, until a new tissue layer is formed and the scaffold is degraded and, finally, 
to implant the novel tissue into the wound.  
Since tissue formation results from cellular action, cell paradigm is a key factor aimed at 
regenerating tissues. In particular, three different strategies are commonly adopted in order to 
generate a new tissue: cell injection, cell induction and cell-seeded scaffolds
52
. Cell injection 
approach involves injection of scaffold cell-free in the defect site
53
. Unfortunately, this kind of 
strategy shows limited effects, since a low engraftment and an inadequate localization of the 
injected cells, in particular in tissue characterized by a continuous movement (such as cardiac 
tissue).  In order to improve this approach, cells have to be injected using a carrier which acts as 
vehicle. This improvement allows an adequate localization, the prevention of a direct contact with 
the immune system and a proper cell proliferation and differentiation
53,54
. Due to their 
characteristics, stem cells are becoming an important tool of tissue engineering and are the most 
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successful candidate for cell injection approach
55
. Stem cells could be divided, according to their 
potency in: totipotent (a single cell divides and produces all of the differentiated cells in an 
organism), pluripotent (cells that have the potency to differentiate into any of the three germ layers: 
endoderm, mesoderm, and ectoderm), multipotent (cells that have the potential to differentiate into 
multiple, but limited cell types), oligopotent (potency to differentiate into a few cell types) and 
unipotent cells (one stem cell has the ability to differentiate in only one cell type)
56
. Stem cells can 
be divided into different types of cells, according to their potential ability, and could be classified as 
Embryonic stem cells (totipotent, pluripotent) and adult stem cells (multipotent, unipotent)
55
. 
Embryonic stem cells (ESCs) are derived from the 5-7 days old blastocyst, prior to germ layer 
formation and, as such, ESCs are thought to be pluripotent and to give rise to progenitor cells from 
all of three germ layers. The clinical application of ESCs is limited, due to ethical issues as well as 
their enhanced possibility to form teratomas after implantation
57
. Adult stem cells can be found in 
adults and are thought to be tissue specific
58
. For example, bone marrow contains mesenchymal 
stem cells (MSCs) that are capable of differentiating into cartilage (chondrocytes), bone 
(osteocytes), muscle (myoblast), tendon (fibroblast) and other connective tissues.  
The second strategy, cell induction therapy,  involves the use of an engineered matrix (biomaterial) 
that induces tissue regeneration without the use of any exogenous biological factor. In fact, a 
biomaterial should mimic the ECM, should serve as a compatible interface with the biological 
system and promote cell functions such as cell adhesion, migration, proliferation, and 
differentiation
59,60
. Furthermore, the designed material should avoid an immune system response. 
The structural, chemical and mechanical properties of biomaterials are also important, as they could 
influence cell functions and the foreign body response in vivo. Moreover, an applied biomaterial 
should maintain the shape of the defect and prevent distortion of surrounding tissues. 
Biocompatibility, adequate mechanical property, biodegradability, porosity and inter pores 
connectivity, depot for sustained release of biomolecules (e.g. growth factor) and cells as well as 
post process and sterilizing ability, are the fundamental characteristics that a material used to induce 
regeneration in a wound tissue should have
51,52,61
. Usually, in cell induction therapy a biomaterial is 
coupled with regulators, since a biomaterial, on its own, is not enough able to induce stem cell 
differentiation and, in most cases, it is recognized as a foreign body by the immune system, which 
tries to isolate it
52,62,63
. Growth factors are biochemical regulators that include proteins, peptides and 
signaling molecules that bind to receptors residing on the cell surface, with the primary result of 
activation or inhibition of cellular functions such as proliferation and differentiation. Many growth 
factors are versatile, stimulating cellular function in numerous cell types, while others are specific 
to a particular cell type. A tissue engineering implant is a combination of biological cues and 
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biomaterials, where the biomaterial could be used as carrier for growth factor and its delivery in 
vivo enhances tissue regeneration
64–66
. The signaling molecules could be incorporated into the 
scaffold during or after fabrication and the degradation rate of the material, as well as the pore size 
and the interconnectivity control the time of releasing
67–70
.  
The third strategy, cell-seeded scaffold, combine all the previous described paradigms: cells, matrix 
and regulators
52,71
. A synergic effect of all components create an engineered tissue, which promotes 
tissue regeneration without immune or inflammatory responses. A complex study of all variables is 
needed, chemical and physical properties of biomaterial should be designed and developed for 
every specific tissues as well as the type of regulators and the type of cells (the most likely 
candidate for such therapies are the MSCs)
72
. There are a lot of concerns about this therapy, 
regulatory and industrialization steps are difficult to be defined, but a construct made by 
combination of materials, cells from a patient and growth factors, ready to be implanted, is the real 
goal of tissue engineering
73
.  
The following paragraph will focus on craniofacial tissue engineering, in particular dental and 
periodontal tissue engineering, with particular emphasis on the state of the art of stem cells, 
regulators and materials.   
1.3  CRANIOFACIAL TISSUE ENGINEERING 
 
Craniofacial region is an unique tissue composed by a multitude of parts, including bone, cartilage, 
nerve, blood vessels and soft tissues. This melting pot of tissues, makes it one of the most difficult 
part of the body to regenerate and requires biological and engineering knowledges in order to 
prepare a correct tissue engineered construct. Furthermore, craniofacial tissues play important 
physiological and anatomical roles and, in addition, have an important aesthetic function
52,74
. Many 
congenital defects, diseases and injuries could affect this tissue equilibrium and require specific 
surgical procedures and therapy in order to replace functionality
75–77
. The most used strategy in 
order to replace the lost tissue, is the use of autologous material, therefore the insufficient host 
tissue and the morbidity of the donor site result in a second surgical procedure, with economical and 
psychological consequences
78
. Nowadays, clinical approach involves more and more the use of 
engineered construct made with natural or synthetic materials, coupled with growth factors that 
could stimulate new tissue regeneration
59,60,79,80
. Researchers are working with even more effort, in 
order to create constructs using stem cells from the body of the patient and to implant a formed 
tissue that reduces immune system responses and inflammation. The use of stem cells is still far 
from a clinical use, because regulatory and practical issues are still to be clarified, but the great 
potential of this tool need all the efforts in order to get clinical available.  
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There are three different approaches for the regeneration of craniofacial region, each one different 
in terms of levels of complexity: conduction, induction by bioactive regulators, and cell 
transplantation
81
. In this research work, we focus on bone tissue engineering, which serves several 
important functions in the craniofacial region. In craniofacial, bone, maintains the mechanical 
integrity of head, protects the soft tissues and the cranial cavity. Many pathologies and injuries 
result in bone deficiencies, such as resorption and loss of alveolar bone, scoliosis of the mandibular 
arch, mandibular asymmetry and defects following removal of sinus. Gold standard strategy for 
bone replacement involves the use of autologous tissue from cranium, iliac crest or rib
79
. This 
approach is associated with some issue, such as bone resorption, problems in the harvesting process 
and site donor pain
82
. Furthermore, in the case of large bone defect, limited autogenous bone does 
not permit to fill the defect site in a properly manner. A tissue engineering approach, that involves 
the use of synthetic or natural materials, bioactive molecules, cells or a combination of the three, 
has the opportunity to conduct regeneration, without creating uneasiness to the patient. Conductive 
approach involves the use of an engineered natural or synthetic matrix alone
59,83–87
. Several 
materials have been developed and some of them are already being used for craniofacial bone 
regeneration, such as synthetic polymers (Poly-lactic acid, Poly(methyl metacrylate), poly(dioxane-
co-glycolide), poly(propylene fumarate), PEO/PBT)
88–91
, ceramic (hydroxyapatite, β-tricalcium 
phosphate, coralline hydroxyapatite, orto-calcium phosphate)
92–96
, natural materials (collagen, 
chitosan, alginate, pectin, hyaluronic acid)
97–99
and combinations of them
100,101
. The implanted 
material in the defect site, acts as a passive three dimensional scaffold on which cells could adhere, 
proliferate and differentiate. In craniofacial bone tissue engineering, and in particular in periodontal 
regeneration, some materials are used as barrier, (guided tissue regeneration, GTR), in order to 
promote proliferation and infiltration of only certain type of cells
33
. For example, in alveolar bone 
regeneration, porous osteoconductive scaffolds and membrane barriers are usually used, in order to 
promote bone growth and to avoid fibroblast infiltration from the gingiva tissue, respectively
102,103
. 
Materials used should have a degradation rate compatible with formation of new tissue, should 
mechanically sustain the surrounding tissues until the new bone has replaced the matrix, produce 
biocompatible by-products from the degradation process, promote cell migration as well as vascular  
infiltration and should not stimulate an immune response. 
However, it is desirable not to only have conduction of tissue growth, but also stimulation and this 
is the case of the induction approach. With this strategy, cells and, subsequently the tissue, are 
controlled and forced to migrate into the scaffold by specific regulators such as peptide, proteins, 
growth factor and signaling molecules. The encapsulation of growth factors into the matrix, reduces 
their degradation and acts as a storage, facilitating the interaction with receptors on the cell surface. 
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There are many growth factors and hormones used to guide osteoid matrix deposition by osteoblasts 
and mineralization: bone morphogenetic proteins (BMPs), basic fibroblast growth factor (bFGFs), 
insulin-like growth factor (IGFs), transforming growth factor β (TGF-β), platelet derived growth 
factor (PDGF), growth hormone (GF) and parathyroid hormone (PTH)
64,104
.  
The strategy involves the release of these bioactive molecules into the defect site, which can 
influence new bone formation through their effect on bone cell recruitment, proliferation and 
differentiation. Many research works, showed the effect of growth factors in vitro and in vivo on 
bone mineralization; for example, the BMP family members BMP-2 and BMP-7 have been shown 
to stimulate formation of periodontal tissue (bone and cementum), in studies in animals including 
rodents, dogs, and non-human primates
51,65,105,106
. Many inductive approaches are still undergoing 
testing and clinical trials prior to approval by the Food and Drug Administration (FDA), however 
the use of this approach in clinical surgery could help in the treatment of large bone defects where 
there is a lack of cellular and vascular invasion from the surrounding tissues, due to pathologies 
such as cancer.  
The third strategy, namely the cell transplantation approach, could involve seeded cells (usually 
MSCs) into an osteoconductive scaffold that acts as carrier, in order to recruit and differentiate 
bone-forming cells
107
. In this technique, typically the cells are taken by a biopsy from a donor, 
isolated, expanded and seeded onto a scaffold. The cells adhere and migrate into the scaffold, 
proliferate and differentiate into specific cell lineages and form a new tissue. This construct then 
could be implanted in the defect site
108
. However, this technique seems to be promising, there are 
many issues, in particular regarding the type of cell used. The best choice are cells from the patient 
himself, since they do not generate any immune response, but this approach takes long time to get a 
construct ready to be implanted in the defect site. Cells from other sources can be more readily but 
have the drawback to generate immunological problem. Regulatory and practical issues make this 
technique nowadays far from the clinical application, but stem cells from the oral facial tissue are 
interesting and many research groups are working on it. There are many sources of stem cells: 
Dental Epithelial stem cells (EpSC), Dental follicle Precursor cells (DFPCs), Dental Follicle Stem 
cells (DFSC), Stem cells from Human Exfoliated deciduous Teeth (SHED), Stem cells from Apical 
papilla (SCAP), Dental Pulp stem cells and Periodontal stem cells
75
. These cells have great potential 
in the transplantation technique and the combination of osteoconductive scaffolds, growth factors 
and stem cells could allow, in the future, new tissue ready to be implanted to be generated and to be 
implied in large defects without any immunological response, with the intended outcome to 
generate new tissue.  
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CHAPTER II 
 
PERIODONTAL TISSUE ENGINEERING 
2.1  CURRENT APPROACHES IN PERIODONTAL TISSUE ENGINEERING 
 
The main objective of periodontal tissue engineering is to regenerate tooth’s supporting tissues. 
Tooth loss is a possible consequence of trauma or periodontal disease, such as gingivitis, 
periodontitis or tissue decay. Periodontal tissue regeneration involves formation of new connective 
tissue (cementum and periodontal ligament) and new alveolar bone. The American Association of 
Oral and Maxillofacial Surgeons reported that 69% of adults aged 35 to 44 have lost at least one 
permanent  tooth and, by age 74, almost 26% of adults have lost all of their permanent teeth
1
. More 
than 300.000 dental implants are placed per year, and until 2020 this number is expected to 
increase
2–4
. The restoration of tooth by using titanium dental implants is nowadays a quite common  
procedure, furthermore the rate of success of dental implant is around 98%, but despite this 
encouraging  number the positive fate of a surgical procedure that involves an insertion of titanium 
screw depends on the quality and quantity of alveolar bone which is present in the extraction site
5
. 
In the last decades beyond hard tissue reconstruction, correction of soft tissue defects has gained 
increasing attention, involving prevention of advanced periodontal defects related to mucogingival 
anomalies, as well as satisfying the increasing aesthetic demands of patients
6
.   
Periodontal regeneration is one of the earliest clinical disciplines that has achieved the therapeutic 
application of tissue engineering-based technology
7
. Many strategies have been studied, some of 
them are already commercially available, while others are under clinical trial investigation. 
Biomaterials, growth factors and stem cells are the three elements that are involved in the treatment 
of periodontal disease.  
Current therapy for periodontal regeneration could be divided in four main groups: conservative 
therapy, radicular conditioner, bone graft and bone substitutes and guide tissue regeneration, or a 
combination of these last two therapies. 
2.1.1 Conservative therapy 
 
Conservative therapy involves a surgical debridement of the periodontal pathogenic bacteria, 
mineralized deposits on the root surface and infected cementum and removal of all the containing 
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toxin tissue parts
8,9
. This approach is still one of the most used methods for periodontal healing, and 
an essential step before any type of regenerative technique is applied.  This approach is based on the 
concept that fibroblast cells from the epithelium possess the fastest growing, so increasing by 
surgery the distance between epithelia layer and the wound allows slower connective tissue 
formation and avoid achieving the radicular surface before the osteogenic cells. The first author that 
reported the importance of the debridement and the morphology of the bone defect was Prichard, 
and his article was published in 1957 
10
. After this first publication, many other clinical studies have 
been developed and, the results, confirm the importance to achieve a clinical situation characterized 
by no inflammation and a controlled bacterial plaque, in which the periodontal tissue could find an 
ideal condition to completely develop its regenerative capacity
11–13
.  
  
 
 
Figure 3. Debridement of periodontal zone. This therapy is an important step before any type of regenerative 
technique used 
8
. 
 
2.1.2 Non –Surgical disinfection 
 
After a surgical procedure, or due to a periodontal disease, the root surface could be exposed to the 
oral cavity, which per definition is full of various type of bacteria, that see the radicular surface as 
an adequate substrate for adhesion and biofilm formation, increasing the inflammatory response
14
. 
In these cases, the use of chemical conditioners is a common approach,  in order to obtain a more 
biocompatible surface, especially in clinical practice
8,15
. Citric acid, EDTA and tetracyclines are the 
most common used acids, in facts their role is to decontaminate the surface from bacteria and 
endotoxins, furthermore the collagen fibers are exposed by their surface to the etching of detergents, 
allowing attachment of tissue-regenerating cells
8
. Like surgical debridement, the nonsurgical 
disinfection therapy gave controversially results, which led to the conclusion that there are no 
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evidences for the use of these chemical agents as providers of clinical benefits for patients, 
compared with conventional surgical procedure 
16
. 
2.2.3 Bone graft materials and guided tissue regeneration membranes 
 
Conventional technique alone promotes a periodontal repair, instead of regeneration; in order to 
achieve a good repopulation of the defect site, researchers developed the so called bone graft 
materials, which have to be used after debridement of the root surface and which promotes bone 
formation
17
. Current approaches are based, in particular, on bone graft materials and guided tissue 
membranes, or a combination of them and on the use of specific growth factor. A more recent 
strategy under development also involves the use of stem cells
18,19
. Stem cell therapy is a 
fascinating approach and their potential could overcome the well-known drawback of the nowadays 
used biomaterials, such as the lack in the induction tissue formation. Despite their great potential, 
there are many regulatory and ethical issues concerning the use of stem cells, furthermore they are 
still far from the practical use. Nevertheless, it is important to understand which are the current 
approaches and which kind of tools are used in order to achieve periodontal regeneration. 
Periodontal regeneration depends on four basic paradigms.. Scaffold materials act as a guide and 
form a three-dimensional template in which new tissue could grow. Cells are the principle actresses 
of the tissue regeneration process, since from their proliferation and differentiation a good 
periodontal regeneration could be achieved. Growth factors target cells activity, promoting 
proliferation and differentiation, as well as new matrix production towards the developing tissue. 
The blood supply provides nutrients for tissue growth and guarantees the homeostasis inside the 
three dimensional scaffold. Before the introduction of tissue engineering and of regenerative 
medicine concepts, the traditional approach to achieve the healing of the wound after surgical 
debridement of the periodontal tissue, was by repair
7
. Repair is defined as the healing of a wound 
by tissue that does not fully restore the architecture and, consequently, the function of the lost 
tissue
20,21
. Regenerative medicine used tissue engineered constructs in order to restore the original 
function and composition of the tissue
22
. Current approaches in periodontal tissue engineering, 
include the use of barrier membranes and bone grafting materials to encourage the growth of key 
surrounding tissues, while excluding unwanted cell types such as epithelial cells
23
.  
The native periodontium is formed by alveolar bone, cementum, junctional epithelium and a 
gingival connective attachment and, based on its embryonic origin, is formed by the interaction of 
mesenchymal and epithelial cells
24,25
. Periodontal regeneration follows a series of independent but 
linked sequence of events: osteogenesis, cementogenesis and connective tissue formation
26
. During 
healing process, cells respond differently to a variety of stimuli, and the quality of healing critically 
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depends on the type of cells that repopulate the wound first
23
. During a periodontal regeneration, 
there are four type of cells that compete: periodontal ligament cells, alveolar bone cells, 
cementoblasts and epithelial cells. The first three types of cells are capable of generating 
periodontal tissue, whereas the epithelial cells are responsible for the soft tissue regeneration, and 
usually migrate ten times faster than other periodontal cell types, this is the reason why periodontal 
therapy typically results in the formation of long junctional epithelium
27
. Infiltration of epithelial 
cells inside the defect promotes repair and formation of unusual architecture with a loss of 
function
28
. Current approaches in periodontal tissue engineering, involve the use of guided tissue 
membranes, which have the function to exclude infiltration of the epithelial cells
29
. If epithelial cells 
could be excluded long enough from the wound, allowing other cell types with regeneration 
potential to become established, epithelial down-growth could be prevented
23
. A combination of 
bone graft material, which acts as osteoconductive material to promote migration and differentiation 
of osteoblast cells, and GTR is the most used approach aimed at achieving periodontal 
regeneration
30,31
.  Conventional techniques have the great disadvantage that results which could be 
obtained are not predictable. In the last three decades, the efforts of researchers in the field of 
periodontal tissue have been directed to find procedures that could regenerate tissue in a predictable 
manner. Many experiments and trials have been done and two types of strategies with the combined 
use of grafts and guided tissue membranes (GTR) have been successfully developed. The 
combination of bone grafts and guided tissue membranes has been demonstrated to stimulate 
alveolar bone regeneration. This synergic effect is based on the biological performance of bone 
grafts and on the “Melcher hypothesis”, which proposed that the nature of the attachment in 
periodontal healing depends on the origin of cells which repopulate the area of the defect and, 
furthermore, the only cells that could achieve complete periodontal regeneration are cells 
originating from the periodontal ligament and from the perivascular bone cells 
8,32,33
.  
The biological principles induced by bone grafting materials, in order to achieve bone lost 
regeneration, could be divided in three interrelated, but not identical, healing processes: 
osteointegration, osteoconduction and osteoinduction 
34
. 
 
Osteointegration
35
 
 
Osteogenesis is achieved by using the so called autologous bone graft. In this case the osteoblastic 
cells and Harvesian system have been replaced by the primitive, undifferentiated, and pluripotent 
cells derived from the graft material itself,  which are somehow stimulated to develop into the bone-
forming cell lineage, for example, osteoblast, which form new bone 
36
. 
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Osteoconduction 
 
The ability of a material to recruit immature cells and to operate as a scaffold to guide the tissue 
regeneration. The material  induces these cells to develop into pre-osteoblasts and osteoblasts from 
the surrounding tissue at the graft-host site, which results in bone growth, and replaced the graft
34,37
.  
Osteoinduction 
 
Osteoinduction is conditioned  by the presence of growth factors on the site and is the ability of a 
material to support the growth of bone over a surface
38
. In that case, the graft material, excludes the 
connective undifferentiated cells and induces the differentiation and proliferation of osteoblast cells, 
into newly bone formation
34,39,40
.  
 
Melcher hypothesis 
 
Melcher hypothesis, involves the use of barrier materials, which enable cells migration from the 
connective tissue, in order to avoid repair process
23,31,41
. The healing process of periodontal tissue 
wounds, is characterized by three correlated steps. Firstly, the internal face of flap is epithelized 
forming the so called long epithelium attachment; more apically, the second step involves the 
maturation of the connective tissue which forms the so called connective attachment and, at the end, 
at the level of alveolar bone, in the deepest point of injury, the recovery of bone architecture and of 
the periodontal ligament takes place. Morphologically, the structure of the new tissue formed in the 
wound could be classified as repair or regeneration 
7
. Repair process is a formation in a bone defect 
of a part of connective tissue formed by cells and fibroblasts, which replace, in part or totally, the 
osteoblasts, inhibiting the deposition of osteoid matrix and, consequently, new bone formation
20,21
. 
On the other side, regeneration involves the completely recovery of the structure and also the 
function of the periodonatal tissue
7,42
. Practically, the Melcher hypothesis is achieved through the 
application of  barrier membranes
43
. Many animal experiments have already proved the efficacy of 
the GTR procedure and, for this purpose, different guide tissue membrane materials have been used, 
both non-resorbable and resorbable
31,41
.  
 
22 
 
 
Figure 4. Steps to achieve periodontal regeneration
7
. 
 
Despite the implementation of this approach, reaching  an optimal periodontal regeneration depends 
on the capacity to control the infection, that derives from the presence of microbial pathogens that 
contaminate periodontal wounds
44–46
. Periodontal defects are often the result of the removal of 
necrotic tissue or of a zone with an acute infection, where there is a high risk of bacterial growth 
and re-infection of new tissue
47,48
. Considering dental defects, bacterial infection possibility 
increases, at the interface with a lot of bacteria from different sources, owing to the natural function 
of mouth and teeth
49
. Hence, it is important to implement appropriate strategies in order to 
regenerate the periodontal tissue and to restrain bacterial growth. The current available strategy, 
aimed at reducing the risk of wound infection, involves the use of a conventional systemic antibiotic 
therapy, which can cause systemic toxicity, with associated renal and liver complications, resulting 
in the need of hospitalization for monitoring
50–53
. However, several research groups are working on 
complex systems in order to release low dosage of antibiotics direct in situ
54–57
. Antibiotic drugs 
used in periodontal tissue engineering, should struggle against bacteria, as well as should be 
biocompatible, nor damage the surrounding host tissue
58–60
. There are many research groups that 
implement antibacterial properties on bone graft materials or on the implant surface, in order to 
avoid bacterial adhesion. Current approaches involve the coating of titanium implants with several 
antibiotic drugs, modification of allograft with chemical groups which inhibit the adhesion of 
bacteria, and the use of specific signaling molecules which act as bactericidal substances
55,61–63
.  
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2.2  BIOMATERIALS IN PERIODONTAL TISSUE ENGINEERING 
 
2.2.1 Types of bone grafting materials 
Bone graft materials are widely used in periodontal tissue engineering, since they are used in order 
to augment the alveolar bone and to provide a mechanical sustain for a future implant. Material 
used as bone grafting could be divided in: autografts, allografts, xenografts and alloplastic 
materials. Different are also the formulations in which bone graft could be produced: particles, 
three-dimensional scaffolds, injectable pastes and in combination with polymeric materials. In the 
last years, one of the most devastating periodontal disease was due to microbial infection, so many 
materials with antibacterial properties have been developed, in order to control the infection and  to 
reduce the failure of the implant.    
2.2.1.1 Autograft  
 
Autogenous grafts are considered the current gold standard bone replacement graft material
64
. 
Autograft is a tissue transplanted from one part of the body to another in the same patient. 
Typically, if the material needed to fill the defect is small, the site from which autograft materials 
are obtained are intraorally, in particular from the extraction sockets, edentulous ridges, ramus, 
symphysis, tuberosity, or from the surrounding buccal plate. In large bone defects, the material 
needed is larger and is typically obtained from extraorally areas, such as the iliac crest or the tibia. 
For autologous bone grafts, the implant survival rate varie from 76% to 100%, with worse results 
for iliac crest bone compared to calvaria bone
65–68
. On the other side, other studies reported that the 
results obtained with intraoral grafts were similar to those obtained with extraoral sources, making 
this source more favorable since the material available is larger
67,69
. This multitude of controversial 
results depend on donor site variability and complications, which allow assessing that there is no 
scientific evidence to indicate which technique is the best
70
. 
The great advantages in using this approach are represented by the fact that these grafts are 
osteogenic, prevent disease transmission and are low cost. Clinical tests show excellent periodontal 
regeneration with new cementum formation. Schallhorn et al. used iliac crest grafts to treat 
infrabony defects and reported up to 4 mm gain in bone healing
71
. However, the main complication 
is that  they require a second surgery and it is important to consider the possible donor site 
complications, such as infection and pain
72
. Furthermore, the limited supply of autograft materials is 
an additional issue that makes this approach always less attractive. 
 
24 
 
2.2.1.2 Allograft 
 
An allogenic material is a graft derived from a donor of the same species, but genetically dissimilar. 
Allograft materials allow overcoming the issue of a second surgical procedure and the limited 
supply source
6
. The graft is typically obtained from tissue banks that process the donor tissues and, 
on the base on which the tissues are processed, allografts could be divided into freeze-dried bone 
allografts (FDBA) and decalcified freeze dried bone allografts (DFDBA). These types of graft have 
the great disadvantage to potentially include a foreign body immune response and the possibility of 
diseases to be transmitted; furthermore, a high risk of graft contamination during processing is 
present
73–75
. Despite these drawbacks, allografts have relatively high success rates and, depending 
on the remaining proteins into the matrix, they could act as osteoconductive or osteoinductive 
materials
76
.  
In particular, the decalcification process exposes bone morphogenic proteins which act as inductive 
molecules for bone regeneration, while ,on the other hand, this type of process causes a higher rate 
of resorption, resulting in less effective scaffolding properties. Several studied compared FDBA and 
DFDBA allograft materials. Yukna et al. performed animal studies in which both FDBA and 
DFDBA were placed into surgically created infrabony defects and evaluated by histological 
analysis
77
. After three months, FDBA allograft showed more substantial new bone formation than 
DFDBA. Excellent results in new bone formation, using FDBA graft, were also reported from 
Altiere et al. and Blumenthal et al.
78,79
. The great variability of these types of graft, is demonstrated 
by the study of Mellonig et al., where DFDBA report similar bone filling percentage compared to 
FDBA in one study and show higher bone filling percentages in a previous study using FDBA 
mixed with an autologous graft material
80,81
. Another disadvantage of these kinds of approach is the 
high material cost, because many commercially available bone graft materials are xenograft
82
. 
2.2.1.3 Xenograft 
Xenograft materials are bone grafts obtained from other  species (typically bovine and porcine) and 
transplanted in human. Tissue banks usually choose these graft materials, because it is possible to 
extract larger amount of bone with a specific microstructure as compared to auto or allografts. Since 
the main disadvantage of xenografts is their antigenicity, tissues are carefully processed to remove 
all organic constituents. There are many commercially available products based on this process, 
such as Geistlich BioOss® particles from bovine source, which is considered the gold standard graft 
material in dental application. However, despite the positive results obtained from studies 
conducted on xenograft materials, the tissue/bone regeneration with this graft material might be 
unpredictable
83
. In one study, where defects were treated with bovine derived bone grafts, at 1 years 
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follow up, 78% of defect healed successfully, even if no difference was detected with the no treated 
lesion
84
. Furthermore, in another study, eight infrabony defects were filled with xenografts and the 
results show that 7 defects went thought successful healing, but ones defect healed by repair 
85
. 
Great advantage of these types of graft is that only one surgical procedure is necessary, on the other 
hand many people are put off by the fact that for this type of procedures animal bone is used.  
2.2.1.4 Alloplast 
 
The graft materials described above have different disadvantages, such as second surgery 
procedures, risk of diseases transmission, limited availability and unpredictable results. In the last 
decades, synthetic materials have aroused even more interest because they can be implanted in the 
host tissue in a large amount, showing diverse advantages in filling large bone defects, such as 
controlled degradation properties, osteoconductive or osteoinductive characteristics, 
biocompatibility and customized mechanical properties
86
.  The development of alloplast grafts is 
divided in two classes: ceramic and polymers, and a mix of the two
64,87
. Ceramic-based materials 
include calcium phosphate, calcium sulfate and bioactive glasses
88,89
. Natural polymers include 
modified polysaccharides, polypeptides and synthetic polymers such as poly(glycolic acid), poly(L-
lactic acid). Natural or synthetic polymers are typically used in addition to the ceramic graft, in 
order to provide osteoinduction properties (peptides), or to increase mechanical properties, and to 
tune the degradation rate and cell adhesion.  
Alloplastic materials are the most commonly investigated grafting materials for periodontal 
regeneration, and many positive results have been reported
64,86,90
.  
2.2.2 Ceramic hard materials 
 
2.2.2.1 Calcium phosphate 
Calcium phosphate (CaP) materials have a long history, in fact the first studies about them appeared 
in the early 1920
91
 and, from that date, numerous studies were conducted and an enormous amount 
of data related to biological actions, chemistry and formulations were produced
92–94
. Calcium 
phosphate materials are widely used in bone and dental tissue engineer, since they are the principal 
compound of inorganic phase in native bone. This kind of composition induces a biological 
response, which is  similar to the one generated during bone remodeling, that is resorption of the old 
bone and, in parallel, formation of new bone. Since the calcium phosphate graft materials are 
chemically similar to the natural bone, the degradation product of the synthetic material are non-
toxic and naturally metabolized without any accumulation of calcium and phosphate in sensible 
organs, such as liver and kidney
95
. Calcium phosphate materials could be formed in different 
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geometry: three-dimensional porous or bulk scaffolds, granules and pastes or cements. The most 
used calcium phosphate materials as bone grafts in periodontal tissue engineering are 
hydroxyapatite, tricalcium phosphate materials and the combination of them. 
 
2.2.2.2 Hydroxyapatite 
Hydroxyapatite (HA),  (Ca10(PO4)6(OH)2),  is the most abundant inorganic component of native 
bone, around 65% of inorganic phase, and it has found many application as bone filler in clinical 
practice. Many studies have  been conducted on the interaction between HA implants and bone
96–
100
. It is well-known that a chemical bond directly occurs between bone and the HA graft, giving 
rise to a kind of bone matrix on the implant surface that is either composed of globular deposits or 
an organized network of collagen fibers, which may enhance the bonding between bone matrix and 
HA
101
. Osteoblastic cells are found on the HA surface, starting mineralized osteoid formation that 
matures into fully mineralized bone on the HA surface
102
. Apatite crystals appear on the surface of 
implanted HA grafts and, these one, are similar to the apatite found adjacent to the alveolar bone
103
. 
However, from a chemical point of view, hydroxyapatite has a great potential as bone filler, since 
osteoconductive properties have been proved, but it has a very slow degradation rate, which limits 
its use alone
104
.  
2.2.2.3 Tri-calcium phosphate 
 
In recent years, due to the limitation of hydroxyapatite in terms of degradation rate, the interest on 
tricalcium phosphate materials (TCP) has been rapidly increased. The most studied TCP phase is 
the β one, which has shown good biocompatibility and osteoconduction properties in many 
studies
90. βTCP materials have been studied in periodontal tissue engineering and have shown 
regenerative properties similar to those of autogenous bone
105. However, βTCP has poor 
mechanical properties and its application as material is recommended just in low bearing 
applications and in particle form. Furthermore, the resorption rate could be too fast in certain 
applications, such as in large bone defects. The mechanism of βTCP resorption is based on two 
main hypothesis. The first manner is due to the dissolution by biological fluids, while the second 
mode hypothesizes that the resorption is due to the action of osteoclast cells
106
. The reality is that 
the two ways are related, in fact more soluble is the material, more extensively it is resorbed by 
osteoclasts
106
. However, a very soluble material might inhibit active resorption, indeed calcium ions 
inhibit osteoclast activity
107,108
. The dissolution of the material depends on many parameters, such 
as sintering process, micro- and macro-porosity, and purity of the row material
109
. The best way to 
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control the degradation rate is to mix the Ca-P materials in a rate which fits the needed 
characteristics
110,111
.  
2.2.2.4 HA/βTCP bi-phasic calcium phosphate 
 
A grafting material used in periodontal tissue engineering should possess peculiar characteristics: 
osteoconductivity, good mechanical properties in order to sustain the load applied on the defect site, 
a resorption rate comparable with formation of new bone and, finally, the degradation products 
should not be toxic for the surrounding tissue
64,112,113
. In the last years many research works have 
been based on the combination of HA and βTCP materials, being aimed at managing the important 
properties and at achieving an excellent and predictable periodontal regeneration. The balance 
between HA and βTCP is a key point to obtain both mechanical strength and degradation and to  
stimulate excellent osteointegration. Several studies were performed in order to understand the best 
HA:βTCP, however the results are difficult to compare, since there are many variables that affect 
the results from one to another group of researchers
110,114,115
. For example, the degradation rate and 
the mechanical properties, as well as the biological properties, strongly depend on the sintering 
parameters, on the mixing technique, on the row material source and on the type of final geometry 
(3D scaffold, porosity, granules, paste, etc.). An interesting study conducted in 1997 by Yamada et 
al., compares different Ca-P ceramic  materials in terms of osteoclastic resorption; HA and βTCP 
was maintained the same, and the percentage of ratio in the bi-phasic material was changed from 
100 % of βTCP, to 100% HA, through 75/25 βTCP/HA and 25/75 βTCP/HA106. The results show 
that resorption lacunae were observed on pure βTCP and 75/25 βTCP/HA material; instead, 
osteoclasts did not resorb the material with a prevalence of HA in the composition. The lobulated 
lacunae detected on the Ca-P biphasic material surface were similar to those formed on natural 
bone, furthermore the high dissolution rate of pure βTCP and the totally absent osteoclast activity 
on the pure HA, suggest that HA/ βTCP biphasic material allows osteoclast to act in a more natural 
way. As osteoblastic bone formation is strongly related with osteoclast resorption during bone 
remodeling, biphasic Ca-P promotes a surface similar to that of the native bone, hence presumably 
the dissolution/precipitation process which occur during osteoclast resorption promotes chemical 
bonding between bone apatite and similar apatite formed on the ceramic surface. By changing the 
ratio between HA and βTCP, it is possible to manage the degradation rate of the bone graft, and 
consequently the bone formation. Mechanical properties of grafting materials, depend on the 
amount of βTCP and HA inside the biphasic material; in particular, as expected, poor mechanical 
properties are associated to the material with a high percentage of βTCP. In a recent study, of 
Morra et al.
116
, a biphasic granulate bone filler was developed with a HA/βTCP ratio of 75/25, and 
animal study showed an excellent new bone formation without any inflammatory response. 
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Furthermore, the mechanical resistance not only depends on the composition, but also on the 
geometry and process parameters (i.e. sintering). These kinds of wide range of possibility make 
these bone grafts highly interesting for periodontal tissue engineering.    
2.2.2.5 Bioactive Glass 
 
A bioactive material, in tissue engineering field, has been defined as a material that undergoes 
specific surface reactions when implanted in the body, promoting the formation of an apatite-like 
layer which allows a strong bond formation between bone and grafting material
87
. This ability is 
different from the osteoinduction stimulation, since the only materials that could promote induction 
are the autogenous grafts. Osteoinduction is the property to induce osteoprogenitor cells and other 
tissues to not only migrate into the structure of the graft material, but to also promote 
differentiation, through affecting gene expression of undifferentiated cells
34
. In the case of 
bioactivity, it is more correct to speak in terms of osteostimulation, as the definition given by 
Schepers and Ducheyne 
117
. Bioactive materials could be added to the autologous graft in large bone 
defects, where the material needed is high
118
. Bioactive glasses showed osteostimulation and high 
mechanical strength. There are three main different bioactive glasses: silicate, borate and phosphate. 
The most used and with a 40-year history, is the silicate bioactive glass, named Bioglass® (45S5), 
for example the key compositional features responsible for the bioactive of  45S5 glass are its low 
SiO2 content, high Na2O and CaO content, and high CaO/P2O5 ratio 
119
. This composition promotes 
formation, on the surface of glass, of the carbonate-hydroxyapatite-like layer, which is similar to the 
mineral constituent of bone, therefore firmly bonds between bone and tissue are obtained
120,121
. In 
clinical evaluation PerioGlas, a commercially available bioactive glass, has shown the ability to 
inhibit the downgrowth of epithelial cells, promoting the regeneration of bone
122,123
. More recent 
studies have proposed borosilicate glass as a bioactive material, although further studies are needed, 
but a first encouraging result was obtained with small animal models, in which borate glasses were 
demonstrated to be non-toxic. Despite bioactive glasses’ brittleness, which constitutes their main 
disadvantage, their unique properties to release ions in the surrounding tissue, which stimulate new 
bone formation, make these materials interesting for periodontal tissue engineering. 
2.2.2.6 Calcium sulfate 
 
Calcium sulfate, also called plaster of Paris, was used as augmentation material for the first time in 
1892, in cavities caused by tuberculosis
124
. From that date, more than thousands of articles have 
been published, on the use of calcium sulfate as bone filler
125
. There are three different forms of 
calcium sulfate, based on the amount of water molecules inside the crystalline structure: anhydrate, 
dehydrate and hemihydrate, the latter state found in medical grade products
126,127
. Calcium sulfate is 
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a biocompatible, osteoconductive and biodegradable material, which is completely dissolved into its 
component elements and recedes leaving behind calcium phosphate deposits that stimulate bone 
growth
125,128
. Furthermore, its porosity and hygroscopic properties allow adsorption and infiltration 
of platelets, in order to stimulate bone formation and enhance angiogenesis. No immunogenic, or 
adverse reactions have been reported in literature and, due to its degradability, it is classified as a 
short term space maintainer. Calcium sulfate material is used, in dentistry, preferably in forms of 
paste or putty, and numerous publication report clinical effectiveness and safety as bone substitutes 
in periodontal defect
129–131
. Furthermore, calcium sulfate has also been used as a barrier membrane 
to prevent ingrowth of soft tissues, no improvement was reported if it is used with a barrier 
membrane
132,133
.  
It has been reported a study in which calcium sulfate pellets were impregnated with a drug and used 
as a system for antibiotic release in situ
134
. Despite many studies showed great potential for the 
application of calcium sulfate as a graft material, its enhanced solubility in contact with blood and 
saliva reduces its conversion from paste to rigid matrix, making the fate of the material 
unpredictable
128,135
. This reason limits its use as graft material but, in order to overcome this 
drawback, the researchers have been trying to combine calcium sulfate with other materials, such as 
calcium phosphate materials, aiming at stabilizing the structure, and controlling the degradation 
rate
130,131,133
. Other approaches involve production of a bi-phasic calcium sulfate, in which both 
dehydrate and hemihydrate forms are mixed, in order to manage the solubility and to obtain a rigid 
matrix after implantation
136
. The primary use of calcium sulfate and composite of calcium sulfate 
bone grafts are as injectable bone fillers for different applications, such as sinus augmentation or 
alveolar bone regeneration, with the great advantage that the use of a barrier membrane is not 
necessary, since the barrier properties of calcium sulfate enable epithelial cell downgrowth.  
2.2.3 Natural soft materials 
 
Non rigid materials are widely used in periodontal tissue engineering as barrier membranes, 
hydrogels and in combination with ceramic materials. Natural soft materials could mimic the 
extracellular matrix (ECM) of bone, allowing cell infiltration, proliferation and new bone 
formation. Elasticity, hydrophilicity, biodegradability, mouldability and biocompatibility are the 
most important properties of these materials. On the other hand, their disadvantages include source 
variability, immunogenicity if they are not pure, limited range of mechanical properties and lack of 
control over pore size. The most used natural biomaterials in periodontal tissue engineering include: 
collagen, chitosan, pectin
137
 and alginate. A briefly introduction for each of them is reported as 
follows. 
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2.2.3.1 Collagen 
 
Collagen is the most used natural material in the field of tissue engineering, since it proven 
biocompatibility and ability of promoting wound healing
138
. It could be extracted from several 
allogenic sources as it is the most prevalent structural protein found in the extracellular matrix of 
different connective tissues like cartilage, bone, tendon, muscle, skin etc.
139
. Several studies and 
commercially available products are based on type I collagen, the most abundant form of collagen 
present in the body and the major component of periodontal connective tissue
138,139
. It offers 
advantages of biocompatibility, cellular adhesion, migration and growth. Collagen materials 
degrade via enzymatic action and the by-products do not cause any inflammatory response
140
. 
Collagen is widely used in barrier membranes, as guiding materials for tissue regeneration, but it 
could be also used in hydrogel sponges and as coting material on ceramic scaffolds or dental 
implants, mimicking the natural component of ECM of bone, thus providing a biomimetic 
surface
79,141
. Collagen material has a good tensile strength, which could be enhanced by 
crosslinking agents, such as EDC, glutaraldehyde and tannic acid. Crosslinking of collagen fiber 
enhances mechanical and degradation properties, but could influence the cell response since most of 
this chemical crosslinking agents are toxic
142,143
.  
2.2.3.2 Chitosan 
 
Chitosan is a natural polysaccharide derived from chitin that can be extracted from the crustaceous 
exoskeleton and is composed by β–(1,4)–glucosamine and N-acetyl-D-glucosamine144. Owing to its 
biocompatibility, its intrinsic antibacterial nature, its ability to not induce any foreign body reaction 
and to promote cell adhesion, proliferation and differentiation, chitosan has aroused great interest in 
tissue engineering and pharmaceuticals, finding many applications especially in bone tissue 
engineering
145,146
. Furthermore, chitosan has a backbone similar to that of glycosaminoglycan, the 
major component of bone ECM
147
. The application of chitosan in patients with periodontitis 
showed reduction of the gingival inflammation, due to its antimicrobial properties
148
. Many 
applications involve combination of ceramic materials with chitosan, for example Ca-P grafts 
mixed with chitosan in order to produce porous sponge or paste
149,150
. Chitosan could be extracted 
also from white mushrooms, eliminating the immunogenic issue due to the animal source.  
Another important characteristic of chitosan materials is its poly-cationic nature, which allows ionic 
interactions with other poly-anionic materials to be created and to generate the so called 
polyelectrolyte (PEI)hydrogel
144,151–153
. These properties were used to produce materials for drug 
release, in particular for drug release in the intestinal track, since this ionic bond is pH sensible and 
the drug could be released more or less depending on the pH of the organ
151,154
.  
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2.2.3.3 Pectin 
 
Pectin is a natural anionic polysaccharide, a major component of citrus cell walls or apple peel by-
product, consisting in a poly D-galacturonic chain with carboxyl groups, in part methoxylated
155,156
. 
Pectin is already widely used in the food industry and, in the last decades, it has found application 
in bone tissue engineering, in particular as a drug carrier
157,158
. Pectin carboxylic groups could be 
ionically crosslinked by calcium ions (Ca
2+) forming the so called “egg box” structure, where a 
divalent cation is bonded with different carboxylic anions
159,160
. Furthermore, ionic interactions 
occur with poly-cationic polysaccharides, to form a well-known polyelectrolyte structure (PEI)
161
 . 
The limit of pectin is its great water-solubility, which causes fast dissolution and, when used as a 
drug carrier, a burst release of the therapeutic molecules occurs
153
. To overcome this problem, many 
research groups have been trying to combine pectin with other materials, such as chitosan, to 
stabilize and increase the resistance in water
152,154,162–164
. Pectin polysaccharide has been used in 
combination with Ca-P particles, since it could mimic the extracellular matrix and guide cell 
proliferation and as a coating material in different medical applications, such as chirurgic mesh as 
antiadhesive material
165–169
. 
2.2.3.4 Alginate 
 
Alginic acid or alginate, is a natural material extracted from a brown algae, or synthetized through 
bacteria biosynthesis, which allow obtaining an alginate with more controllable structure.  Alginic 
acid is a linear copolymer containing block of (1,4)-linked β-D-mannuronate (M) and α-L-
guluronate residues (G) 
170
. The blocks are composed of consecutive G and M residues, whose 
different amounts define the characteristics of the alginate material, since they affect the physical 
properties of the material, for example only the G residues could be ionically crosslinked by 
calcium ions
171
. Alginate is an anionic natural polymer that has been widely investigated and used 
for many biomedical applications, because of its biocompatibility, low toxicity, relatively low cost 
and simplicity of gelation by addition of divalent cationic ions, such as Ca
2+113
. Alginate, like all 
other natural polymers, has a low mechanical strength; for this reason, it is usually coupled with 
other materials, such as pectin, chitosan, or ceramic tricalcium phosphate or bioactive glasses
152
. 
Alginate hydrogels and alginate/bioactive glasses composite hydrogels have been used in 
periodontal tissue engineering, having shown an induction in osteoblast-like cell differentiation and 
enhanced alkaline phosphatase activity of human periodontal ligament fibroblast cells
172,173
.  
2.2.3.5 Hyaluronic acid 
 
Hyaluronic acid (HyA) is one of the most used natural material, along with collagen, in the 
biomedical field and, in particular, in periodontal tissue engineering, since it is one of the 
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glycosaminoglycans present in the extracellular matrix of connective tissue, with an excellent 
potential as scaffold for tissue regeneration
174
. Hyaluronic acid is a linear polysaccharide and, in 
dentistry, it has shown anti-inflammatory and anti-bacterial effects in the treatment of periodontal 
diseases
175
. Furthermore, due to its tissue healing properties, it could be used as an adjunct in the 
treatment of periodontitis. The precise chemical structure of hyaluronic acid, is a repeating unit of 
d-glucoronic acid and N-acetyl-d-glucosamine
176,177
. The most important characteristics of HyA 
are: a hygroscopic nature, which allows the material to adsorb huge amount of water maintaining 
conformational stiffness
177,178
, viscoelastic properties, which allow the material to maintain the 
space and to protect the surface in periodontal regeneration
179
. Furthermore, the viscoelastic nature 
makes unable virus and bacteria penetration. Recent studies have showed a bacteriostatic effect of 
HyA, making this material a suitable tool for barrier membranes, in order to reduce the bacterial 
contamination of surgical wounds, thus reducing the risk of post-surgical infections and promoting 
a more predictable regeneration
180–182
.  
2.3  MORPHOLOGY OF BONE GRAFT MATERIALS 
Bone grafting materials could be shaped in different forms and formulations, depending on the 
application and on preference of the dental technician
30
. Bone graft materials should fill the void, 
avoiding collapse of the defect, promoting platelet, vessels and cells infiltration, should be easy to 
manage and to degrade, with the same rate in which the new bone growth. Hence, the important 
characteristics such as mechanical properties, porosity and degradability depend in part on the 
chemical composition of the scaffold and, in part, on the final material morphology. Porosity is the 
most important feature, because all other parameters depends on it
183
. Many studies and lot of 
works have been done to understand which pore size and porosity are the best, in order to promote 
osteoblast proliferation and bone ingrowth
184
.  
2.3.1 Porosity of bone graft materials and osteogenesis 
 
The scaffolds used as bone graft, have primarily the function of osteoconduction and serve as 
template in which the cells could proliferate and differentiate
185,186
. In order to achieve an optimal 
osteointegration, the material should mimic bone morphology and allow blood vessel infiltration, 
nutrients transportation and the degradation rate should follow the new bone regeneration. Natural 
bone is composed of hydroxyapatite crystals deposited in a collagen matrix
187
. The morphology of 
bone is characterized by a trabecular bone, which is typically a porous environment within 50% to 
90%, and pore sizes in the order of 1 mm and, surrounded by dense cortical bone, with a porosity 
between 3–12%188–190. Bone is a dynamic tissue, in constant remodeling, with osteoblasts producing 
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and mineralizing new bone matrix, and osteoclasts resorbing the matrix. The mechanical properties 
of bone vary by age and from the place in the body, for example in the femoral zone, the Young’s 
modulus could vary from 7 to 17 GPa
190
. Of course, a scaffold material could not reach these 
properties, because if it promotes mineralization in vivo, properties will increase and allow a 
mechanical sustainment. Porosity and pore size of biomaterial scaffolds play a critical role in bone 
formation in vivo and in vitro
184
. The morphology of the bone graft influences the osteogenesis, as 
well as the mechanical properties and the degradation rate
191
. Porosity is defined as the percentage 
of void space in a solid and is independent from the nature of the material
192
. Pores are fundamental 
for bone tissue, because they allow osteoblast migration and proliferation as well as vascularization; 
furthermore, the porosity allows a better stability of the implant, since a better interlocking between 
the biomaterial and the surrounding tissue occur.   
There are many techniques that could be used to obtain porous materials, such as gas foaming
193
, 
salt leaching
194
, phase transformation
195
, freeze-drying
196
, and sintering
197
. Of course, the process 
technique depends on the material used and, in the case of ceramic materials, the most used 
technique is a sponge replication, which allows an interconnected porosity to be obtained, with a 
controlled pore size
119
.  
The importance of porosity in bone regeneration has been shown by Kuboki et al. using a rat ectopic 
model, in which porous and dense particles of hydroxyapatite were implanted
191
. The results show 
that no new bone has formed on the dense particles, while porous particles promote new bone 
formation. The percentage of void (porosity) and the size of these voids (pore sizes), have been 
studied for long time from many research groups. Microporosity allows in vitro osteogenesis 
through suppressing cell proliferation and forcing cell aggregation; however, in vivo lower porosity 
promotes osteochondral differentiation, since hypoxia conditions are favored. Macroporosity 
promotes in vivo osteogenic differentiation, since it allows cell infiltration, bone ingrowth and 
vascularization; on the other side, macroporosity reduces the mechanical properties of the scaffold. 
Hulbert et al. define, as the lowest limit for osteogenic promotion, 100 µm of pore size. They used 
calcium aluminate material, with different pore size and a constant porosity of 46%, and then they 
implanted the scaffolds in a femoral dog
198
. The results show that no bone ingrowth was present in 
the scaffold with a pore size lower than 100 µm, while the highest rate of new bone formation was 
detected for the sample with a pore size between 150 and 200µm. These results are in agreement 
with the diameter of the Harvesian system, which reaches values around 100–200 µm, but in 
contrast with other research group works, which demonstrated no significant variation between 
samples with pores lower than 100 µm and samples with pores higher than 100µm. Bone ingrowth 
was similar in all of the pore sizes of the material implanted in rabbit femoral defects under non-
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loading bearing condition. These results demonstrated that 100µm are not a critical size for non-
loading bearing applications.  
The effect of pore size and porosity, depends on the study, because if it is conducted in vitro or in 
vivo, different results are obtained in the two cases and what is demonstrated in one study is usually 
totally opposite in the other study
191,198,199
. This is mainly due to the different complexity of the two 
systems: in vivo osteogenesis depends on many variables and, in particular, from vascularization, 
furthermore there is a concurrence between osteochondral and osteogenic formation, and pore size 
and porosity influence in a heavier way these processes. 
2.3.2 Porosity and pore size in vitro 
 
The effect of porosity and pore size, was evaluated in vitro using osteoblasts and mesenchymal 
cells
200,201
. Small size pores allow cells aggregation and inhibit cells proliferation in vitro, resulting 
in an increase of expression of alkaline phosphatase activity and osteocalcin
202
. Macroporosity 
allows cell proliferation, since large pore size and higher porosity enhance nutrients and oxygen 
transportation. In general, in vitro, osteogenesis is not affected by pore size, but it is enhanced by 
lower porosity
184
. Akay et al. studied the effect of pore size in a primary rat osteoblast culture and 
showed that more cells were found in smaller pores than in large pores, where however cells 
migrate faster, but the mineralization was not affected by pore size
201
.  
2.3.3 Porosity and pore size in vivo 
 
In vivo condition is characterized by many variables, for example osteogenesis depends, in 
particular, on the degree of vascularization, which is promoted by higher porosity and large pore 
size. Furthermore, small pores (around 100µm) promote chondrogenesis before osteogenesis and 
low porosity does not permit nutrients transportation
203,204
. In vivo it is demonstrated that high 
porosity and large pores promote osteogenesis by recruitment of cells, which are stimulated to 
migrate into the scaffold, as well as vascularization is enhanced and promote new bone 
formation
184
. Furthermore, this assumption is supported by the fact that no clinical results on the 
positive effect of pore lower than 40µm are present. In particular, higher porosity showed an 
increase in bone formation and bone ingrowth when a scaffold with a higher porosity is implanted. 
Pore size plays a critical role in bone formation and many studies were conducted to understand the 
better pore size range for bone regeneration in vivo. Porous hydroxyapatite scaffolds, with different 
pore size, were implanted subcutaneously in rats and the results showed that an increase between 
300–400 µm in the expression of alkaline phosphatase activity was calculated for the material with 
a pore size range, furthermore capillary infiltration was detected just above this range
204,205
. 
However, there are many other articles that do not observe any statistical significant difference 
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between samples with different ranges of pore size
199,206
. Another interesting aspect about porosity 
and pore size, is the impact on the progression towards osteogenesis. Large dimension pores 
promote osteogenesis, small pores, in contrast, promote chondrogenesis first
203,204,207
. Furthermore, 
large pores allow vascularization and oxygen ah nutrients transportation promoting direct bone 
formation
203
. Pore geometry also affects bone regeneration: long channel pore promotes infiltration 
of cells and bone ingrowth, on the other side curved pores on the surface of the scaffold, without 
interconnection, hinder osteoblast precursor cells penetration and capillaries infiltration, promoting 
a bone formation only on the surface 
203
.  
The mechanical properties of scaffolds used for bone regeneration, are affected by the degree of 
porosity, the pore size and, of course, the interconnectivity. Although increased porosity and pore 
size result in a promotion of bone ingrowth, the drawback is a reduction in mechanical properties, 
since the large volume of void compromises the structural integrity of the scaffold.  
The degradation rate of the material used to produce the scaffold, should be taken into account, 
because if the material has a fast degradation rate, the porosity should not be high, since the rapid 
erosion of the trabeculae and the bridge of the material could compromise mechanical and structural 
integrity, before substitution by newly formed bone. On the other side, if the degradation rate of the 
biomaterial is low, it is possible to reach high porosity, since the presence of channels and 
interconnected pores can accelerate degradation due to macrophages via oxidation and/or 
hydrolysis.  
There is not an exact porosity and pore size suggested to achieve an optimal bone regeneration, 
since the multitude of studies in vitro and in vivo presents different results, depending on the 
biomaterial used, from the cells and cytokines used and from the bone features in vivo.  
A balance between micro- and macro-porosity is recommended, in fact it is necessary that the 
material possesses both pore <100µm which allow protein adsorption and promote cells aggregation 
and large pore >300 µm, which allow vascularization and new bone ingrowth
208
. Furthermore, a 
balance between large and small pore allows controlling the mechanical properties and the 
degradation rate. In order to increase and customize the mechanical properties and the degradation 
behavior, ceramic or hard materials are coupled with a natural or synthetic polymer
209
. Furthermore, 
coating the bone graft ceramic with, for example, natural materials such as collagen protein, gives 
to the material such biomimetic properties and could enhance the osteointegration of the scaffold
116
. 
Ceramic materials used as bone graft materials, could be formed in different ways, such as particles, 
three-dimensional scaffolds, injectable pastes
210
. On the base of the application, it is possible to 
choose a different type of bone graft material. In large bone defects, dental technician prefers to use 
three-dimensional scaffolds to fill the void and sustain the surrounding tissues. Particles as bone 
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graft are widely used, since they could be mixed with blood and could also fill irregular or small 
shape around titanium dental implants. Injectable bone grafts are usually a mix of natural or 
synthetic polymers with ceramic micro-particles; their use is increased in the last years, since they 
are easy to use and could fill irregular void and defects, otherwise difficult to reach.  
Bone grafts are usually coupled with membranes, in order to achieve an excellent osteointegration 
which excludes gingival epithelial cells from the bone socket 
41
.  
2.4  GUIDED TISSUE REGENERATION MEMBRANES (GTR) 
 
Melcher’s hypothesis assumes that certain cell populations will have the potential to generate new 
cementum, alveolar bone and periodontal ligament, if they have the opportunity to populate the 
periodontal wound
23
. This condition is obtained when epithelial cells or fibroblast cells from 
gingiva front and connective tissue are excluded from the wound space. This goal is arised through 
development of a membrane barrier, which guides soft tissue regeneration without downgrowth in 
the defect site
31
. Characteristics for guided tissue regeneration membranes should include 
biocompatibility, cell exclusion, space maintenance, tissue integration and ease of use. Membrane 
should separate the gingiva flap from the coagulum in the wound space, furthermore it should 
withstand the masticatory stress, the flap tension and avoid the collapse of the soft tissue, 
maintaining the space for the regeneration of new alveolar bone
41
. An important property is the 
tissue integration ability, since it could ensure the stabilization of the wound and guide fibroblast 
cells to regenerate soft tissue without a downgrowth in the periodontal defect space. Finally, it is 
really important that the developed membrane for GTR is manageable and easy to use by the dental 
technician, without any additional difficult during the surgical procedures. The first material used as 
barrier membrane was cellulose acetate filter and, for the first time, the guided tissue process was 
histological verified. From that point of view, different types of barrier materials have been 
developed, resorbable and non-resorbable, natural and synthetic 
2.4.1 Non-resorbable 
The mechanical stability, the ability to retain their shape, besides the proved capacity to exclude cell 
migration from the gingiva in the wound defect, are the principle advantages of nonresorbable 
membranes
41
. Despite the encouraging results obtained with this type of GTR, the second surgical 
procedure and the possibility to interfere with the healing process are the principle drawbacks and, 
thus, further efforts in the development of resorbable membranes are necessary. Non-resorbable 
membranes include expanded polytetrafluorethylene (ePTFE) and titanium reinforced PTFE 
meshes.   
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The ePTFE membrane was the first membrane approved for clinical use
211
. ePTFE is chemically 
indentical to PTFE, but while PTFE is non-porous, the high thermal tensile stress process in ePTFE 
allows formation of a porous microstructure and fibrils, which allow connective tissue ingrowth. 
ePTFE, also called commercially Goretex®, is formed by two layers: the first is an open structure 
which promotes cell ingrowth, the second layer is an occlusive membrane serving as a space 
provider for regeneration, inhibiting the cell downgrowth and giving structural stability
212,213
. The 
first layer is 1 mm thick and has 90% of porosity, instead the second layer is around 0.15 mm thick 
and 30% porous. Goretex® non-resorbable membrane, has an exceptional inertness, 
biocompatibility, and does not elicit foreign body reaction. Many clinical trials have been done, and 
histological analysis revealed that ePTFE membrane can lead to significant periodontal regeneration 
after 3 months healing period
212,214
. Although many studies demonstrated the efficacy of ePTFE 
membranes, some studies did not find any significant difference between the use of ePTFE 
membrane and the conventional debridement therapy with open flap, furthermore the insertion of 
ePTFE GTR membrane has been seen to cause additional complication such as pain, purulence and 
additional costs for the second surgery procedure
215
.  
Another non-resorbable membrane with ePTFE reinforced with a titanium mesh between the two 
layers was made, increasing the mechanical strength and the maintenance of a better space
41,216
. The 
addition of a titanium mesh allows a better positioning under the flap by the dental practice and 
increases the stability of the membrane, avoiding collapse. Furthermore, the microporosity of the 
membrane avoids cell ingrowth, but allows fluid infiltrations. Animal studies demonstrated relevant 
cementum and bone regeneration
217,218
, although in clinical trials no difference was detected 
between ePTFE membrane and titanium mesh GTR
216,219
. Furthermore, the main disadvantage is 
the increased exposure, due to its stiffness and also to a more complex secondary surgery to remove 
it
220
.  
The future of periodonatal tissue regeneration, and of tissue engineering in general is to develop and 
use materials which could degrade during tissue formation without any further surgical procedure, 
in order to decrease patient’s pain and hospitalization costs.  Furthermore, the use of natural 
resorbable membranes allows bioactivity to be promoted during the regeneration process. For these 
reasons, in the last decades many efforts have been spent, in order to study and develop degradable 
membranes made with both natural or synthetic materials
31,41
.   
2.4.2 Resorbable 
 
Natural. Due to the need of a second surgery to retrieve non-resorbable membranes, in the last 
decades the demand for bio-absorbable membranes with comparable, and even better clinical 
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outcome, became real. Furthermore, the resorbable membrane reduces the patient discomfort, as 
well as costs and eliminates any possible surgical complication
41
. A disadvantage of resorbable 
membranes is the unpredictable resorption, due to the different degradation process which could 
take place, enzymatically or by hydrolysis. In addition, it is mandatory that the degradation products 
do not interfere with the regeneration process and do not induce any inflammatory response
31
. 
Resorbable membranes could be derived  from natural sources or made by a synthetic process. 
Natural membranes have the advantage to be biocompatible, to be no cytotoxic and to be potentially 
bioactive, but they lack of degradation rate and mechanical properties
41,221
. On the other hand, 
synthetic materials are more predictable since it is possible to tune the degradability and mechanical 
properties, but are less biocompatible and could generate foreign–body reaction.  
Type I collagen is the major component of periodontal connective tissue, and has been used in 
medicine so far, as biocompatibility, low immunogenicity, hemostatic properties and ability to 
attract and activate periodontal ligament and gingival fibroblast cells have been proven
141
. The 
bioactivity of collagen and its potential to augment tissue thickness is demonstrated by the 
interaction with various cell types during the healing process. Several commercially available 
collagen membranes have been developed, such as Geistlich BioOss®, Tecnoss Osteobiol®, 
Zimmer BioMend® and BioMend Extended®, Braun Lyoplant®, etc.. The behavior of the collagen 
GTR depends on the source of the collagen used and from the process technique
222
. Collagen is 
usually extracted from skin, tendons, or pericardium of animals, usually bovine and porcine
141
. 
Collagen extracted from animal sources need to be purified and, according to the EU guidelines, 
chemical elimination of viral and bacterial contamination must be performed, then the collagen 
antigenicity is eliminated by removing lipid and non-collagen protein remnants. A sequential 
segment analysis, biocompatibility and sterility are checked step by step
31
. The most common 
chemical modification process, after purification, is the chemical crosslinking, usually performed 
using aldehyde treatment, which increases the mechanical strength, reduces the degradation rate and 
the water uptake capacity, but increases the risk of cytotoxicity, mostly due to the possibility of 
crosslinking traces inside the collagen network
143
.  Degradation of collagen is due to collagenase 
enzymes, which cut the collagen chain and transform it in gelatin, which is then degraded via 
aminoacids gelatinases
31,141
. The resorption time of collagen GTR varies from 4 weeks to 6 months, 
depending on the source and on the crosslinking processes
223,224
. Several research groups compared 
non-resorbable ePTFE membranes with collagen membranes and the results show that collagen 
membranes stimulate proliferation of gingival fibroblast cells, promoting extracellular matrix 
synthesis in a significant high amount. Wang et al. showed higher osteoblast adhesion on collagen 
surfaces and collagen membrane to stay intact since the epithelial proliferation is critical, preventing 
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apical proliferation
225
. Animal studies conducted on BioOss Collagen® membrane showed that the 
collagen membrane led to periodontal regeneration, that the material resorbs in 8 weeks and that, 
during resorption, a slightly inflammatory zone, completely disappeared after total resorption, is 
visible around the implant
79,223
. A huge amount of studies on collagen membranes has been 
conducted, and all of them reveal excellent biocompatibility and promotion of periodontal 
regeneration, but collagen membrane show limited toughness and low space maintenance
31,226
. 
Therefore, there is still the opportunity and the need to develop a material which could swell and fill 
the irregular shape of the gingiva flap, in order to stabilize the membrane, coupled with 
antiadhesive properties which guides epithelial regeneration without generating inflammatory 
reactions and to prevent cell in-growth in the wound  defect. 
Synthetic. Synthetic materials used in GTR are usually based on organic aliphatic thermoplastic 
polymers, such as poly-lactic, poly-glycolic and co-polymers of them. The advantage of using 
synthetic materials, is that it is possible to customize some properties, such as degradation kinetic 
and mechanical properties, by varying the length of the chain and the amount of lactides or 
glycols
227
. The most important drawback associated with this materials is that, during the 
hydrolysis, by-products increase the local pH and usually cause cytotoxicity
228
. Furthermore, these 
materials typically degrade trough a bulk degradation, compromising the mechanical stability and 
interfering with periodontal regeneration. There are some commercially available synthetic 
products, the first of which to appear on the market was Guidor®, a double-layer membrane, made 
of polylactic acid and citric acid ester acetyl tributyl citrate. This membrane is the example of how 
it is possible to produce a particular morphology in a precise manner. The external layer of 
Guidor® has rectangular perforations to promote tissue integration, while the internal layer has 
smaller circular perforations and an outer space to maintain the space between the membrane and 
the root surface
41,229
. Between the two layers, an internal spacer promotes tissue ingrowth. Animal 
studies showed complete resorption of the membrane within 12 weeks, even if it was detected as a 
foreign-body. Several other products have been developed, such as Resolute®, made of poly-lactic-
co-glycolic acid co-polymer, reinforced with polyglycolide fiber
230
, Vycril Periodontal Mesh® , 
made of a co-polymer of lactide and glycolide
231
, Atrisorb®, which is produced in a flowable form 
of polylactic and is formed after exposure in 0.9% saline solution for 6 minutes, by the dental 
practice
232
. All these membranes have been tested in vitro and in vivo and show good periodontal 
regeneration, but many of them provoke foreign-body reaction, mostly due to degradation of by-
products
41
. Besides the already mentioned polyester membranes, some research groups have been 
trying to produce polyurethane membranes, which degrade via enzymatic degradation
233
. Animal 
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studies showed that these membranes cause inflammation and that recession was more pronounced 
than in polylactic membranes
41,234
.  
2.5  GROWTH FACTORS IN PERIODONTAL TISSUE ENGINEERING 
Bone grafts and membrane materials promote periodontal regeneration, usually in an 
osteoconductive manner
112
. In order to enhance healing and to promote periodontal regeneration via 
induction of osteoblast differentiation, incorporation of bioactive molecules into the scaffold and 
their local release for a period of time is a potential approach
235
. Two different procedures to 
incorporate growth factors are available, one of which is during the preparation of the material
236
, 
the second one is after the fabrication
237,238
. The bioactive molecules which are demonstrated to 
exert strong effects in promoting periodontal wound repair in preclinical and clinical studies, 
include Platelet-rich growth factor (PDGF), Bone morphogenetic proteins (BMPs) and enamel 
matrix derivative (EMD)
235,239–241
. The high potential of growth factors derives from their  ability to 
stimulate the interaction between mesenchymal stem cells and epithelial stem cells during tooth 
formation, with all the consequent processes, such as collagen formation, mineralized matrix 
deposition and fibroblast proliferation, etc
235,242
. Bone grafts or membranes alone, have the potential 
to conduct new periodontal tissue formation, thus by adding these kinds of active molecules it is 
possible to produce osteoinductive materials. The morphology of the scaffold, in which signaling 
molecules are incorporated, is fundamental in order to achieve a prolonged and effective release. In 
particular, the incorporated molecules are released in a diffusion mechanism which depends on 
porosity and interconnectivity of the material. Furthermore, the degradation properties of the graft 
or of the membrane could affect the release of growth factors, that would be fast because of  the 
degradation rate, and also the way in which the material degrades, for example by surface or bulk 
degradation, resulting in a controlled or burst release, respectively
184,243–245
. The research and 
development process, aimed at obtaining a commercially available product containing growth 
factors, is difficult in terms of cost and regulatory steps, but of course growth factors have a great 
potential in tissue engineering, hence it is important to know which are their potential and possible 
applications. 
Platelet-rich growth factor (PDGF): is one of the principal growth factors related to wound healing, 
since several in vitro and in vivo studies showed enhanced proliferation and migration of 
periodontal ligament cells. In nature, PDGF is formed by the conjugation of two polypeptides, 
growth factor-BB and growth factor-AA, encoded by two different genes. Several investigators 
have demonstrated that all isoforms have effect on proliferative activity in vitro 
246,247
. PDGF is a 
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chemotactic growth factor, which promotes collagen synthesis, stimulates gingival fibroblast 
hyaluronate synthesis and fibroblast proliferation. Furthermore, in culture with osteoblast-like cells, 
PDGF regulates the expression of alkaline phosphatase and osteocalcin
248
. PDGF was applied, by 
Lynch et al.
249
, in conjunction with another growth factor, the insulin-like growth factor-1, in dog 
experiments, and the results demonstrated an important effectiveness on periodontal regeneration. 
Furthermore, human clinical trials showed that the combination of these two growth factors 
stimulate significant bone regeneration in periodontal defects
250
. Several studies were performed, in 
order to compare the effect of PDGF and IGF-1, and the results indicate that PDGF alone could 
significant stimulate formation of new cementum and collagen production
251
. Molecular cloning 
and large scale purification has allowed production of recombinant human platelet-derived growth 
factor and a combination of this molecule with β-TCP is commercially available (GEM 21®, 
Osteohealth)
252
.  
Bone morphogenetic proteins (BMPs): BMPs are members of the superfamily of transforming 
growth factor-beta (TGF-β)235,252. BMPs are abundant proteins in bone and are produced by several 
cell types, including osteoblasts. BMPs are retained in bone allografts, in particular BMP-2, -4 and -
7; due to this characteristics, allograft materials are defined osteoinductive and could influence cell 
behavior in vivo. Several animal and human studies demonstrated the potential of BMPs growth 
factors in periodontal regeneration, showing a significant increase in alveolar bone healing
253–255
. 
BMPs influence cells, in particular could encourage division and chemotaxis of undifferentiated 
mesenchymal cells and osteoblast precursors, inducing expression of genes involved in bone 
formation, like osteocalcin and alkaline phosphatase
256
.  
Enamel matrix derivative (EMD): in order to achieve periodontal regeneration, mimicking the 
process that takes place during tooth formation is a fascinating approach. During the development 
of a nascent root and periodontal tissue, Hertwig’s cells secrete enamel matrix proteins, which are 
deposited onto root surface, providing an initial and essential step in which the surrounding cells are 
influenced to migrate and form cementum, periodontal ligament and alveolar bone
257,258
. The 
presence of this layer between the peripheral dentin and the developing cementum, have led to the 
development of Enamel matrix derivatives in the form of purified acid extracts of proteins from pig 
enamel matrix (Emdogain®, Strauman AG, Basel, Switzerland)
259,260
. The principal component of 
EMD is Amelogenin, which is composed by highly conserved extracellular matrix proteins codified 
by one gene
241
. Amelogenin, under physiological condition, is assembled into nanospheres which 
form an extracellular matrix, that during degradation by enzyme metalloproteinases, release in a 
controlled process bioactive peptides for weeks
42,242
. This process promotes wound healing, bone 
42 
 
formation and root resorption. EMD could mimic odontogenesis by the recruitment and stimulation 
of cementoblasts to form root-cementum in the root-surface
261
. Then, the new root-cementum will 
lead to regeneration of periodontal fibers and alveolar bone. The first application of Emdogian® 
was in 1997 and nowadays it is the only product on the market that has the potential for triggering 
clinically significant regenerative responses in periodontal ligament cells
259
.  
2.6  GENE THERAPY APPROACH IN PERIODONTAL TISSUE  
ENGINEERING 
 
The major drawback associated with the use of local delivery of growth factors is their short 
biological half-life in vivo
240,262
. Furthermore, a high dosage of bioactive molecules is typically 
required to promote tissue regeneration; hence, an alternative approach to growth factor delivery is 
the use of gene therapy for periodontal regeneration
262
. Gene therapy consists in the insertion of 
genes into an individual’s cells in order to promote the expression of a specific growth factor, and 
consequently a biological effect
37,239,263
. Two main strategies have been developed to induce cells to 
produce specific growth factors: 1) in vivo technique, in which the gene vector could be introduced 
directly into the target site
262,264
; 2) ex vivo technique, in which selected cells can be harvested, 
expanded and genetically transduced and then re-implanted
265
.  
 
 
Figure 5. Gene delivery approaches in periodontal tissue engineering
240
. 
 
Gene therapy has been applied to induce the expression of the most used growth factors, such as 
PDGF
266–268
 and BMPs
269
. In the in vivo technique the gene of interest is directly delivered in the 
body, altering the normal expression of the target cells. In the ex vivo technique, instead, the target 
cells are taken with a biopsy and then, by usually using an adenovirus vector, the genetic material is 
43 
 
incorporated into cells and transfected cells are subsequently re-implanted in the periodontal 
defect
240,270
. Despite the great potential of these technique, there are several issues, in particular 
related to the safety of the adenovirus vector, that mean gene therapy could be a potent approach for 
the future, but many studies have still to be done to prove the safety
263,271
.  
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CHAPTER III 
PERIODONTAL DISEASES 
 
Periodontium is defined as a complex system of tissues supporting and casing the tooth
1
. 
Periodontium tissue includes root cementum, periodontal ligament, dentogingival junction and  
alveolar bone
1,2
. Each of the periodontal tissues has its specialized structure, which defines its 
function, that is only achieved through structural integrity and interaction between components. The 
National Institute of Dental and Craniofacial Research reports that 86% of adults over 70 years has 
a moderate periodontitis and, over 22% has lost its own teeth which involve several health, 
psychological and economical issues
3
. Any disorder that affects the surrounding tissue which 
supports the teeth, related to inflammation, trauma, genetic, metabolic or neoplastic development is 
considered as a periodontal disease
4
. The most common procedure to replace tooth loss is by using 
titanium implants, but practice is successful if there is sufficient bone which could sustain the 
implant and the future crown
5–7
. Periodontal diseases are usually referred to as common 
inflammatory disorders of gingivitis, which could evolve in periodontitis, caused by pathogenic 
microflora in the biofilm or dental plaque which forms around the teeth
8–10
. Many studies have been 
conducted to understand the cause of these diseases, prevention procedures and many solutions 
have been developed to control inflammation and infection, to achieve a complete periodontal 
regeneration. The most effective prevention and treatment involves controlling of the bacterial 
biofilm and other risk factors, in order to arrest the progressive disease and to restore the lost 
surrounding tissue
11,12
.   
3.1 GINGIVITIS AND PERIODONTITIS  
 
By its nature, the masticatory apparatus provides contiguity of a rich of bacteria environment (oral 
cavity) with soft and skeletal tissue. The mildest form of periodontal disease, known as gingivitis, is 
caused by the bacterial biofilm that accumulates on teeth adjacent to the gingiva
13–16
. Gingivitis 
affects around 90% of adults worldwide, in particular periodontal diseases, in developing country, 
are very common, although no correlation is present between gingivitis and the indigenous 
populations
17,18
, in fact this is just the result of a low oral hygiene, being, by the way, a readily 
reversible disease through a simple, effective oral care
19–21
. Gingivitis does not affect the tissue that 
supports tooth, however if the gingivitis is not controlled, inflammation and bacterial contamination 
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could deeply extend into tissues and cause loss of supporting connective tissue and alveolar bone, 
causing the so called periodontitis. Once a periodontal pocket is formed and has been filled with 
bacteria, the situation becomes largely irreversible with a high probability of tooth loss
22
. 
Periodontitis is the major cause of tooth loss, as the result of bone resorption around the tooth. The 
bacterial contact continuously stimulates immune system cells, which react activating defensive 
mechanism that result in an inflammatory response
23
. Inflammation is the result of a cascade of 
correlated events: the immune system responses after an external stimuli, like bacterial infection, is 
triggered, through production of cytokines and chemokines (such as interleukin 1β); these cytokines 
promote cells to differentiate into osteoclasts, causing loss of physiological homeostasis between 
osteoblasts and osteoclasts, that means an imbalance between resorption and production of new 
mineralized bone, which causes tooth loss, pain, discomfort, impaired mastication and, furthermore, 
many expensive procedures and psychological consequences
4,23
. 
Gingivitis and successive periodontitis are the result of accumulation of pathogenic microorganisms 
in the biofilm, which could be enhanced by genetic and environmental factor, for example tobacco 
use. Furthermore, many studies demonstrated the correlation between periodontitis and other 
pathologies, for example periodontal disease have been associated with cardiovascular disease, 
stroke, pulmonary disease, and diabetes
24,25
. 
3.1.1 Causes of gingivitis and periodontitis 
 
3.1.1.1 Oral microorganisms 
 
Enormous effort has been devoted to the study of periodontal disease associated to the microflora. 
Cultural studies revealed that more than 500 distinct microbial species can be found in dental 
plaque, furthermore even more of this well-studied and familiar microbial environment remains 
uncharacterized
26
. The oral cavity, like all the surfaces of body in contact with the external 
environment, has a substantial microflora living in symbiosis with a healthy host. Hundreds of 
different species of aerobic and anaerobic bacteria, grow on tooth surface as complex, colonies and 
form the so called biofilm
27,28
. First, bacteria adhere on the tooth surface and, following 
accumulation, they produce an extracellular polymeric substance forming a complex multilayer 
structure called biofilm, which protects cells from the action of immune system and external agents. 
Bacterial counts in the supragingival zone, on one tooth surface can exceed 1 x 10
9
 bacteria, below 
the gum, the number of bacteria for a healthy shallow crevice could reach 1 x 10
3
, and increase until 
1 x 10
8 
in the periodontal pocket
29
. During maturation of dental plaque and until the state that is 
associated with periodontal disease, the number of gram-negative and gram-positive bacteria 
increases. A constant and frequent cleaning of the teeth, (every 48 h) can maintain the biofilm mass 
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at an amount compatible with gingival health
30,31
. Research efforts have identified specific clusters 
of bacteria species that are commonly present in the subgingival sites and are associated with 
periodontal disease. These pathogens include Porphyromonas gingivalis, Tannerella forsythensis,  
Trepnema denticola, and Actinobacillus actinomycetemcomitans
32–34
. These and other bacteria and 
fungi as Candida albicans, are associated with periodontal disease, in particular in young adults
35
. 
Infections of periodontal tissues caused by these and other organisms are accompanied by the 
release of bacterial leucotoxin, proteolytic enzymes such as collagenases, fibrinolysin and others, 
which degrade the connective tissue and modify the bone homeostasis. In addition to biofilm 
formation, and consequently penetration of bacteria in periodontal pocket from gingival sites, other 
co-factors could enhance and promote periodontal disease, such as genetics, smoke, stress, 
concomitant pathologies
36
.  
3.1.1.2 Tobacco and alcohol use 
 
Tobacco use is a major risk factor for periodontal disease
37
. The rate of periodontal disease 
progression is increased in smokers and decreased to the same rate as non-smokers after tobacco 
cessation
38
. Tobacco enhances biofilm formation and could promote gingivitis, loss of tooth support 
and precancerous gingival leukoplakia. Furthermore, treatments after diagnosis of periodontitis are 
less effective in smokers and regeneration of periodontal tissue after surgical procedures is 
compromised by tobacco, which could promote new biofilm formation in the periodontal socket and 
cause the so called peri-implantitis, the resorption of bone around the titanium implant
38–41
. In the 
US, about half the risk of periodontitis can be attributable to smoking
42
.  
Alcohol consumption has also a significant correlation with loss of periodontal support
43
. Many 
studies on the negative effects of alcohol consumption on degeneration of periodontal disease
43
 
have been conducted. Researchers demonstrated that consumption of alcohol can occasionally cause 
inflammation of the gingiva and, if it falls in the abuse, the alcohol’s drying effect on mouth can 
contribute to the formation of plaque, a sticky bacterial layer that can trigger an inflammatory 
response in gums. Alcohol slows production of saliva, which helps to neutralize the acids produced 
by plaque, so an accumulation of these acids can lead to the development of the early stages of 
periodontal disease
44
. The effects of alcohol or tobacco on periodontal disease have been explained 
by poor oral hygiene of chronic alcoholic consumers or smokers. However, biologic plausibility of 
this relationship exists, in fact both alcohol and tobacco have adverse effect on the neutrophil’s 
function, on the clotting mechanisms, causing complement deficiency, increased resorption and 
decreased formation of bone, reducing the vitamin B-complex production and having direct toxic 
effects on periodontal tissues
45–47
. 
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3.1.1.3 Presence of other pathologies 
 
Several studies conducted on patients with osteoporosis, showed a possible correlation between the 
presence of osteopenia and the increased progression of periodontal attachment loss
48,49
.  
People affected by type I and type 2 diabetes, have more widespread or severe periodontal disease 
than individual without diabetes
50
. However, people with a controlled diabetes do not show any 
increased risk of periodontal disease than people without diabetes
51
. The correlation between 
diabetes and periodontitis is not unexpected, since diabetes is associated with impaired wound 
healing, increased monocyte response to dental plaque antigens and impaired neutrophil 
chemotactic responses and all of these events can lead to increased local tissue destruction
52
.  
Finally, people with HIV disease have a relation with oral necrotizing at gingiva and periodontal 
level
53
. Before the advent of highly active antiretroviral therapies (HAART), the oral disorder in 
patient with HIV virus were more common
54
. The disorder was characterized by pain, bleeding 
gums, halitosis, low-grade fever and malaise. The severity of oral symptoms of HIV has generally 
reduced in population with access to HAART
54
.  
3.1.1.4 Nutrition and stress 
 
Nutrition and stress are two causes which have poor demonstration in correlation with periodontal 
disease
55
. It is demonstrated that a Vitamin C deficiency causes a decrease in the formation and 
maintenance of collagen, an increase in periodontal inflammation, hemorrhages and tooth loss
564
. 
However, in developed countries studies trying to demonstrate correlation between hypovitaminosis 
and periodontal disease failed, and also in the developing country the relation is poorly  quantified. 
For sure, malnutrition is an important factor which may promote gingivitis and future periodontitis, 
in particular in populations which could acquire unusual species of oral bacteria from living near 
cattle
57
. Physio-social disease, as many other diseases, may have an effect in the progression of 
periodontal disease, but their precise role in the pathogenesis is unknown
58,59
.  
3.1.1.5 Genetics 
 
During the last decades, the scientific literature has seen an exponential increase in the number of 
reports claiming links for genetic polymorphisms with a variety of medical diseases, particularly 
chronic immune and inflammatory conditions
60
. Periodontal diseases are multifactorial in nature, 
while microbial and other environmental factors are believed to initiate and modulate periodontal 
disease progression, there now exist strong supporting data that genetic and environmental risk 
factors play a role in the predisposition to and progression of periodontal diseases
61,62
. Several 
features like cytokines, cell-surface receptors, chemokines, enzymes and others that are related to 
antigen recognition, the immune system, host response, among others, are determined by genetic 
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components, polymorphisms of which may increase the susceptibility of an individual to 
periodontal disease
63
. The application of genetic information, identifying genes and their 
polymorphisms, can result in a novel diagnostic method for risk assessment, early detection, and 
selection of treatment approaches. The relation between microbial cause and periodontal disease 
was demonstrated and well established
22
. However, if periodontitis was simply caused by a 
combination of specific periodontal pathogens, the disease should have developed in the majority of 
subjects infected by these organisms, which happens just in the subject with gingivitis and minor 
periodontitis. In subjects in whom the disease quickly progressed from chronic gingivitis to 
destructive periodontitis, the cause could not be explained by the microbiology alone. The scientific 
literature, during the last decades, has been seeing an exponential increase in the number of reports 
claiming links for genetic polymorphisms with a variety of medical diseases, particularly chronic 
immune and inflammatory conditions
64,65
. Most of genetic research in periodontitis has now 
focused on gene polymorphisms that play a role in immunoregulation or metabolism, such as 
cytokines, cell-surface receptors, chemokines, enzymes and others that are related to antigen 
recognition. Future strategies for utilization of genetic polymorphisms in periodontics should 
consider two factors. The first, is to perform large-scale genetic analysis in different populations 
using many target genes; the second factor is the need to develop a statistical analysis which 
combines genetic aspects with environmental factors
60,66,67
.  
3.2 PATHOGENESIS AND DIAGNOSIS 
 
Pathogenesis is the mode of origin or development of diseases. Gingivitis and chronic periodontitis 
are due to a combination of multiple factors; in particular, the bacteria biofilm is the principal 
responsible of gingivitis and, if not treated, it could transform into periodontitis. Although bacteria 
are necessary for periodontal disease to take place, a susceptible host is however needed. Chronic 
marginal gingivitis is clinically characterized by gingival redness, edema, bleeding, changes in 
contour, loss of tissue adaption to the teeth and increased flow of gingival crevicular fluid
23
. The 
inflammatory and immune system response, which is stimulated in the gingival and periodontal 
tissues in response to the chronic presence of plaque bacteria, results in a destruction of the 
periodontal tissues leading to clinical signs of periodontitis. During an infection, the host response 
is essentially protective, but both hypo-responsiveness and hyper-responsiveness of certain 
pathways could result in enhanced tissue destruction
68
. Both the host and bacteria in the periodontal 
biofilm release proteolytic enzymes that damage tissue. The initial stage of gingivitis involves an 
initial lesion which appears as an acute inflammatory response with characteristic neutrophilic 
infiltration
69
. This first stage is due to chemotactic attraction of neutrophils by bacterial constituents 
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and direct vasodilatory effects of bacterial products
23,70
. Progression of lesion is dominated by the 
expression of cytokines which are responsible for recruitment, differentiation and growth of the 
characteristic cell types with progressive chronicity of the lesion
23
. At this time point, an accurate 
removal of plaque results in a restoration of healthy tissue without residual tissue destruction
71
. If 
not treated, chronic lesion could necrotize as acute ulcerative gingivitis, which is an acute infection 
of the gingiva characterized by interdental soft tissue necrosis, ulceration, pain and bleeding
72
. It is 
histologically characterized by a bacterial infiltration in the connective tissue. A common feature of 
nearly all cases is a very poor oral hygiene and nearly all cases can be managed with local 
debridement, improved plaque control, and judicious use of antibiotics
22,23
.  
Periodontitis is clinically different from gingivitis, since it is characterized by loss of the connective 
tissue attachment to the teeth in presence of gingival inflammation
8,73
. Many studies demonstrated 
the similarity in the histopathology between gingivitis and periodontitis, and seems that periodontal 
inflammation is a consequence of gingiva inflammation
74
, but the mechanisms of this progression 
are not clear, and the factors that lead to the initiation of periodontitis lesions are unknown
75
. The 
infiltration of bacteria in the periodontal pocket is the major cause of progression of gingivitis in 
periodontitis, and results in a loss of periodontal ligament and disruption of its attachment to the 
cementum, as well as to the alveolar bone resorption
23
. Bone resorption occurs when inflammatory 
mediators reach a critical concentration, which depends on the expression of pro-inflammatory 
cytokines, such as interleukin 1β  (IL-1β) 76. On the opposite site, pro-inflammatory cytokines 
expression levels are controlled by the expression of anti-inflammatory cytokines, like interleukin 
10 (IL-10)
77
. In normal physiological conditions, there is a balance between bone formation and 
bone resorption. As it happens in certain inflammatory conditions, this balance can be altered and, 
in the case of bone tissue, bone formation could be enhanced, or diminished. This equilibrium is 
regulated by the relative expression of proteins, such as receptor activator of nuclear factor kappa-B 
(RANKL) and the soluble decoy receptor osteoprotegerin (OPG). During an inflammation response, 
RANKL/OPG ratio is altered by the action of pro-inflammatory cytokines, such as IL-1β, that 
induces osteoclastogenesis increasing the expression of RANKL, while counteraction by anti-
inflammatory mediators, such as IL-10, decreases RANKL or increases OPG, in order to inhibit 
osteoclastogenesis. During periodontitis, this equilibrium is loss and osteoclastogenesis is 
promoted, resulting in alveolar bone resorption; without an adequate treatment, active periodontitis 
leads to tooth loss
71
.  
Diagnosis of gingivitis and further periodontitis is important to find a possible treatment strategy 
and to avoid tooth loss. Chronic gingivitis usually results in bleeding from the gum during tooth 
brushing, or in the most critical case could be present an underlying blood dyscrasias or bleeding 
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disorders. Gingivitis could be avoided by an accurate oral hygiene, and systematic controls by 
specialists.  Otherwise, chronic periodontitis is usually asymptomatic, until the disease is so severe 
that teeth shift, loosen, or are lost. Furthermore, patients with advanced periodontitis may also have 
recurrent periodontal abscesses and halitosis. The clinical diagnosis of periodontal disease is based 
on visual and radiographic assessment of the periodontal tissues and on measurement of the space 
between gum and tooth, which is usually around 1 to 3 mm
78
. During a clinical examination, pocket 
depth and tissue support are measured at four to six locations around every tooth and the amount of 
supragingival periodontal biofilm, dental calculus, gingival bleeding and exudate are recorded
79,80
. 
These methods are used to diagnose an existing disease, to determine the prognosis and to monitor 
the disease progression. Emerging diagnostic methods include the use of biomarker assays, intraoral 
computer tomography (CT) and saliva-based diagnostic methods. The first emerging diagnostic 
method is based on the fact that the inflammatory exudate adjacent to the teeth contains several 
biomarkers of periodontal inflammation that might be useful in the prediction of future disease 
risk
81
. CT could be used in future to obtain a three-dimensional reconstruction of alveolar bone and 
to calculate important parameter such us height, porosity, density and the possibility to compare 
data from different site and from different time points
82
. Finally, saliva in the future will replace 
blood for many diagnostic assays, and is already used to monitor the concentration of drug and viral 
load, for example
83
. For periodontal disease, saliva-based diagnostic methods are promising because 
periodontal pathogens are readily detectable in it
84
. 
3.3 PREVENTION AND TREATMENT OF GINGIVITIS AND 
PERIODONTITIS 
 
Controlling risk factors that cause gingivitis and periodontitis is the common approach to prevent 
degeneration of periodontal disease. The widely accepted causes related to the gingivitis and 
periodontitis is the formation of bacteria plaque on teeth, in the absence of proper oral 
hygiene
15,16,31
. Furthermore, several ancillary factors such as smoking, diabetes, poor education, 
infrequent dental attendance and stress could enhance the progression of periodontal disease
4,8
. 
Tooth brushing and the use of dental floss and other devices to remove bacterial plaque from the 
teeth are the most common ways of disrupting or removing the periodontal biofilm from teeth, 
however these procedures are effective if used every days
31
. In fact, after oral hygiene procedures 
are ceased, the biofilm begins to form on the teeth within 24 hours and could cause gingivitis in 10 
days
85
. However, through tooth cleaning, the gingiva could return in healthy conditions in about 1 
week, that means that, by accurate tooth cleaning, gingivitis could be controlled and periodontitis 
could be avoided for many years
31,85
. In the last years, many mouthwashes and dentifrices with 
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antimicrobial effect have become commercially available, and could be helpful in the disruption of 
biofilm. In addition, mechanical cleaning methods, performed by practitioners, can reduce 
gingivitis
86,87
. The role of these prevention methods, have not been established in the prevention of 
periodontitis, but there are evidences that antimicrobial compounds, and a proper cleaning of teeth, 
can reduce recurrence of periodontal disease after non-surgical periodontal treatment
86,88
. The major 
ancillary risk associated with the progression of periodontal disease, is the use of tobacco
39
. The 
rate of periodontal disease progression increases in smokers than in non-smokers, furthermore 
treatments of periodontitis are less efficacy in smokers people
89–92
.  These approaches need an 
adequate health education and promotion program, in particular in the developing country, where 
poor general health, restricted access to dental care and inadequate oral hygiene usually translate 
into a high occurrence of gingivitis and periodontitis. Gingivitis could be prevented and treated, 
usually with dental care and, in some case with the use of antimicrobial compounds, on the other 
hand, periodontitis treatments would involve both non-surgical and surgical approach in the most 
chronic case
93–95
. Dental plaque and calculus can be removed from tooth and root surface manually 
or with specific instruments, in particular it is important to mechanically act and with attention to 
the periodontal pocket. Once a periodontal pocket becomes filled with bacteria, the situation 
becomes largely irreversible and, in this case, a surgical procedure might be necessary
8,10
. For 
patients with advanced disease, a variety of types of periodontal surgery to reduce the depth of 
periodontal pocket is used, gaining access for debridement of residual dental calculus and plaque, 
and to stimulate regeneration of lost periodontal tissue support by using bone grafting materials, 
guided tissue regeneration membranes and biological substances
96,97
. Coupled with surgical or non-
surgical treatment, a supplemental use of systemic antibiotics is usually provided
98
 or local 
antiseptic drugs
99
, which provide additional benefit compared with debridement alone
100,101
.  
In addition to mechanical therapy, a novel approach using high and low level energy laser lights has 
attracted considerable attention in periodontics
102,103
. Recent evidences have demonstrated that the 
application of laser energy could be useful to kill bacteria and to control inflammation, furthermore 
it could stimulate tissue regeneration in periodontal and peri-implant disease
104,105
. High-level laser 
therapy is nowadays used to debride diseased tissues and to render aseptic and nontoxic the treated 
sites
106
. When a high-level laser light is applied, a low level of energy penetrates or scatters into the 
surrounding tissues and this low level energy is used to stimulate tissues and cells without 
substantially changing the tissue, and recent studies showed the effect in the increase of periodontal 
wound healing
107
. If high- and low- level laser therapy are properly used, the combined effects 
would result in improved pocket healing, in combination with the regeneration of soft and bone 
tissues
106
. 
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3.4 PERI-IMPLANTITIS AND PERI-PROSTHETIC INFECTION 
 
In order to replace the function of a tooth loss, the most common procedure is the use of a screw 
dental implant
5
. Implants could be divided in three categories: endosteal (implant within the bone), 
subperiosteal (framework placed on bone) or transosteal (implants placed through the bone from the 
superior to the inferior aspect)
108
. The most used dental implant is endosteal and could be placed 
inside the bone with the external cap covered by soft tissue, before to place the crown, or the 
coronal aspect could be placed at the margin of gingiva and not covered with soft tissue. The most 
commonly used metal for dental implant is Titanium and Titanium-Aluminum-Vanadium alloy 
(Ti6Al4V)
109
.  The osteointegration of Titanium implant is related to the design of the screw, the 
surface roughness, the presence of bioactive molecules on the surface, and the status of the 
surrounding tissue
110,111
. Nowadays, surface treatment of dental implant is a well-known technique 
which allows obtaining a micro-roughness surface that directly interacts with osteoblast cells and 
promote a strong fixation between bone and implant
112,113
. New concepts about the surface of the 
implant are the use of biological molecules, such as collagen and hyaluronic acid on the surface not 
only to conduct new bone formation, but also to stimulate it
114–116
. 
As in natural teeth, also for implants many external factors could influence the success of the 
surgical procedures. The main problem is the bacterial contamination of the implant surface, which 
results in an early inflammation of the soft tissue and could progress in a resorption of bone and 
connective tissues around the implant and a consequent failure of it
117,118
. Peri-implantitis is a site-
specific infectious disease that causes an inflammatory process in soft tissues and bone loss around 
an osteointegrated implant in function.  
Although high success rates for endosteal implants have been reported, failures occur, and same 
implants are lost or removed. Around 1% to 5% of implants at 15 years of follow up fail, and in the 
10% of failure the cause could be related to the peri-implantitis
119–121
. One of the major causes of 
peri-implantitits is the bacterial colonization of implant surfaces, but ancillary risk factors are 
involved, such as previous periodontitis, poor oral hygiene, tobacco and alcohol consumption, pre-
and post-operative therapies and genetic susceptibility.  The microflora present in mouth has a 
fundamental impact on the biofilm formation on the surface of the implant, furthermore periodontal 
compromised patients have a higher risk of peri-implantitits than unaffected patients, a transmission 
of periodontal pathogens from periodontal sites to implant is possible
122
. Several researchers studied 
the possible associations between a previous periodontitis and peri-implantitis, and found that 
subjects with a history of periodontitis have a higher risk of re-infection of the implant site
123–125
. 
The peri-implant disease refers to the pathological inflammatory situation that affects the tissue 
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surrounding the implant, and could be classified in peri-implantitis mucositis and peri-
implantitis
11,126
. Mucositis, as gingivitis, is defined as a reversible inflammation of the soft tissue 
surrounding the implant, and could be controlled after the surgical procedures with a proper oral 
hygiene, and by the use of antimicrobial compounds and antibiotic drugs, via systemic or local 
administration
127
. Peri-implantitis is an inflammatory reaction at the interface between implant and 
bone, due to an infiltration of bacteria, which causes a loss of bone and consequent mobility and 
failure of the implant
11
. Most of the bacteria found in the plaque during periodontitis is  also found 
in the biofilm formation on the failed implant, that means the histopathology of periodontitis is 
similar to that of peri-implantitis
128–130
. Peri-implantitis could be also caused by the biomechanical 
issue, due to an overloading at the bone implant surface, that could provoke loss of osteointegration 
and losing of the artificial support, causing infection of the surrounding tissues and consequently 
inflammatory process.
131
  
Diagnosis of peri-implantitis is based on color changes of soft tissue, radiology evidence of a 
vertical resorption of alveolar bone, bleeding, suppuration, swelling of the peri-implant tissues and 
formation of a peri-implant pocket
132
. Treatments of peri-implantitis are quite similar to those 
adopted for periodontitis. There are surgical and non-surgical approaches, which involve 
debridement of the infected site and administration of local or systemic antibiotic drugs
11
. However, 
the reasons why peri-implantitis occurs are poorly understood, even if oral microflora seems to be a 
defining factor for success or failure of a dental implant. Techniques to prevent peri-implantitis 
involve the prevention of bacteria biofilm formation on the implant surface and the removal of all 
microorganisms adhered to the sites of implantation
133,134
. When an implant is exposed to the oral 
cavity, its surface becomes immediately covered by a salivary pellicle and a protein layer, forming a 
substrate further colonized by oral microorganisms, which start forming the biofilm
27,135
. 
A biofilm is an assembling of microbial cells that is irreversible associated with a surface and 
enclosed in a matrix of primarily polysaccharide material. Biofilms are primarily composed of 
microbial cells and extracellular polymeric substances (EPS). EPS may account for 50 % to 90 % of 
total organic carbon of biofilms and could be considered the primary matrix material of biofilm
136
. 
EPS may vary in chemical and physical properties, but it is primarily composed of polysaccharides. 
Van Leeuwenhoek, first observed microorganisms on tooth surface by using a simple optical 
microscope, and can be credited with the first discovery of a microbial biofilm
27,137,138
. 
Periprosthetic infection (PPI) is a consequence of implant insertion procedures and could be due to 
a previously periodontitis, to an infection of the prosthesis during insertion, or during the healing 
process due to a poor oral hygiene
139,140
. In order to avoid contamination of the dental implant 
surface, there are three different approaches: local debridement, surface decontamination and 
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antibiotic therapy
132
, coupled with regenerative procedures using bone graft substitutes in 
combination with membranes
97
. The decontamination of dental implants prior to surgical insertion, 
could be done using different techniques, such as air-powder abrasive techniques followed by citric 
acid application, air-powder abrasive technique alone, gauze soaked in saline followed by citric acid 
or in chlorhexidine
141,142
. These approaches could reduce the nosocomial infection, but do not 
reduce the risk of infection if the microorganisms are still present in the insertion site. Local 
debridement of the infected site, coupled with a regenerative procedure using bone graft and 
membrane, is the most promising and used technique. In addition, it is possible to administrate a 
systemic or local antibiotic therapy
143–146
. Conventional systemic delivery of a high dose antibiotic 
drug causes systemic toxicity with associated renal and liver complications, resulting in the need for 
hospitalization for monitoring
147,148
. For this reason, in the last decades, many studies have been 
conducted aimed at developing bone graft which have the ability to release antibiotics in situ
99,149
. 
 
3.5 ANTIBACTERIAL MATERIALS 
 
Coupling bone grafts and titanium implant is still one of the best solutions to replace bone and 
dental tissue loss, in particular in large defects, where the present bone is not enough to ensure 
stability for the implant. It is necessary the insertion of a so called bone filler material. This kind of 
surgical approach, promotes bone formation and gives stability, guiding bone regeneration around 
the implant. Despite the high success rate, in 1-5% of procedures, the implant fails and must be 
removed
121,139
. Many studies have been done on the side of titanium and titanium alloy implants, in 
order to achieve a good implant bone interface anchorage, in particular surface treatments of 
implants are nowadays well developed and could ensure their stability
112–114,116
, if combined with a 
biomaterial that guides bone regeneration and controls the infection, to avoid the devastating 
consequences of periprosthetic infection (PPI) that are hospitalization, high dosage antibiotic 
therapies, implant removal, limitation in oral function and more surgical procedures, all culminating 
in financial and psychological burden for both patients and healthcare team. 
Current strategies to PPI prevention involve either increasing the rate of new bone formation or the 
release of antibiotics, in most of the cases with a conventional systemic delivery of a high dose that 
is not effective in the control of PPI,  due to a specific adhesion of bacteria on the biomaterials, and 
to the very low penetration of the antibiotic into the osseous defect
27,101,149
. Scaffolding properties 
alone is not enough, large bone defects, zones with acute infections, where bacterial growth is a 
high possibility and re-infection of native bone are often the result of necrotic tissue removal. 
Furthermore, if we take in consideration dental defects, bacterial infection risk increases, mostly 
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due to the natural function of the mouth and teeth, at the interface with a lot of bacteria from 
different sources.   
Obviously, it is necessary to find strategies to prevent PPI, hence the most suitable solution is to 
release an antibiotic drug in situ, using a complex release system to reduce infection and, at the 
same time, to promote bone formation avoiding fibroblast infiltration from the surrounding soft 
tissues.  
Antibiotics used in drug release complexes should be effective against bacteria, as well as 
biocompatible, and not to damage the surrounding native tissues.  
Staphylococcus epidermidis was inserted in the list of National Nosocomial Surveillance System 
Report as one of the most often isolated bacterial pathogens in hospitals, and as the most important 
pathogen involved in nosocomial and periprosthetic infections 
135,150,151
. S. epidermidis colonizes 
the skin and the mucous membranes of the human body and is the most abundant bacterium present 
at the interface between body and external environment
150
. Apart chronic diseases due to previous 
periodontal pathologies, another important factor which could affect the fate of a dental implant, is 
the possibility of a contamination of the implant before insertion. Concerning this possibility the 
most important group of infections caused by S. epidermidis are infections caused by foreign 
bodies, such as implanted devices. This possibility, is one of the most usually cause of PPI, which 
involves the failure of the surgical procedure. On these devices, bacteria and, in particular, S. 
epidermidis, form the so called biofilm
152
. Due to the poor penetration of antibiotics inside the 
polysaccharide matrix, the infection results difficult to be eradicated, in particular in submerged 
implants
11,153
. The infection related to bone defects are quite common not only in periodontal tissue 
engineering, but in all the surgical procedures which involve open bone fractures and trauma, in 
particular many studies related to the infection of the hip joint replacement have been 
conducted
143,145
. Conventional treatments which involve debridement of the pathological site, can 
only control but not treat the local infection, however synchronous bone regeneration and control of 
the infection are necessary in clinical treatment. Recently, vancomycin hydrochloride (VCA.HCL 
or VCA), as one of the most commonly used antibiotic drugs for the treatment of serious, life-
threatening infections, has been proved effective against Gram-positive bacteria, and specifically 
against Staphiloccocus epidermidis, which is related to the infection of bone defects, in particular in 
the nosocomial infections
154,155
. Vancomycin is a widely used antibiotic that provides bactericidal 
activity and biocompatibility
155,156
. In the clinical practice, vancomycin is normally administered 
intravenously for systemic therapy, and the dose levels should be monitored in an effort to reduce 
adverse effects, such as renal disease and toxicity. However, in order to reach effective local 
dosage, it is necessary to give a high systemic dosage; furthermore, penetration of antibiotics in the 
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biofilm matrix is difficult if the antibiotic dose provided intravenously is low. For these reasons, 
local drug delivery systems have aroused great interest in the treatment of PPI and many different 
systems have been developed or are under developing. The most critical part during the developing 
of a system for bone regeneration drug delivery is the selection of bone graft materials, since they 
should have drug-sustained release ability but also an effective ossification bioactivity. The first 
material used in general bone tissue engineering as drug delivery system, was 
poly(methylmethacrylate) (PMMA) cement, which is impregnated with antibiotic during the 
synthesis
157,158
. However, although PMMA cement combined with antibiotic is still considered the 
gold standard, it has many disadvantages, such as exothermic reaction which avoids the use of 
sensitive antibiotic drugs, the slow rate of degradation or the non–degradable characteristic make 
the kinetic release and period of antibiotic deliver difficult to be accurately controlled. In order to 
overcome the drawbacks of PMMA cement and other non-resorbable materials (i.e. hydroxyapatite 
cement, allograft), several biodegradable and absorbable bone materials have been developed as 
antibiotic carriers to prevent or control PPI
11,159–161
. One possible solution, aimed at controlling the 
release in situ and at providing a sustained release for a long time, is to covalently bond antibiotic to 
the surface of bone graft, or directly on the surface of the titanium implant
12,162–164
. The second way, 
is to combine biopolymers with bioceramic materials to create a complex system which is able to 
regenerate new bone and release, in a controlled manner, antibiotic drugs over time. Antoci et al. 
covalently bonded vancomycin on the surface of titanium alloy
162
, and tested it against 
Staphiloccocus aureus and Staphiloccocus epidermidis. Attachment of bacteria to the implant 
surface is the first step in the development of PPI and, for these reasons, preventing this adhesion 
could be a solution to prevent bacterial colonization and infection of the wound site. They tested 
bacterial adhesion and biofilm formation with different assays and demonstrated that vancomycin 
bonded on the titanium surface is able to inhibit bacterial growth within 4 weeks. This system has a 
great potential in the prevention of the devastating bone PPI, however the main drawback is that the 
use of titanium dental implant is dependent on the amount of bone which is present in the defect 
site. Periodontal disease usually involves the extraction of the tooth and the loss of consistent 
amount of bone; so, it is usually mandatory to use a previous bone grafting material to achieve bone 
regeneration, which could sustain the future implant fixation
97
. Usually, tissues affected by 
gingivitis or periodontitis have the highest probability to be re-infected after surgical procedures, so 
it is necessary to use a material able to prevent and control bacterial growth during bone 
regeneration. For example, Lian et al.
159
 developed a complex system, made of nano-hydroxyapatite 
coated with collagen and poly(lactic acid) loaded with vancomycin. The aim of this work, was to 
develop a bone graft with the ability to regenerate new bone and, in parallel, to prevent bacterial 
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proliferation through a sustained release for long time. They demonstrated that the addition of 
vancomycin to the system did not affect the in vitro and in vivo biocompatibility of the composite, 
which showed excellent cell adhesion, spreading and proliferation. Furthermore, no specific 
inflammation response was detected in subcutaneous implantation. Finally, a long-term release was 
assessed, with effective and safe antibacterial ability. However, polyester material made with lactic 
acid or glycolic acid, go through a bulk degradation, which make the system unpredictable, 
furthermore many studies showed that the degradation products of this kind of polyester increase 
the local acidity and stimulate a foreign response
165
. Hence, an approach more predictable is to be 
preferred, thus using natural materials which could mimic the extracellular environment and could 
release the drug in a sustained way for the first week, the time-point in which the highest possibility 
of re-infection exists.   
As it is explained in the following paragraphs, the objective of this research work was to design, 
develop and characterize a set of materials which could prevent PPI, promoting new bone formation 
and achieving an excellent periodontal regeneration.   
 
3.6 OBJECTIVE OF THE PhD THESIS 
 
Periodontium is a complex system of different tissues, such as connective tissue, cartilage and bone, 
which work together to sustain the tooth
2
. Gingivitis and periodontitis are devastating diseases that 
could affect the structure and function of the periodontal tissue
4
. When the gingivitis are not treated 
and controlled with a correct oral hygiene, they could evolve in periodontitis, which could seriously 
damage the tissue surrounding the tooth and lead tooth loss
8,22
. The main objective of periodontal 
tissue engineering is to regenerate the tooth’s supporting tissues. Periodontal tissue regeneration 
involves formation of new connective tissue (cementum and periodontal ligament) and new alveolar 
bone. The restoration of tooth by using a titanium dental implant is nowadays a quite common 
procedure
5
. However, the positive fate of a surgical procedure that involves an insertion of titanium 
screw depends on the quality and quantity of alveolar bone which is present in the extraction site
6
. 
Conventional procedures involve the debridement of the infected site and the use of a bone graft 
material and GTR membranes aimed at promoting new alveolar bone formation and soft tissue 
restoration
97
. Autogenous grafts are considered the current gold standard bone replacement graft 
materials
166
. However, the main complication is that they require a second surgery and it is 
important to consider the possible donor site complications such as infection and pain. On the other 
side, allografts from a donor of the same species could be a source of disease transmission and 
could stimulate a foreign body reaction
167
. In the last decades, the use of synthetic materials has 
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aroused great interest, in particular synthetic ceramic materials such as tricalcium phosphate and 
hydroxyapatite have been used for their good reproducibility, biocompatibility, and non-
immunogenicity, but especially because of their similarity to the components of the native bone 
mineral phase
168
. However, the commercially available products work well as bone graft materials 
in order to promote bone regeneration but they have not effect against possible re-infections. 
Periodontal defects are usually due to periodontitis and the probability of a new re-infection, around 
the titanium implant or before placing it, is high. Hence, it is important to not only promote new 
bone regeneration, but also to control the bacterial contamination and the possible peri-implantitis 
or periprosthetic infection (PPI). Whereas peri-implantitis are usually due to an infection which 
follows a previous periodontitis, PPI could may be also due to a nosocomial infection or to the 
natural function of the oral cavity which is full of bacteria. Titanium implant surface is a perfect 
field on which the bacteria could grow fast and form a biofilm which is hard to eliminate and leads 
to the implant failure
117
. Conventional therapy to control infection of the wound site involves the 
use of an antibiotic treatment via systemic delivery during the regeneration time
100
. Classical 
antibiotic therapy is not effective in the control of the infection, mainly due to a specific adhesion of 
bacteria on the biomaterials and to the very low penetration of the antibiotic into the osseous defect. 
Furthermore, in order to achieve an effective dosage in the defect site, a prolonged and high 
delivery dosage via systemic administration, which could generate renal disease, is necessary.  
The main objective of this doctoral thesis is to develop a set of novel biomaterials, designed to 
improve periodontal bone regeneration in patients and to control or prevent the bacterial infection in 
the wound site, via a sustained in situ drug release. The PhD thesis was conducted in the R&D 
department of Nobil Bio Ricerche srl (NBR), a biomedical company founded in 1994 and located in 
Portacomaro, in the Italian region of Piemonte. NBR is involved in the bone-contacting medical 
devices area and its core business is the surface treatment and packaging of titanium dental 
implants. Costumers are small to medium-size companies that produce dental implants and operate 
in the market of dental devices. NBR treated, last year, about 400.000 dental implants, serving more 
than 30 different producers from Italy and other West European countries. Beside acting as a 
provider to dental implant producers, the company developed and market a bone filler for oral 
surgery and it is developing several other biomaterials, in particular focusing on biomimetic 
materials in order to achieve an excellent bone regeneration and a prevention/control of infections. 
Materials developed are based on a combination of synthetic and natural materials. 
Materials developed during the Doctoral research period are based on β-tricalcium  phosphate and 
hydroxyapatite, used as osteoconductive ceramic materials to produce porous scaffolds or particles, 
since they are widely used as material in bone regeneration and many works have assessed they 
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efficacy in bone regeneration during in vivo studies
169–172
. These hard materials were coupled with 
natural polysaccharides, pectin and chitosan. Pectin and chitosan are nontoxic natural 
polysaccharides that have aroused great interest in the last years in tissue engineering, for their 
ability to crosslink by means of intermolecular interactions, and to form stable and biocompatible 
complexes which may simulate the extracellular matrix and interact with cells from the surrounding 
tissues
173,174
. Pectin is already widely used in food industry but, in the last decades, it has found 
such application in bone tissue engineering, in particular as a drug carrier. Chitosan is a widely used 
material and, owing to its biocompatibility, its intrinsic antibacterial nature, its ability to not induce 
a foreign body reaction and to promote cell adhesion, proliferation and differentiation, it finds many 
applications, especially in bone tissue engineering.  
Three different materials have been developed and characterized: 
 
1. Three-dimensional porous scaffold coated with a polyelectrolyte complex for periprosthetic 
infection prevention 
2. Bioceramic-reinforced hydrogel for alveolar bone regeneration 
3. Antiadhesive guided tissue regeneration membrane  
 
The first project was aimed to develop a complex system in order to prevent periprosthetic infection 
(PPI) in large bone defects. PPI is a consequence of implant insertion procedures and strategies for 
its prevention involve either an increase in the rate of new bone formation or the release of 
antibiotics such as vancomycin. Modern surface-engineering approaches allow combining these 
strategies: in this work, a novel three-dimensional porous scaffold produced using HA and β-TCP, 
coupled with pectin (PEC)-chitosan (CHIT) polyelectrolyte (PEI), and loaded with vancomycin 
(VCA) was developed and characterized.  
The osteointegration of dental implants and the consequent long-term success is guaranteed by the 
presence, in the extraction site, of a healthy and sufficient alveolar bone
6,7
. Placement of titanium 
implants is contraindicated until a vertical bone augmentation is obtained. This goal is achieved 
using bone graft materials, which should simulate extracellular matrix (ECM), in order to promote 
osteoblast proliferation and fill the void, maintaining the space without collapsing until the new 
bone is formed. The goal of the second project was to design, develop and characterize a novel 
chitosan-pectin hydrogel reinforced with biphasic calcium phosphate particles within 100-300 µm. 
The polysaccharide nature of hydrogels simulates the ECM of natural bone, and the ceramic 
particles promote high osteoblast proliferation. Furthermore, the mouldability of the scaffold allows 
its easy use in highly irregular defects, too.  
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Melcher’s hypothesis175 assesses that an excellent periodontal regeneration could be achieved if the 
epithelial and fibroblast cells were excluded from the root site, where stimulating the migration of 
pre-osteoblast cells is very important. On the basis of this hypothesis, many guided tissue 
membranes, resorbable and non-resorbable, have been developed in the last years. The gold 
standard ePTFE membrane has the great disadvantage that it makes a second surgery to be 
necessary, while on the other side the resorbable membranes currently available showed an 
unpredictable resorption time and consequent unpredictable periodontal regeneration
176,177
. In the 
third project, we developed a biomimetic GTR membrane, using a polyelectrolyte complex bulk 
material and coated with an antiadhesive hyaluronic acid. In this way, we hypothesized to control 
the regeneration of soft tissue on the membrane surface avoiding the cells down growth, and the 
stability of the PEI complex could sustain the tissue and could make the regeneration of the tissues 
predictable. Furthermore, the swelling behavior of the materials allows the membrane to act as a 
bearing and reduces the possible inflammation response of the surrounding tissues.  
The main results about these three projects are shown in the following sections. Since the research 
work was conducted in the R&D department of NBR company, several other projects have been 
developed and are under developing, in the field of biomaterials for periodontal regeneration, 
however the results will not be shown in this thesis.  
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CHAPTER IV  
 
RESEARCH AND DEVELOPMENT  
4.1  MATERIALS 
4.1.1 Treatment of periprosthetic infection using an engineered porous scaffold 
4.1.1.1 Materials 
In this work we designed, developed and characterized a macroporous ceramic scaffold, 
functionalized with a polyelectrolyte coating loaded with vancomycin. β-tricalcium phosphate (β-
TCP), chitosan (CHIT) with medium molecular weight (Mw = 400 kDa) from crab shell, pectin 
(PEC) from citrus peel, vancomycin (VCA) and all other chemicals were purchased from Sigma-
Aldrich. Hydroxyapatite (HA) was purchased from Fluidinova (Portugal) and the dispersing agent 
Dolapix CE 64 was purchased from Zschimmer&Schwarz (Germany). 
4.1.1.2 Three-dimensional porous scaffold preparation 
HA was used because of its ability to enhance the mechanical strength of the scaffold, while β-TCP 
because of its degradability; they were mixed in a percentage of 25 wt.% and 75 wt.%, respectively, 
to reach an optimum compromise between the two properties. Briefly, the preparation of the 
ceramic scaffolds involved the mixing of the HA and β-TCP powders (45 wt.%) with a binding 
agent (poly(vinyl alcohol), 8 wt.%), and ultrapure water (47 wt.%) to obtain a ceramic slurry. 
Dolapix CE 64 was added as a dispersing agent (0.5 wt.% of the solid load). Polyurethane (PU) 
sponge impregnation method was used to obtain macroporous ceramic scaffolds
1,2
. A commercial 
PU sponge cube (45 ppi) of 11x11x11 mm
3
 was soaked into the ceramic slurry for 90 s, followed by 
compression along the three spatial directions (20 kPa), until 30% of height and left at room 
temperature for 5 min before repeating the cycle. Impregnation/compression cycles were repeated 
for 3 times. The ceramic-coated PU sponge was left to dry overnight at 37 °C and then sintered in a 
furnace at 1150 °C for 12 h in air (heating rate 5 °C/min), in order to obtain a porous HA/βTCP 
scaffold of 10x10x10 mm
3
 (a volumetric retention of 24% was calculated). 
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4.1.1.3 Engineered coating preparation 
Pectin powder was dissolved in a concentration of 1% in acetate buffer (pH 5.5); then, in the same 
solution, 1% of vancomycin was dissolved. Separately, chitosan 0.5% powder was dissolved in 
acetate buffer (pH 5.5). The coating process involves two steps of immersion. In the first step, the 
sintered ceramic scaffold was immersed in the pectin-vancomycin (PEC-VCA) solution for a 
defined time (60 s). In this step, pectin polyanionic polysaccharides were crosslinked on the surface 
of the ceramic scaffold due to the Ca
2+
 ions released from the scaffold; then, the clad material was 
freeze-dried overnight and a HA/βTCP_PEC/VCA scaffold was obtained. The first step allows 
obtaining a pectin-vancomycin coating with a mass of 7.24 ± 1.77 mg, of which 5.04 ± 0.31 mg of 
vancomycin (calculated from HPLC release studies). In the second step, the HA/βTCP_PEC/VCA 
scaffold was immersed for 30 minutes in a chitosan solution: a polyelectrolyte was generated from 
polycationic chitosan and polyanionic pectin. The construct was then freeze-dried overnight and a 
final material called HA/βTCP_PEC/VCA_CHIT was obtained. The coating process was evaluated 
on 20 samples and showed to be repeatable with a final mass value of 11.07 ± 1.7 mg. 
4.1.2 Novel bioceramic-reinforced hydrogel for alveolar bone regeneration 
 
4.1.2.1 Materials 
In this work, a chitosan/pectin hydrogel reinforced with biphasic calcium phosphate particles was 
designed, developed and characterized. β-tricalcium phosphate (βTCP), chitosan with medium 
molecular weight from crab shell (Mw = 400 kDa), pectin from citrus peel and all other chemicals 
were purchased from Sigma-Aldrich. Hydroxyapatite (HA) was purchased from Fluidinova. 
4.1.2.2 Preparation of calcium phosphate particles 
 
HA and β-TCP were mixed in a percentage of 25 wt.% and 75 wt.% respectively, on the basis of a 
previous study by Morra et al.
3
. Briefly, the preparation of the ceramic slurry involved the mixing 
of the HA and β-TCP powders (31 wt.%) in ultrapure water (69%). Guar gum was previously 
dissolved in ultrapure water (3% wt.% of the water content), acting as a pore forming. The slurry 
was then desiccated in oven at 80 °C for 8 h and then shaped in circular disks using a hydraulic 
press (Mignon EA/SSN) with a pressure of 17.5 MPa for 10 s. The ceramic disks were then sintered 
in a furnace at 1100 °C for 1 h in air (heating rate 1 °C/min)
3
. Sintered disks were ground in 
particles using a grinder machine (GM200, Retsch) and the resulting ceramic powder was sieved in 
order to obtain a range of particles between 100 and 300 µm. The biphasic calcium phosphate 
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particles obtained were washed in ultrapure water and desiccated overnight at room temperature 
under laminar flow.  
4.1.2.3 Preparation of composite hydrogel 
Pectin powder (P) was dissolved in a concentration of 7% wt. in acetate buffer (pH 5.5); in the same 
solution chitosan powder (C) was added to obtain a chitosan solution of 4% wt. and a 
pectin/chitosan rate of 20/80. The solution was kept under stirring for 6 h, then it was centrifuged 
and the polyelectrolyte (PEI) precipitated was collected. PEI complex (10 % wt.) was mixed using a 
Thinky Mixer (Retsch) with HA/βTCP particles (90% wt.). The resulting slurry was poured in a 
circular shape polyester mold and freeze-dried with Lyo5P for 12 h, at 0.06 mbar and -56 °C in 
order to obtain pectin/chitosan_ceramic particles (PCC) composite hydrogel. For the 
pectin_chitosan based hydrogel (PC), we poured the PEI solution in a circular polyester mold, and 
freeze-dried with Lyo5P for 12 h, at 0.06 mbar and -56 °C. 
4.1.3 Novel pectin/chitosan guided tissue regeneration membrane coated with hyaluronic 
acid 
 
4.1.3.1 Materials 
Chitosan (C) with medium molecular weight (Mw = 400 kDa) from crab shell and pectin (P) from 
citrus peel, were purchased from Sigma-Aldrich. Hyaluronic acid (HyA) with medium molecular 
weight were purchased from HTL Biotechnology. 
4.1.3.2 Preparation of pectin/chitosan-hyaluronic acid membrane 
 
 
Pectin powder was dissolved in a concentration of 7% wt. in acetate buffer (pH 5.5); in the same 
solution, chitosan powder was added in order to obtain a chitosan solution of 4% wt. and a 
pectin/chitosan rate of 20/80. The solution was kept under stirring for 6 h, then it was centrifuged 
and the polyelectrolyte (PEI) precipitated was collected. The resulting slurry was poured in a 
rectangular polystyrene mold and freeze-dried with Lyo5P for 12 h, at 0.06 mbar and -56 °C in 
order to obtain pectin/chitosan membrane (PCm). Pectin/chitosan membranes were soaked in a 
solution of hyaluronic acid 0.1% w/w for 2 h and crosslinked using ionic interaction between 
carboxylic group of  hyaluronic acid and amine group of chitosan.  The resulting material was re-
lyophilized for 12 h, at 0.06 mbar and -56 °C, in order to obtain an antiadhesive surface (PCmHyA). 
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4.2  METHODS 
The following paragraphs describe the procedures and protocols used to characterize the materials 
developed. At the end of the section, a table summarizes which test has been performed for each 
research work. 
4.2.1 Chemical characterization 
ATR-IR 
Attenuated total reflectance infrared spectroscopy analysis were performed using a Nicolet iS 10 
ATR-IR spectrometer, produced by Thermo Scientific and equipped with a diamond crystal. 
Samples to be analyzed were placed on the crystal and kept in place by the specific crimping tool. 
Experimental setup was conducted by acquisition of 32 scans in the range of 500 – 4000 cm-1, with 
a resolution of 4 cm
-1 
 
XPS 
X-Ray photoelectron spectra were obtained using a Perkin Elmer PHI 5400 ESCA system, equipped 
with a Mg anode operating at 10 kV and 200 W. Base pressure was 10
-8
 Pa and the diameter of the 
analyzed spot 2 mm. A wide range survey spectra was acquired from 0 to 1000 eV of binding 
energy, and detailed high resolution peaks of relevant elements were also collected. Quantification 
of elements was performed using the software and sensitivity factors were supplied by the 
manufacturer. Samples were fixed to the instruments sample holder on one side, while 
measurements were performed on the other side. 
 
XRD 
Phase analysis was conducted using X-ray diffraction (XRD, X’Pert Philips, Cu Kα radiation) 
during a preliminary study to detect phase composition and phase transformation of the HA/βTCP 
mix after the sintering process at two different temperatures, in order to decide which processing 
temperature was the optimal. The test was carried out on the material powder at room temperature. 
4.2.2 Structural characterization 
 
SEM 
Scanning Electron Microscopy (SEM) analysis was performed to analyze the morphology of porous 
scaffolds. The samples were mounted on the aluminum stubs and sputtered with gold at 15 mA for 
2 min using Agar Sputter Coater. The morphology of samples was captured using a scanning 
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electron microscope using EVO MA10 system (Zeiss) equipped with a micro-analysis system 
AZTec (Oxford University UK). The quantitative investigation of the organic surface layer on the 
ceramic scaffold, was performed with the Energy Dispersive X-ray spectroscopy (EDX) system. 
µCT 
The microstructure of the scaffold was studied in a nondestructive manner by micro-computed 
tomography (µ-CT), with a desktop μ-CT scanner (SkyScan 1174, Aartselaar, Belgium). The 
scanner was set at a voltage of 50 kV and a current of 800 μA, and the sample was scanned at 9.23 
µm pixel resolution.  
For the ceramic porous scaffold the exposure time per projection was 10000 ms and an aluminum 
filter of 720 µm was used. The samples scanned had a size of 10x10x10 mm
3
.  
For the composite hydrogel, the exposure time per projection was 2300 ms and no filter was used. 
The sample had a cylindrical size of 10mm of diameter and 10mm of height. Imaging analysis were 
conducted using the CT-Analyzer software, reconstructing 2D tomographic raw images. No 
contrasting agent was used. Imaging analysis were conducted using the CT Analyzer software, 
reconstructing 2D tomographic raw images. The threshold levels of the grayscale images were 
equally adjusted for all the samples to allow the measurement of the porosity. 
4.2.3 Physical characterization 
Swelling study 
For investigating the hydration kinetic, the samples  (10mm diameter, 2 mm thickness, three for 
each case studied) were allowed to swell in different solutions (pH of 2.5, 5.5 and 7.4 for composite 
hydrogel and pH of 7.4 phosphate buffered saline solution (PBS) for GTR membrane), after 
recording the initial weight (W0) at 37 °C. The swollen disks were taken out of the solution at 
regular time intervals, blotted with filter paper to remove excess surface water, and their swollen 
weights (Ws) were noted. The water uptake by the network was determined by the following 
equation: 
Hydration Degree (%) = [(Ws – W0)/Ws] x 100   (1)  
Degradation study 
The stability of the samples was analyzed at different pH (2.5, 5.5 and 7.4 for composite hydrogel, 3 
and 7.4 for the porous ceramic scaffold and 7.4 PBS for GTR membrane) at 37 °C. The samples, 
three for each type, were cut in a cylindrical or cubic shape (10 mm of diameter and 2 mm of 
height; or 1x1x1 cm
3
) and immersed in different solutions, after recording their initial weight (W0). 
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During the degradation study, samples were taken out at specific time intervals, freeze-dried and 
weighted (Wf). The mass loss percentage was calculated using the following equation: 
Mass Loss (%) = [(W0 – Wf)/W0] x 100   (2) 
 
Solution at pH 2.5: 100 g of potassium dihydrogen phosphate were dissolved in 800 ml of ultrapure 
water; the pH was adjusted to 2.5 with hydrochloric acid and sufficient water to produce 1000 ml.  
 
Buffer Solution at pH 3: was prepared following the instruction reported in ISO 10993-14:2001 
(“Biological evaluation of medical devices: Identification and quantification of degradation 
products from ceramics”). 21 g of citric acid monohydrate were dissolved in 500 ml of ultrapure 
water in a 1000 ml volumetric flask, then 200 ml of sodium hydroxide 1 M was added and the 
solution diluted to the mark with water; 40.4 ml of this solution were mixed with 59.6 ml of 0.1 M 
hydrochloric acid. 
 
Solution at pH 5.5: 0.49 g of sodium phosphate dihydrate, 13.8 g of potassium phosphate and 0.49 
g of sodium chloride were dissolved in 1000 ml of ultrapure water. 
 
Solution at pH 7.4: 0.78 g of sodium phosphate dihydrate, 0.097 g of potassium phosphate and 4 g 
of sodium chloride were dissolved in 500 ml of ultrapure water. 
 
Buffer solution at pH 7.4: was prepared following the instruction reported in ISO 10993-14:2001 
(“Biological evaluation of medical devices: Identification and quantification of degradation 
products from ceramics”). TRIS-HCl solution was prepared by dissolving 13.25 g of 
tris(hydroxymethyl) aminomethane in 500 ml of water; pH 7.4 was reached adding an appropriate 
amount of hydrochloric acid 1 M. 
 
Dulbecco’s Phosphate Buffered Saline solution (PBS): was purchased from Gibco® by Life 
Technologies (Life Technologies Corporation, Paisley, UK). 
 
High performance liquid chromatography 
A release study was performed using High Performance Liquid Chromatography (Shimatdzu LC 
2010 AHT equipped with Diode array Shimadzu SPD-M10AVP) technique. Three specimens 
(10x10x10 mm size) for each sample were immersed in PBS solution at 37 °C for 1 week. At each 
time point, samples were taken out and immersed in fresh PBS solution. The releasing solution was 
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then filtered with 0.2μm cellulose acetate filters and analyzed using a low pressure gradient method, 
with a mobile phase made-up by 5 mM ammonium acetate in 0.5 % glacial acetic acid in water and 
5 mM ammonium acetate in 0.5% glacial acetic acid in acetonitrile. We used a C18 Kinetex reverse 
phase column (Phenomenex, Torrance, USA) with a flow rate of 1 ml/min and an injection volume 
of 20 µl. Vancomycin peak was analyzed at 280 nm. 
The amount of vancomycin released was calculated from a linear regression curve (from 0.025 
mg/ml to 2.5 mg/ml) with R
2
>0.999. 
4.2.4 Mechanical characterization  
Mechanical characterization was performed using a Bose ElectroForce 5500 equipped with 100 N 
load cell. 
Compressive test 
For porous ceramic scaffolds, samples were tested in a cubic shape of 10 mm gauge length, 10 mm 
of width and 10 mm of thickness, and tested until failure, with a crosshead speed of 1 mm/min.  
For composite hydrogel, samples were cut in a circular shape with 10 mm of diameter, and 10 mm 
of gauge length, with a constant crosshead speed of 1 mm/min. The mechanical properties were 
performed in both dry and hydrated conditions (soaked in PBS at 37 °C for 24 h). For the composite 
hydrogel, during preliminary tests no sample could reach a failure, so we decided to perform the 
compressive test until 40% of the height of the sample which was considered a sufficient value to 
see elastic and plastic deformation of the samples. 
Force-displacement curves obtained from the software-machine, were converted to stress-strain 
curves. Stress (σ, MPa) was obtained by dividing the applied force (N) with the cross section area 
(mm
2
), while strain was obtained from the displacement using ((L-L0)x100/(L0)), where L0 was 
initial gauge length and L was instantaneous gauge length.  
For porous ceramic scaffolds the 5-15% of strain region was used to measure the modulus of 
samples and instantaneous drop in more than 20% stress was considered as a fracture point.  
For composite hydrogels, the elastic modulus was calculated in the linear region between 0.5% to 5 
% of strain, and the stress at 40% of strain was related as maximum elastic stress. The area under 
the stress-strain curve was calculated and related to the toughness of the sample. 
 
Cyclic compressive stress 
For cycling testing, 100 loading and unloading cycles were performed. A first load until 16% of 
initial height was performed and then a sinus cyclic curve with a frequency of 0.5 Hz and a constant 
crosshead speed of 1.2 mm/min was performed between 16 and 41% of initial height. Stress-strain 
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curve was reported and the amount of energy adsorbed and percentage recovered during the 
deformation cycle were calculated every 10 cycles. 
 
Tensile test 
Soft membranes were cut in a rectangular shape with 20 mm gauge length, 2 mm width and a 
thickness around 2 mm. The mechanical properties were tested in both as-prepared (dry) and 
hydrated conditions (soaked in PBS for 10 min). For the uniaxial tensile test, samples were 
stretched until failure (or until the maximum displacement of the testing machine) at the crosshead 
of 0.2 mm/s. Force-displacement curves, obtained from the machine, were converted to stress-strain 
curves. The stress (σ, MPa) was obtained by dividing the applied force (N) with cross section area 
(mm
2
) and strain was obtained from the displacement using ((L-L0) x 100/(L0)), where L0 was the 
initial gauge length and L was instantaneous gauge length. Young’s Modulus was calculated in the 
linear stress-strain region by fitting a straight line. 
 
Suture retention test 
A suture retention test was performed on soft membranes and the protocol setup of 
ANSI/AAMI/ISO 7198:1998/2001/(R) 2004 “Cardiovascular implants-tubular vascular prostheses” 
was followed. In accordance with it, the suture was carried out at 2 mm from the side of the sample, 
the crosshead speed is fixed at 1 mm/s, and the amplitude of analysis was fixed at the maximum of 
the machine, 12 mm. Force-displacement curves obtained from the machine were converted to 
stress-strain curves. The stress (σ, MPa) was obtained by dividing the applied force (N) with cross 
section area (mm
2
) and strain was obtained from the displacement using ((L-L0) x 100/(L0)), where 
L0 was the initial gauge length and L was instantaneous gauge length. Suture retention strength was 
defined as fracture strength during the process test.  
 
4.2.5 Biological characterization 
 
Antibacterial properties 
The strain S. epidermidis RP62A (ATCC 35984) used in this study is a slime and capsular 
polysaccharide producer. It was routinely maintained on both tryptic soy agar (TSA, Sigma) plates 
and monthly transferred to new plates and as frozen suspension in liquid culture medium 
supplemented with 10% glycerol. The bacterial suspension was obtained by inoculating 100 ml 
tryptic soy broth (TSB, Sigma) and incubating overnight at 37 °C. After overnight incubation, the 
suspension was washed three times with PBS, and finally re-suspended in PBS.  PBS used for this 
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experiment has the following composition: 0.2gl
-1
 KCL, 0.2 gl
-1
 KH2PO4, 8.0 gl
-1
 NaCl, 1.15 gl
-1
 
Na2HPO4 with pH at room temperature = 7.3 ± 0.3 and osmolality (mOsm kg
-1
 H2O) = 290 ± 5%. 
The bacterial suspension, according to previous experiments, was spectrophotometrically adjusted 
to the optical density required to obtain 1x10
9 
colony forming units [(CFU)ml
-1
]. 
 
Serial bacterial dilution 
For the serial dilution test, 5 ml of bacterial suspension were poured in 6-wells plate (Greiner) 
containing a total of two replicates for each sample, for each time point (0 h, 24 h and 1week). The 
bacterial suspension was then incubated with samples for 2 h at 37 °C. The number of viable CFU 
in the inoculum was determined by spreading 0.1 ml portions from the serial tenfold dilutions of 
bacterial suspension on TSA. CFU were counted after 48 h of incubation at 37 °C. At the end of the 
incubation time, samples were carefully rinsed with sterile PBS in order to remove loosely adherent 
bacteria, and were then sonicated for 10 min in 3 ml of PBS. Previous experiments have shown that, 
by this way, it is possible to achieve a complete detachment of all bacterial cells from the 
specimens. The number of viable CFU was evaluated by spreading portions of 0.1 ml from the 
serial tenfold dilutions (four dilutions and three replicates each) of suspension on TSA plates. Also 
in this case, CFU counting was performed after 48 h of incubation at 37 °C. 
 
Bacteria adhesion test 
For adhesion experiments, 5 ml of bacterial suspension were poured in 6-wells plates (Greiner) 
containing a total of two replicates for each sample, for each time point (0 h, 24 h and 1week). The 
bacterial suspension was incubated with the samples for 2 h at 37 °C. After incubation time, 
samples were carefully rinsed with PBS in order to remove non-adherent bacterial cells, then were 
fixed in 5% glutaraldehyde – PBS solution and dehydrated using increasing concentration of 
ethanol in water–ethanol solutions up to 100% ethanol. Dehydrated samples were gold sputter-
coated (AGAR Sputter Coater) and observed with an EVO MA10 (Zeiss) scanning electron 
microscope (SEM) equipped with a micro analysis system AZTec (Oxford University UK). 
Adherent bacteria on each replicate were counted in five different fields and reported as percentage 
of analyzed area. 
 
Inflammatory response: TaqMan Real-Time PCR 
The murine macrophage cell line J774.2 (European Collection of Cell Cultures) was maintained in 
Dulbecco’s modified Eagle’s medium (Gibco Invitrogen, Cergy-Pontoise, France) supplemented 
with 10% fetal bovine serum, penicillin (100 U ml
−1
), streptomycin (100 μg ml−1) and 4 mM l-
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glutamine. Cells were grown in a 100% humidified incubator at 37 °C with 10% CO2 and passaged 
2–3 days before use. The J774.A1 cells (2 × 104 ml−1) were seeded into 6-wells tissue culture 
polystyrene plates (9.6 cm
2
 of growth area; Falcon™) containing the samples. 
After 4 h, RNA was isolated from J774.A1 cell line using the MagMax-96 Total RNA Isolation Kit 
(Life Technologies) and then reverse-transcribed using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems), according to the manufacturer’s instructions. Total RNA 
concentration was then measured by using a Spectrophotometer (UV-1700, Shimadzu) and RNA 
quality was assessed by evaluating A260/A280 ratio ranging from 1.8 to 2.1. Real-time PCR was 
performed with the TaqMan Gene Expression Master Mix (Applied Biosystems) with the Applied 
Biosystems StepOne Plus instrument (Applied Biosystems). The primer sets for the Real-time PCR 
of mouse interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10), monocyte chemotactic 
protein-1 (MCP-1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Applied 
Biosystems Assay’s ID: Mm01336189_m1, Mm99999056_m1, Mm99999062_m1, 
Mm99999056_m1, Mm03302249_g1 respectively) were chosen from the collection of the TaqMan 
Gene Expression Assays (Applied Biosystems). The analysis was conducted using the method of 
Comparative CT (ΔΔCT), which was designed following the manufacturer’s instructions.   
 
Osteoblast – like cell culture 
Osteoblast-like SaOS-2 cells were used for the cell growth experiments. Experimental cell culture 
medium (BIOCHROM KG, Berlin) consisted of Minimum Eagle's Medium without l-glutamine, 
10% fetal bovine serum, streptomycin (100 μg/l), penicillin (100 U/ml), and 2 mmoles/l l-glutamine 
in 250-ml plastic culture flask (Corning™). Cells were cultured at 37°C in a humidified incubator 
equilibrated with 5% CO2. Cells were harvested prior to confluence by means of a sterile trypsin-
EDTA solution (0.5 trypsin g/l, 0.2 g/l EDTA in normal phosphate buffered saline, pH 7.4), re-
suspended in the experimental cell culture medium, and diluted to 1×10
5
 cells/ml. For experiments, 
5 ml of the cell suspension were seeded into 6-well tissue culture polystyrene plates (9.6 cm
2
 of 
growth area; Falcon™), containing the samples. Experiments were performed in triplicate. For 
SEM analysis, at the selected time point, samples were carefully rinsed with PBS and fixed in 5% 
glutaraldehyde-PBS. Samples were dehydrated using increasing concentration of ethanol in water-
ethanol solutions up to 100% ethanol. Dehydrated samples were gold sputter-coated (AGAR 
Sputter Coater). Scanning electron microscopy (SEM) was performed using an EVO MA10 (Zeiss), 
equipped with a micro-analysis system AZTec (Oxford Instruments, UK).  
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The expression of  Collagen (COLL1A1); Osteopontin (OPN); Osteocalcin (OCN); Runt-related 
transcription factor 2 (RUNX2); Alkaline Phosphatase (ALP) and Osteonectin (SPARC)  genes as 
cell proliferation, differentiation and mineralization markers, was assessed using the real time 
reverse transcription polymerase chain reaction (qRT-PCR). Osteoblast –like SaOS-2 cells were 
cultured as previously described and the total RNA was extracted using MagMax Total RNA 
Isolation Kit (Applied Biosystems, Milan, Italy) following the manufacturer’s instruction. RNA 
quality was assessed by checking the A260/A280 ratio (1.6 – 2.0). Then, total RNA was used as a 
template for cDNA synthesis using random hexamers as primers and the MultiScribe® Reverse 
Transcriptase (high capacity cDNA RT Kit from Applied Biosystems). cDNA amplification and 
relative gene quantification were performed using TaqMan probe and primers from Applied 
Biosystems (Hs 00164004_m1, COLL1A1; Hs 00960641_m1, OPN; Hs 00609452_m1, OCN; Hs 
01047976_m1, RUNX2; Hs 01029144_m1, ALP; Hs 00234160_m1, SPARC). Real time PCR was 
performed in duplicate for all samples and targets on a Step-One instrument (Applied Biosystems). 
PCRs were carried out in a total volume of 20 µl and the amplification was performed as follows: 
after an initial denaturation at 95 °C for 10 min, the PCR was run for 40 cycles at 95 °C for 15 s and 
at 60 °C for 1 min. To normalize the content of cDNA samples, the comparative threshold (Ct) 
cycle method, consisting on the normalization of the number of target gene copies versus the 
endogenous reference gene GAPDH, was used. The Ct is defined as the fractional cycle number at 
which the fluorescence generated by cleavage of the probe passes a fixed threshold baseline when 
amplification of the PCR product is first detected. For comparative analysis of gene expression, data 
were obtained using ΔCT method.  
 
Fibroblast cell culture and adhesion test 
Fibroblast L929 was used in the cell adhesion experiments. Experimental cell culture medium 
(BIOCHROM KG, Berlin) consisted of Minimum Eagle’s Medium without L-glutamine, 10 % fetal 
bovine serum, streptomycin (100 g/l), penicillin 100 U/ml, and 2 mmol/l L-glutamine in 250 ml 
plastic culture flask (Corning TM). Cells were cultured at 37 °C in a humidified incubator 
equilibrated with 5 % CO2. Cells were harvested prior to confluence by means of a sterile trypsin-
EDTA solution (0.5 g/l trypsin, 0.2 g/l EDTA in normal phosphate buffered saline, pH 7.4), re-
suspended in the experimental cell culture medium, and diluted to 1 x 10
5 
cells per ml. For 
experiments, 5 ml of the cell suspension were seeded into six-well tissue culture polystyrene plates, 
containing the samples (GTR membranes). Experiments were performed in triplicate, at two 
different time points (24 h and 1 week). To evaluate cell adhesion, cells were seeded at a given 
density on test samples. At given time intervals, 24 h and 1 week, DNA quantification was 
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performed, by removing samples from the wells, rinsing with PBS and placing them in another 
multiwall plate. The total DNA was extracted after 1 week using MagMax Total DNA Isolation Kit 
(Applied Biosystems, Italy) following the manufacturer’s instruction, and the absorbance at 260 nm 
proper of DNA material was detected.  
Cytotoxicity test was performed using neutral red assay. Briefly, it is based on the ability of viable 
cells to incorporate and bind the supravital dye neutral red in the lysosomes. The samples after 24 h 
and 1 week of fibroblast cells culture, were incubated for 2 h with a medium containing neutral red, 
and subsequently washed with ultrapure water. The stained cells were visualized using an inverted 
microscope in a standard mode (Leica DMI 4000 B, Germany). 
 
Statistical analysis 
Experimental data were presented as mean ± standard deviation. Statistical differences between 
samples were analyzed using two-way ANOVA using Tukey’s multiple comparison test, one-way 
ANOVA using Tukey’s analysis and Student’s t-test. Statistical significance was represented as 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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4.3  SUMMARY OF THE TESTS PERFORMED 
 
SAMPLE ATR-IR XPS EDX XRD 
Engineered scaffold x x x x 
Composite hydrogel x  x x 
GTR Membrane x x   
 
SAMPLE µCT SEM 
Engineered scaffold x x 
Composite hydrogel x x 
GTR Membrane  x 
 
SAMPLE Release study Swelling study Degradation study 
Engineered scaffold x  x 
Composite hydrogel  x x 
GTR Membrane  x x 
 
SAMPLE 
Compressive 
test 
Tensile 
test 
Compressive 
cycle test 
Suture retention 
stress test 
Engineered scaffold x    
Composite hydrogel x  x  
GTR Membrane  x  x 
 
SAMPLE Antibacterial 
properties 
Inflammation 
gene expression 
Osteoblast-like 
cell culture 
Fibroblast 
cell culture 
Engineered scaffold x x x  
Composite hydrogel  x x  
GTR Membrane    x 
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4.4 TREATMENT OF PERIPROSTHETIC INFECTION USING AN 
ENGINEERED POROUS SCAFFOLD 
 
 
Figure 6. Graphical abstract of engineered scaffold developed. 
 
4.4.1 Introduction 
Coupling bone graft and titanium implants is still one of the best available solutions to replace bone 
and dental tissue loss. In particular, in large defects, where the residual bone is not enough to ensure 
stability for the implant, the insertion of a so-called bone filler material is often necessary. This kind 
of surgical approach promotes bone formation and gives stability, guiding bone regeneration around 
the implant. Many of these procedures are successful, with an implant survival rate greater than 
90% at 10-15 years of follow-up
1–4
. Despite this success rate, in 1-5% of the procedures, the 
implant fails and must be removed
5,6
. The reason for this could be explained by the biomechanical 
issue on one side, due to an overloading at the bone implant surface
7–9
, and by the biological failure 
on the other side, associated with microbial plaque accumulation and bacterial contamination
10–12
. 
Current strategies for the prevention of PPI involve either an increase in the rate of new bone 
formation by graft material and systemic administration of antibiotics. In the last decades, the 
development of grafting materials has aroused great interest
13–15
. In particular, synthetic ceramic 
materials as tricalcium phosphate and hydroxyapatite have been used for their good reproducibility, 
biocompatibility, and non-immunogenicity, but especially because of their similarity to the 
components of the native bone mineral phase
16–18
. In large bone defects, completely filling the void 
and giving a sufficient mechanical resistance to the implant are the principal issues as they are a key 
factor for the induction of cell migration and proliferation inside the scaffold, in order to achieve a 
satisfactory osteointegration. The hydroxyapatite/β-tricalcium phosphate mix is one of the most 
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used biphasic materials for its great biocompatibility, good degradation rate and mechanical 
support
19
. Morra et al., in a recent work
20
, developed a new bone filler in particles, named 
Synergoss®, made with HA/βTCP in percentage of 25 wt.% and 75 wt.% respectively. In vivo 
studies demonstrated that this filler allows new bone formation, coupled with a compatible 
degradation rate
20
. The balance between HA and βTCP is a key point to obtain both mechanical 
strength and degradation, and to stimulate excellent osteointegration
21,22
. However, dentistry 
practices for large bone defects are expected to use three–dimensional (3D) porous scaffold, in 
order to fill large voids, to stimulate cell infiltration through interconnected pores and to increase 
mechanical stability for the immediate implant loading. The scaffold properties, alone, are not 
enough, in fact large bone defects are often the result of the removal of necrotic tissue or of a zone 
with an acute infection; furthermore, considering the natural function of the oral cavity which is  at 
the interface with a lot of bacteria, bacterial growth and re-infection of native bone are a strong 
possibility
23–25
. The traditional antibiotic therapy is not effective in the control of PPI, because of 
the bacteria specific adhesion on the biomaterials, and to the very low antibiotic’s penetration into 
the osseous defect
10,26,27
. Furthermore, systemic delivery of a high dose can causes systemic toxicity 
with associated renal and liver complications, resulting in the need for hospitalization for 
monitoring
3,28–30
. Development of a complex release system aimed at reducing infection and, at the 
same time, at promoting bone formation, could be a solution. Antibiotics used in drug release 
complexes should be effective against bacteria, as well as biocompatible and they should not 
damage the surrounding native tissues. Vancomycin is a widely used antibiotic that provides 
bactericidal activity against the most relevant germs and shows efficacy and biocompatibility in 
clinical use
31–33
. One solution is the combination of the ceramic material with a polymeric coating, 
which allows encapsulation of drugs and increases the biocompatibility, thus generating a 
biomimetic surface
13,34
. In particular, collagenous materials were used, since collagen is a key 
component of bone, is biocompatible and its degradation products are nontoxic
20
. Collagen is a very 
expensive component and, in order to obtain a stable surface functionalization without a faster 
degradation in vivo, a chemical crosslinking is needed, which implies the use of chemical 
compounds such as glutaraldehyde, which may cause cytotoxic effect on the surrounding tissues
35
. 
Pectin and chitosan are nontoxic natural polysaccharides that have aroused great interest in the last 
years in tissue engineering, due to their ability to crosslink by means of intermolecular interactions 
and to form stable and biocompatible complexes which may simulate the extracellular matrix and 
interact with cells from surrounding tissues
36–41
. Pectin is a natural anionic polysaccharide, a major 
component of citrus cell walls or apple peel by-product, consisting in a poly D - galacturonic chain 
with carboxyl groups, which could be ionically crosslinked by calcium ions (Ca
2+
) forming the so 
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called “egg box” structure. Furthermore, ionic interactions occur with polycationic polysaccharides, 
in order to form a well-known polyelectrolyte structure (PEI)
36
. Pectin is already widely used in the 
food industry and, in the last decades, it has found application in bone tissue engineering, in 
particular as a drug carrier
42–45
. The limit of pectin is its great water-solubility, which causes fast 
dissolution and, when used as a drug carrier, a burst release of the therapeutic molecules occurs. To 
overcome this problem, many research groups have been trying to combine pectin with other 
materials
46–51
. In particular, chitosan is a natural polycationic material that could form a stable 
polyelectrolyte composite in acidic environment when mixed with pectin. Chitosan derives from 
chitin, which can be extracted from crustaceous exoskeleton and is composed by β–(1,4)–
glucosamine and N-acetyl-D-glucosamine. Owing to its biocompatibility, its intrinsic antibacterial 
nature, its ability to not induce any foreign body reaction and to promote cell adhesion, proliferation 
and differentiation, chitosan has aroused great interest in tissue engineering and pharmaceuticals, 
founding many applications, especially in bone tissue engineering
39,40,52–54
. In this work, we 
developed and produced an engineered scaffold coupling inorganic and organic phases loaded with 
vancomycin, as a novel system to prevent and control periprosthetic infection in dental large bone 
defects. As inorganic phase, we used a highly porous 3D biphasic ceramic (25 wt.% of 
hydroxyapatite  and 75 wt.% of β-tricalcium phosphate). We hypothesized and demonstrated that 
the functionalization of the ceramic scaffold with a pectin-chitosan PEI coating allows the control 
of vancomycin release, inhibits bacterial proliferation and biofilm formation, stabilizes the 
degradation rate in physiological and acidic environment and promotes osteoblast proliferation 
without compromising the mechanical properties; moreover, gene expression results demonstrated 
that PEI treatment elicits anti-inflammatory responses. We therefore successfully manufactured a 
three dimensional construct that could prevent the generation of periprosthetic infection and 
promote new bone formation in large dental bone defects.   
4.4.2 Results and Discussion 
Calcium phosphate materials are widely used in bone and dental tissue engineering, since they are 
the principal compound of inorganic phase in native bone
15,20,55
. In particular, hydroxyapatite 
(Ca10(PO4)6(OH)2) is the most stable form of calcium phosphate and the most abundant component 
in bone, around 65%
56,57
. Many studies show osteoconduction stimulation coupled with good 
mechanical properties; therefore, the degradation rate of hydroxyapatite is very slow
58,59
. In this 
work, we decided to combine hydroxyapatite with β-tricalcium phosphate, in the percentage of 25 
% - 75 % respectively, in order to manage the degradation properties of the scaffold and to achieve 
a replacement by the host bone during implantation with a physiological rate. Preparation of the 
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three dimensional scaffold involved a three step process. In the first one, a polyurethane sponge was 
impregnated with a ceramic slurry in a properly manner and, after one night in oven to allow water 
to evaporate, it was sintered. In the second step, the ceramic porous scaffold was impregnated with 
a solution of pectin and vancomycin, lyophilized and, in the third step, it was soaked in a solution of 
chitosan to form a polyelectrolyte (PEI) on the surface of the material; the resulting material is 
called HA/βTCP_PEC/VCA_CHIT scaffold.  In this work, we compared this material with a 
ceramic porous scaffold (HA/βTCP), a ceramic porous scaffold impregnated with vancomycin 
(HA/βTCP_VCA) and a ceramic porous scaffold impregnated with a solution of pectin and 
vancomycin (HA/βTCP_PEC/VCA). 
4.4.2.1 Chemical characterization 
ATR-IR 
In order to control the preparation process of the ceramic scaffold and, in particular, the formation 
of the PEI complex on the surface, we performed different surface analysis. ATR-IR spectra 
reported in Figure 7 a confirm that all peaks belong to the inorganic material. In particular, 
spectrum of HA/βTCP sintered materials contained peaks from both hydroxyapatite and tricalcium 
phosphate. Typically, a peak at 1125 cm
-1
 belongs to tricalcium phosphate, while peaks at lower 
wavenumbers are typically associated with hydroxyapatite. Figure 8 a is a focus on triply 
degenerated asymmetric stretching mode (ν3) of the P-O bond of the phosphate group (1125 cm-1 
and 1025 cm
-1
-1010 cm
-1
)
60,61
. Figure 7 b shows spectra of pectin powder, chitosan powder, 
pectin/chitosan physical mixture, a pectin/chitosan polyelectrolyte complex and a HA/βTCP 
scaffold with a PEI functionalization. Pectin and chitosan show typical spectra of polysaccharides; 
in particular, the region between 3700 cm
-1
 and 3000 cm
-1
 for pectin and chitosan is assigned to the 
O–H stretching vibration (νOH), while the region between 3000–2800 cm-1 belongs to C-H 
stretching vibration (νCH) (Figure 8 b). Deeper analysis on pectin spectra show two bands 
associated with the stretching vibration at 1740 cm
-1
 of carbonyl group, corresponding to the methyl 
ester group (COOCH3) and carboxyl acid (COOH), while the band at 1606 cm
-1
 belongs to the 
stretching vibration of the carbonyl group of the carboxylate ion (COO
-
). Concerning chitosan 
spectra, the band at 1647 cm
-1
 is due to the C=O stretching vibration of amide I, whilst the band at 
1580 cm
-1
 is due to the NH bending amide II, maybe overlapped to the N-H vibration of the amine 
groups. (Figure 8 b).  
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Figure 7. ATR-IR spectra of raw materials and HA/βTCP scaffold (a) and of HA/βTCP_PEC/CHIT scaffold (b). 
 
The polyelectrolyte complex is formed and stabilized by the electrostatic interactions that occur 
between the positive charge of chitosan, NH3
+
, and the negative one of pectin, COO
-
 (Figure 8 b); 
amine band shift to 1557 cm
-1
 confirms the formation of a pectin-chitosan complex. A series of 
overlapping are also present in the PEI spectra, due to H-bonding interactions between COOH 
groups of pectin or NH2 groups of chitosan and OH or COOCH3 groups within the complex. Band 
assignment is consistent with available literature
36,38
. The most important observation is underlined 
by the spectra of the HA/βTCP_PEC/CHIT scaffold, where both bands, the one assigned to the PEI 
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complex and the other one belonging to the inorganic phase, are presents, in particular the band at 
1557 cm
-1
 and those between 950 cm
-1
 and 1140 cm
-1
, respectively (Figure 8 b). This analysis 
confirms the successful preparation of the materials, with a ceramic material functionalized with a 
polyelectrolyte on the surface. Furthermore, XRD analysis show that no phase transformation 
occurs at the sintering temperature (Figure 9 a, b, c). 
 
Figure 8. a) IR spectra of HA, βTCP powder, and HA/βTCP (25/75 wt.%) biphasic composite before and after 
sintering process, the peak at 1125 cm
-1
 its belongs tricalcium phosphate, while the peak at the lower 
wavenumber are typically associated to hydroxyapatite. b) IR spectra of pectin powder, chitosan powder, pectin-
chitosan as physical mixture, pectin-chitosan as polyelectrolyte complex, and the engineered scaffold 
HA/βTCP_PEC/CHIT, (it is possible to observe the shift of the amine band to 1557 cm-1, due to the PEI complex, 
and the bands belonging inorganic phase, in particular between 950 cm
-1
 and 1140 cm
-1
). 
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Figure 9. XRD analysis on HA/βTCP scaffold sintered at 1150 °C (blue line) and 1300 °C (red line). Sintering 
process performed at 1300 °C leads the transformation of βTCP in αTCP. After these analysis the sintering 
temperature of 1150 °C was chosen, in order to preserve the βTCP structure. 
 
XPS Analysis and EDX analysis 
Chemical composition of the surface of four different ceramic disks functionalized with pectin, 
chitosan and the pectin-chitosan polyelectrolyte complex, has been detected by XPS analysis, as it 
is shown in Figure 10 a. As expected, the percentage of Ca and P is high on the surface of 
HA/βTCP, while a significant reduction of Ca and P and an increase of N and C were detected on 
HA/βTCP_PEC/CHIT samples. Spectra in Figure 10 b show a reduction of the peaks associated to 
Ca 2p3 and P 2p3 and the appearance of N 1s peak for the sample functionalized with PEI complex. 
Samples with pectin have a greater reduction for Ca and P compared to the one functionalized with 
chitosan, showing that the procedure to functionalize with pectin first, is an optimal way to obtain a 
stable and uniform coating available for chitosan, in order to generate a stable and uniform 
polyelectrolyte complex on the surface of ceramic (Table 1). 
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Figure 10. a, b) XPS spectra of HA/βTCP, HA/βTCP_PEC, HA/βTCP_CHIT and HA/βTCP_PEC/CHIT, a 
reduction of the peak associated at Ca 2p3 and P 2p3 and the appearance of N 1s peak for HA/βTCP_PEC/CHIT 
sample was detected.   
 
 
  O C Ca P N 
HA/βTCP 30 34,3 19,5 16,2 0 
HA/βTCP_PEC 26,1 64,2 4,3 3,4 2 
HA/βTCP_CHIT 32 52 6,9 5,7 3,4 
HA/βTCP_PEC/CHIT 25,6 65 2,4 1,9 5,1 
 
Table 1. Chemical composition (at.%) of HA/βTCP, HA/βTCP_PEC, HA/βTCP_CHIT and 
HA/βTCP_PEC/CHIT. 
 
Furthermore, EDX analysis made on the surface of HA/βTCP porous scaffold and 
HA/βTCP_PEC/CHIT scaffold confirm the presence of organic material through the appearance of 
Carbon (C) peaks in the spectra (Figure 11). 
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Figure 11. EDX analysis on HA/βTCP and HA/βTCP_PEC/VCA_CHIT porous scaffold confirm the presence of 
organic materials, through the appearance of C peak. Scale bar: 200 µm. 
 
4.4.2.2 Structural characterization 
μCT analysis 
High porosity and interconnectivity of our ceramic scaffold HA/βTCP were qualitatively 
demonstrated by a capillarity test using red ink  (Figure 12 a). In order to confirm this hypothesis, 
we studied the morphological properties of our materials using the µCT and SEM techniques, on 
HA/βTCP and HA/βTCP_PEC/VCA_CHIT scaffolds. A 3-D representation of HA/βTCP ceramic 
scaffolds morphology is shown in Figure 12 b. The results demonstrated that the ceramic scaffolds 
resulting from the impregnation process of the PU open cells sponge, is characterized by open and 
interconnected macro-pores. The calculated porosity for both scaffolds is about 45 - 50 vol.%, in 
particular macropore size ranged within 100 –1100 µm for HA/ βTCP and HA/βTCP_PEC/CHIT 
scaffolds.  
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Figure 12. a) capillarity test performed on HA/βTCP scaffold. b) Three dimensional reconstruction of 
HA/βTCP_PEC/VCA_CHIT scaffold. 
 
The qualitative interconnection and open porosity, demonstrated through capillarity test, were also 
confirmed by the morphometric parameters calculated from 3-D image analysis. The value of total 
porosity (P), structural thickness (St.Th.), structural separation (St. Sp.), Total Porosity (P) and 
Open porosity (OP) have been compared between HA/βTCP  and HA/βTCP _PEC/CHIT 62 (Table 
2). 
 
Sample  
St. Sp. 
[µm] 
St. Th. 
[µm] 
P 
[%] 
OP 
[%] 
HA/βTCP 839.98 414.46 49.57 98.02 
HA/βTCP_PEC/VCA_CHIT 807.68 441.59 45.98 98.34 
Table 2. Microstructural parameters calculated from µCT analysis.  HA/βTCP_PEC/CHIT scaffold shows a 
similar morphology to the natural bone.  
As expected, the St.Sp. decreases with the addition of PEI complex, from 839.9 µm to 807.7 µm; as 
well as the total porosity (P) decreases from 49.6 % for HA/βTCP to 45.9 % for 
HA/βTCP_PEC/CHIT. We hypothesize that the addition of pectin_chitosan, as a coating complex, 
increases the thickness of the trabeculae, reinforcing the mechanical structure of the scaffold. This 
assumption was assessed through the calculation of St.Th. parameters, which increases from 414.46 
µm for HA/ βTCP to 441.6 µm for HA/ βTCP_PEC/CHIT scaffold. PEI functionalization slightly 
decreases the porosity, decreases the structure separation and increases the structure thickness. 
However, the open porosity is maintained around 98%  of the total porosity, which is an important 
characteristic to promote cell infiltration into the scaffold. This distribution was also assessed by 
SEM investigation (Figure 13), where interconnected macropores with their struts are shown. SEM 
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investigation shows a particular and explanatory case where a huge macropore is divided and the 
trabeculae are reinforced by PEI polymer (Figure 13)
63
. Comparing the value found through the 
calculation of the morphometric parameter with the reference parameter from a study conducted on 
46 bone implant sites of the maxilla and mandible from 32 volunteers, it was found that the values 
of the engineered porous scaffold were in the range or in the same order of magnitude of the native 
mandibular bone 
62
. 
 
Figure 13. SEM investigation before (HA/βTCP) and after coating with PEI (HA/βTCP_PEC/VCA_CHIT). PEI 
polymer reinforced the structure and maintained the interconnected porosity. 
Morphologic analysis showed that PEI functionalization allows achieving a scaffold with a 
porosity, a pore size distribution, a trabecular internal arrangement and a surface area that could 
potentially direct vascularization and nutrients and promote cellular infiltration and bone growth 
inside the pores. A critical role in bone formation is played by porosity, pore size and 
interconnectivity of biomaterials. Pores in biomaterials for bone regeneration are necessary for 
tissue formation, since they allow migration and proliferation of osteoblasts and mesenchymal cells, 
promote vascularization and improve mechanical strength, by promoting anchoring between natural 
tissues and biomaterials at the interface
64
. Pores could be divided in two classes: micropores (< 5 
um) and macropores (> 100 um), both of them important for bioresorption of materials, however 
macroporosities are fundamental to the promotion of new bone growth 
64,65
 .  
Osteogenesis in vitro and in vivo is affected by the morphology of the materials, as well as the 
mechanical properties. Lower and micro-porosity show high osteogenesis in vitro, because cells are 
forced to aggregation; instead, in vivo higher and interconnected porosity results in an increase of 
bone growth, however higher porosity coupled with high pore size translates in poor mechanical 
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properties, too
64
. Micro-porosity creates a hypoxia environment that promotes osteochondral 
differentiation before osteogenesis, instead macropores promote vascularization and facilitate  the 
oxygen transport inside the scaffold. Many researchers have studied optimum pore sizes for bone 
and have shown that alkaline phosphatase activity, osteocalcin content and new bone formation are 
higher in sample with a high percentage of pore, namely between 300 and 400 µm 
66
. However, 
many studies show that even microporosity contributes to induct protein adsorption and bone-like 
apatite formation with its larger surface area. Another important property is the interconnectivity of 
pores, because a spatial continuous connection promotes bone ingrowth. In addition to new bone 
formation, even morphology influences the mechanical stability of the scaffold, in fact high 
porosity, high pore size and high interconnection are translated in a loss of mechanical properties 
67,68
. One possible strategy to achieve high porosity and good mechanical properties, is to combine a 
highly porous ceramic scaffold with a polymeric phase, that could reinforce the structure and in 
parallel maintain the porosity in a range that allows new bone infiltration 
63
. 
4.4.2.3 Mechanical characterization 
Compression Test 
Compressive stress is the principal load to which a scaffold developed for bone and dental tissue 
regeneration is subjected. A biomaterial should not only resist to stress, but it is also quite important 
that a complete disintegration does not happen; this is because some debris could migrate and cause 
an inflammatory response (Figure 14 a). In this study, we compared the mechanical properties of 
HA/βTCP, HA/βTCP_VCA, HA/βTCP_PEC/VCA and HA/βTCP_PEC/VCA_CHIT scaffolds, in 
order to assess how PEI functionalization can affect the resistance of the materials.  In Figure 14 
b,d an example of stress-strain curve for HA/βTCP scaffold and for HA/βTCP_PEC/VCA_CHIT 
scaffold is reported. For both samples, the stress-strain curve shows a so called “pop-in behavior”, 
already reported in other works, related to the crack propagation inside the material trabeculae
69
. 
After an initial increase of stress, the trabecular structure starts to drop, but the scaffold is still able 
to withstand the load, so stress rises again until a maximum is reached, where the struts cracking 
occur. The HA/βTCP_PEC/VCA_CHIT scaffold shows a compressive strength of 1.12 ± 0.14 MPa, 
compared to 0.51 ± 0.14 MPa for the HA/βTCP one, 0.47 ± 0.03 MPa for HA/βTCP_VCA, and 
0.73 ± 0.11 MPa for HA/βTCP_PEC/VCA (Figure 14 e). These results suggest that the addition of 
a polysaccharide in the structure of the scaffold could help to increase the mechanical strength. The 
addition of pectin or a pectin-chitosan complex produces a reinforced composite scaffold, with the 
result of an increase in the mechanical properties. Elastic modulus calculated from the linear part of 
the stress-strain curve confirms the trend already assessed for the compressive strength; 46.7 ± 3.48 
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MPa for HA/βTCP, 24.34 ± 4.01 MPa for HA/βTCP_VCA, 59.78 ± 4.67 MPa for 
HA/βTCP_PEC/VCA and 77.61 ± 13.14 MPa for HA/βTCP_PEC/VCA_CHIT (Figure 14 f). The 
ceramic scaffold treated with vancomycin (HA/βTCP_VCA) alone shows a mechanical strength 
slightly lower than the control HA/βTCP; a reason for this could be vancomycin treatment’s 
procedure, which involves the scaffold immersion in an acidic environment that could start 
degrading the trabeculae and the sintering necks, thus making the scaffold less resistant. The PEI 
complex yields a more cohesive scaffold, also after a critical stress was reached, making the 
structure not subjected to collapse, differently from the HA/βTCP scaffold which undergoes a 
catastrophic failure, with debris production that could cause some problems in vivo (Figure 14 a, c). 
 
 
Figure 14. a,b) An example of compressive test and stress-strain curve for HA/βTCP and for 
HA/βTCP_PEC/VCA_CHIT (c,d) are reported. The PEI functionalization makes the material more cohesive and 
resistant, since the compressive strength and compressive modulus increase with the coating process (e, f).The 
data are represented as mean ± standard deviation (n=3). (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-
way ANOVA with Tukey analysis test). 
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4.4.2.4 Physical characterization 
Degradation properties of the developed material have been tested in neutral conditions (buffer 
solution at pH 7.4) and in acidic environment (buffer solution at pH 3). We compared 
HA/βTCP_PEC/VCA_CHIT scaffolds with the HA/βTCP, HA/βTCP_VCA, HA/βTCP_PEC/VCA 
one, three samples for each were analyzed. Initial weight was recorded and, at each time point, 
samples were taken out from solution, lyophilized and weighted. The percentage of mass loss was 
calculated from the initial weight and from the weight after soaking by Eq. (1). 
Degradation at pH 7.4 
Results of the degradation test in physiological condition for HA/βTCP, HA/βTCP_VCA, 
HA/βTCP_PEC/VCA, and HA/βTCP_PEC/VCA_CHIT samples show a linear low degradation for 
all samples; in particular, pH 7.4 does not affect the ceramic structure within 1 week, in fact 1.33 ± 
0.05 % and 5.83 ± 0.19 % of mass loss was reached for HA/βTCP and HA/βTCP _VCA scaffolds, 
respectively (Figure 15 a). In the case of scaffolds functionalized with pectin or pectin_chitosan, 
pH is an important factor that could change the behavior of the coating.  
In particular, in HA/βTCP_PEC/VCA_CHIT scaffolds weight loss mainly occurs for a ionic 
interaction break, established between pectin and chitosan chains, with the subsequent free chain 
solubilization. Ionized amino groups of chitosan (NH
3+
) transformation in non-ionized amino 
groups (NH2) and preservation of ionized state of COO
-
, occur at pH 7.4. With non-ionized NH2 
groups, chitosan results insoluble in water, while ionized pectin is completely solubilized through 
water uptake. In the case of HA/βTCP_PEC/VCA scaffolds, the presence of a ionized pectin (COO-
) allows water uptake and consequent solubilization of chain. Moreover, the possible interaction 
between COO
-
 and Ca
2+
 could be neutralized from counterions present in the water uptake, inside 
the network. 
For this reason, mass loss for HA/βTCP_PEC/VCA, 22.08 ± 1.25 mg and 
HA/βTCP_PEC/VCA/CHIT, 11.79 ± 3.28 mg, is mainly ascribed to pectin polymer solubilization, 
which dissolution probably carries away some CaP material. This hypothesis could be confirmed by 
SEM investigations after 1 week (Figure 16), when pectin is almost totally absent on the 
HA/βTCP_PEC/VCA scaffold surface, while a network is still preserved on  
HA/βTCP_PEC/VCA_CHIT scaffolds. The pH trend in solution was monitored during the 
degradation test, in order to see if the degradation products could affect the surrounding 
environment (Figure 15 b).  No significant changing in the pH was recorded, but a slight decrease 
between 48 and 96 h for HA/βTCP_PEC/VCA and HA/βTCP_PEC/VCA_CHIT scaffolds, 
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probably due to a maximum degradation of pectin polymers dissolved in the solution; however, at 
168 h, pH for HA/βTCP_PEC/VCA_CHIT scaffolds was 7.45. 
 
 
Figure 15. Degradation stability in physiological condition was evaluated for HA/βTCP, HA/βTCP_VCA, 
HA/βTCP_PEC/VCA and HA/βTCP_PEC/VCA_CHIT scaffolds. a) The mass loss of engineered scaffolds was 
monitored over a period of 1 week (168 h). In neutral physiological solution, the neutralization of chitosan 
occurs, and the solubility of pectin increase. b) pH trend of the solution was monitored over the degradation test. 
Degradation products do not affect significantly the pH of the solution. The data represented as mean ± standard 
deviation (n=3). (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA with Tukey analysis test). 
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Figure 16. SEM investigation for each sample at two different magnification (200x and 500x), after 1 week of 
soaking at pH 7.4, confirm dissolution of pectin on HA/βTCP_PEC/VCA scaffold, and the partial dissolution on 
HA/βTCP_PEC/VCA_CHIT scaffold. Scale bar: 200 µm and 2 µm. 
 
Degradation at pH 3 
Acidic condition represents an extreme working condition for calcium phosphate bone substitute. 
During PPI, it is quite normal that pH is less than the physiological one (7.4), since PPIs are usually 
the consequence of a bacterial infection. Presence of bacteria in a bone wound may decrease the 
level of tissue pH below its normal value, because bacteria subtract nutrients and oxygen to cells, 
creating ischemic conditions which result in an hypoxia, making metabolism to become more 
anaerobic, which is more acidic. Hence, it is important to evaluate the material behavior in an acidic 
environment. Biphasic calcium phosphate scaffold degradation depends on materials composition, 
for example βTCP dissolves to a greater extent and, therefore, faster than HA40,58,59. Moreover, 
acidic conditions cause a faster dissolution of calcium phosphate materials and an increase in the 
107 
 
tendency to fractures. HA/βTCP_PEC/VCA scaffolds are stable till 48 h, until pectin coating resists 
in the acidic environment in which pectin is soluble, and at 72 h, HA/βTCP_PEC/VCA scaffolds 
are completely dissolved. Pectin-chitosan complex coating on HA/βTCP scaffolds protects the 
calcium phosphate material from degradation in acidic environment and, after 168 h. 
HA/βTCP_PEC/VCA_CHIT scaffolds loss 9.06 ± 2.01 % of initial mass  (Figure 17).  
 
Figure 17. Optical images at time zero, after 24h and 168h of soaking at pH 3. The integrity of 
HA/βTCP_PEC/VCA_CHIT scaffold is clearly visible after 1 week. 
 
HA/βTCP_PEC/VCA scaffolds are stable till 48 h, until pectin coating resists in the acidic 
environment in which pectin is soluble, furthermore pectin neutralization in the acidic environment 
could separate the interaction between Ca ions and COO- neutralized, and at 72 h, 
HA/βTCP_PEC/VCA scaffolds are completely dissolved. Pectin_chitosan complex coating on 
HA/βTCP scaffolds protects the calcium phosphate one, from degradation in acidic environment 
and, after 168 h, HA/βTCP_PEC/VCA_CHIT scaffolds loss 9.06 ± 2.01 mg of initial mass (Figure 
18 a).  
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Figure 18. The stability of the engineered HA/βTCP_PEC/VCA_CHIT scaffold was monitored in acidic 
environment over a time of 168 h (1 week). a) mass loss of ceramic and ceramic coated scaffold was reported. 
HA/βTCP_PEC/VCA_CHIT scaffold shows a stable behavior during degradation in a pH 3 solution, due to the 
interaction between pectin and chitosan which protect ceramic materials from the acidic attack. b) pH trend was 
monitored every hour, within the first 8 h and after 24 h and 168 h. A slight increase in the pH value was 
detected for all sample tested, due to the dissolution of phosphate. The data are represented as mean ± standard 
deviation (n=3). (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA with Tukey analysis test). 
 
The pH measurement was recorded every hour upon the first 8 h and, at 24 and 168 h: a slight 
increase in pH trend was recorded compared to control solution, from 3 to 3.64 for 
HA/βTCP_PEC/VCA_CHIT, to 3.81 for HA/βTCP_PEC/VCA, to 3.79 for HA/βTCP_VCA and to 
3.16 for HA/BTCP (Figure 18 b).  
SEM investigations show that, after 1 week in acidic environment, PEI surface coating, is degraded 
but still present, able to protect ceramic from a massive degradation (Figure 19). Furthermore, 
since scaffold microarchitecture could influence the degradation rate, the reduced pore size 
resulting from PEI functionalization protects also grain and trabeculae from the acidic solution’s 
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attack inside the scaffold. These results support the choice of HA/βTCP_PEC/VCA 
_CHIT materials as bone substitutes for preventing PPI, since structure is also conserved in acidic 
environment, allowing vancomycin release in situ, bacterial growth and adhesion reduction and new 
bone formation support. 
 
 
Figure 19. d) SEM investigation at different magnification (100x, 200x and 1000x) of the surface before (T0) and 
after 168 h of soaking in acidic solution (pH 3). 
 
Release study and Agar Germ test 
Infection of dental and orthopedic implants is a devastating consequence of bacterial presence in the 
bone wound site that necessitates a complete removal and antibiotic therapy via systemic 
administration
32,33
. A strategy to target bone healing and to avoid PPI is to provide a bone substitute 
which could fill the void and, in parallel, could release an antibiotic drug in situ, in order to reduce 
bacterial growth and proliferation. Further systemic administration of antibiotics reaches a poor 
infiltration in the bone substitute and makes bacterial infections difficult to treat
70
. Vancomycin is a 
glycopeptidic bactericidal antibiotic marked as a hydrochloride salt and it is in worldwide clinical 
use; results of vancomycin release for HA/βTCP_VCA, HA/βTCP_PEC/VCA and 
HA/βTCP_PEC/VCA_CHIT scaffolds during 30 min, 2 h, 4 h, 8 h, 24 h, 48 h, 168 h, and 336 h (2 
week) performed in physiological solution at physiological pH are reported. For HA/βTCP_VCA 
scaffolds, a massive burst release was recorded within 4 and 8 h, since vancomycin is a high soluble 
drug and, without any kind of interaction or encapsulation, but simply by adsorption on the ceramic 
surface and after soaking in physiological solution, all antibiotic is released in a few hours. Addition 
of pectin (HA/βTCP_PEC/VCA scaffold) permitted a prolonged retention of vancomycin; however 
the high swelling rate of pectin at physiological conditions causes a  burst release within 24 h 
(Figure 20). 
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Figure 20. HA/βTCP_VCA, HA/βTCP_PEC/VCA and HA/βTCP_PEC/VCA_CHIT scaffolds was soaked in 
physiological solution at 37 °C and at each time point, 30 min, 2 h, 4 h, 8 h, 24 h, 48 h, 168 h, and 336 h (2 week), 
the released solution was filtered and analyzed by High Performance Liquid Chromatography. (a) A burst 
release was reported for HA/βTCP_VCA and HA/βTCP_PEC/VCA scaffolds, within 8 h and 24 h respectively. 
HA/βTCP_PEC_VCA/CHIT scaffold shows a controlled and prolonged release until 2 week. The data are 
represented as mean ± standard deviation (n=3). 
 
HA/βTCP_PEC/VCA_CHIT scaffolds show a controlled and prolonged release until 2 weeks, 
because the addition of chitosan and the formation of polyelectrolyte complex permit the creation of 
an engineered coating that controls vancomycin release (Figure 20). The presence of the 
polyelectrolyte network allows vancomycin to be encapsulated and the PEI coating slow 
degradation allows a prolonged release to be reached, which is favorable in order to manage 
bacteria. The agar germ test confirms that the entrapped antibiotic is able to inhibit the growth and 
proliferation of Staphylococcus epidermidis (Figure 21).  Staphylococcus epidermidis is a 
microorganism usually present on skin and it is the main bacterium found in hospitals; for this 
reason, it has become the primary responsible of prosthetic infections, and since these infections are 
often indolent and clinically silent, diagnosis and consequent therapy are difficult
6,71
. The formation 
of a multilayer biofilm on the foreign body surface is difficult to be contrasted with a systemic 
antibiotic therapy; furthermore, it inhibits osteoblast proliferation up to implant failure
72
. In this 
work, we evaluated how bacteria (Staphylococcus epidermidis) adhere and proliferate and, 
eventually, form the biofilm on the scaffold surface; serial dilution test and SEM investigation were 
performed.   
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Figure 21. Agar germ test confirm that entrapped vancomycin scaffold is able to inhibit the growth and 
proliferation of Staphylococcus epidermidis. Inhibition zones are visible until the release of vancomycin persists, 4 
h for HA/βTCP_VCA; 24 h for HA/βTCP_PEC/VCA and up to 2 weeks for HA/βTCP_PEC/VCA_CHIT. No 
inhibition zones are visible for HA/βTCP scaffold. 
 
4.4.2.5 Biological characterization 
Staphylococcus epidermidis is a microorganism usually present on skin and it is the main bacterium 
found in hospitals; for this reason, it has become the primary responsible of prosthetic infections, 
and since these infections are often indolent and clinically silent, diagnosis and consequent therapy 
are difficult to act
6,71
.  
During a periprosthetic infection, due to the presence of a foreign body, two different stages have 
been distinguished: the first step is the adhesion of bacteria on the implant surface and the second 
step is slower and involves bacteria proliferation, accumulation and cell-cell interactions that 
stimulate production of polysaccharides that result in a multilayer biofilm, which is difficult to 
contrast with a systemic antibiotic therapy, furthermore it inhibits osteoblast proliferation until 
implant failure occurs
72
. In this study, we evaluated how bacteria adhere and proliferate and, 
eventually, form the biofilm on the scaffold surface. We performed a serial dilution test on 
HA/βTCP, HA/βTCP_VCA, HA/βTCP_PEC/VCA and HA/βTCP_PEC/VCA_CHIT scaffolds 
using a Staphylococcus epidermidis to quantify bacteria adhesion and proliferation through 
counting bacteria colonies forming units (CFU) (Figure 22). In order to evaluate the tendency of 
scaffolds to promote or to avoid a biofilm formation on the surface, SEM investigations were 
performed at different time points of vancomycin release.  
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Serial bacterial dilution test  
 
 
Figure 22. Schematic diagram of serial dilution test protocol 
 
 
We tested the samples at three different time points of releasing, as prepared (T0), at 24 h and after 
1 week. These data correlated with the HPLC vancomycin release test, giving a more precise 
quantification of bacteria growth on the surface. Bacteria adhesion depends on the vancomycin 
release but on the surface chemistry of the scaffold, too. In Figure 23, the reduction of CFU 
proliferated on the engineered HA/βTCP_PEC/VCA_CHIT, compared to the other scaffolds, at 
different time points, is clearly  showed. HA/βTCP scaffold is highly colonized by bacteria within 
all-time points; obviously, surface micro-porosity, roughness, high macro-porosity and 
interconnectivity, as well as absence of a bactericidal action, leave the scaffold surface free for 
bacterial colonization; this is what could happen in vivo and, in this case, the most likely solution 
would be the implant to be removed, followed by intensive antibiotic therapies and a prolonged 
hospitalization period. 
 
Figure 23. Images of Agar germ plate at time zero, after 24h and after 1 week. Photos shows the absence of CFU 
on Agar germ plate for HA/βTCP_PEC/VCA_CHIT scaffold at already at low dilution of the starting solution. 
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In Figure 24, the count of proliferated CFU on the scaffold surface at different time points is 
reported. HA/βTCP_VCA scaffold shows a CFU count of 1.28 x 106 at T0 and an increase of CFU 
at 1 week until 2.42 x 10
7
; this behavior is confirmed by the release study, where after 8 h 
HA/βTCP_VCA all adsorbed vancomycin has been released in a burst. HA/βTCP_PEC/VCA at T0 
released enough vancomycin to kill bacteria and to inhibit proliferation on scaffolds; CFU count of 
1.88 x 10
5
 increased at 24h 1 x 10
6
 till at 1 week, reaching CFU 3.75 x 10
6
.  The engineered 
HA/βTCP_PEC/VCA_CHIT scaffold shows a similar CFU count compared to the 
HA/βTCP_PEC/VCA one, in the first time due to the slow release, but control provided by PEI 
coating allows bacterial adhesion and proliferation to be maintained low until 1 week, which is one 
order of magnitude low with respect to HA/βTCP_PEC/VCA and two orders of magnitude lower 
compared to HA/βTCP and HA/βTCP_VCA scaffolds. As it was demonstrated by HPLC release, a 
controlled and prolonged release allows inhibition of bacterial growth and proliferation on the 
biomaterial surface, which means that the material developed, HA/βTCP_PEC/VCA_CHIT, shows 
a behavior that confirms its potential use as bone filler to prevent periprosthetic infection, inhibiting 
the first step of infection: the bacterial adhesion. 
 
 
Figure 24. Graph of CFU counted on Agar germ plate at different dilution, the data confirm the low density of 
bacteria adhered on the surface of engineered HA/βTCP_PEC/VCA_CHIT material.  The data are represented 
as mean ± standard deviation (n=4). (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, Two-way ANOVA with 
Tukey’s multiple comparison test). 
Bacterial adhesion test 
Nosocomial infections are the most frequent type of infections caused by Staphylococcus 
epidermidis, which is the most frequently bacterium found in periprosthetic infection
71
. Biofilm 
formation is a two-step process, in which Staphilococcus epidermidis, first adheres on the material 
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surface and through an accumulation it produces an extracellular polymeric substance forming a 
multilayer structure complex called biofilm
73
. The ability of bacteria to adhere and grow in a 
biofilm structure inhibits the reaction of the immune system, furthermore the polysaccharides 
structure that envelops bacteria protects them from the antibiotic effects. Our goal was to design and 
develop a complex system which was able to inhibit the adhesion of bacteria and the consequent 
biofilm formation, coupling both the effect of a widely and successfully used antibiotic, and a layer-
by-layer surface coating, exposing on the surface a chitosan layer, that has a well-known 
antimicrobial activity. In order to confirm that during the release process the proliferation and 
biofilm formation are controlled, SEM investigation was performed on the engineered scaffold 
HA/βTCP_PEC_VCA/CHIT material, in comparison with HA/βTCP, HA/βTCP_VCA and 
HA/βTCP_PEC/VCA samples (Figure 25). 
All samples, two for each case, were cultured with Staphylococcus epidermidis in as prepared (T0) 
conditions and after a release in physiological solution for 24 h and 1 week. Then, 5 SEM images 
for each sample have been taken on the surface of scaffolds, at three different magnification 2000X, 
5000X and 10000X. For each images at 10000X, Staphylococcus epidermidis were manually 
counted by ImageJ software and a percentage of area covered by bacteria respect the total area of 
the images was calculated. HA/βTCP sample, as already proven by the serial dilution test, shows 
high bacterial adhesion and growth at each time point. The microporosity on the surface and the 
interconnected macropores are perfect niches for bacterial proliferation. SEM images at 30000X 
show an initial accumulation of bacteria inside the pores and an early deposition of polysaccharides 
materials (Figure 26).   
The addition of vancomycin, just adsorbed on the ceramic surface (HA/βTCP_VCA), partially 
inhibits bacterial adhesion and proliferation at the first point, in as prepared condition; but at 24h 
and even more after 1 week of release, the presence of Staphylococcus epidermidis on the surface 
was similar to the HA/βTCP sample, furthermore at 1 week SEM images taken at 30000x show a 
cell-cell interaction and an initial deposition of extracellular polysaccharides matrix (Figure 26). 
Pectin_vancomycin complex (HA/βTCP_PEC/VCA) allows bacterial growth to be inhibited, in 
particular at time zero and after 24 h, then the coating’s degradation makes ceramic surface to be 
available and a later colonization to start at 1 week. 
A completely different situation was visualized for the engineered developed scaffold 
(HA/βTCP_PEC/VCA_CHIT), in which the presence of a bilayer on the surface, which entrapped a 
vancomycin drug active in a long-term release, inhibits the first adhesion step and, therefore, 
biofilm formation until 1 week of release (Figure 25, Figure 26).  
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Chitosan has been investigated for a long time as an antimicrobial material, in such a way that in 
last decades the tendency is to consider chitosan as a bacteriostatic material that hinders bacterial 
growth, rather than a bactericidal one
53
. Different mechanisms aimed at explaining how chitosan 
interacts with bacteria and inhibits growth are under investigations; the most probably hypothesis 
are as following: 1) wall cell leakage, due to ionic surface interactions, since chitosan is a 
polycationic material, 2) penetration of chitosan inside the nuclei of microorganisms which inhibits 
mRNA and protein synthesis and 3) suppression of nutrients necessary for microbial growth by 
formation of an external barrier
53,54
. Nowadays, it is not well understood which one of these 
mechanisms is the predominant one, probably a combination of effects is to take into account, but it 
is proven that chitosan has an antibacterial activity against gram positive and gram negative 
bacteria, particularly medium and low molecular weight chitosan. 
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Figure 25. All samples was kept in physiological solution at 37 °C for 24 h and 1 week, then Staphylococcus 
epidermidis was grown on the surface for 2 h and then a fixation process was performed in order to investigate 
the surface by SEM analysis.  SEM images of HA/βTCP, HA/βTCP_VCA, HA/βTCP_PEC/VCA, 
HA/βTCP_PEC/VCA_CHIT scaffolds in as prepared condition (T 0 h, no release), after 24 h of releasing and 
after 1 week of releasing. Images were taken at 10000x, scale bar 2 µm. Low bacterial adhesion on 
HA/βTCP_PEC/VCA_CHIT at each time point was detected. Images at different magnification as supplemental 
data.  
We report the percentage of the reference material surface area (660 µm
2
) covered by bacteria cells 
(Figure 27). As mean value of bacteria diameter, we consider 0.95 ± 0.12 µm that means an area of 
0.71 ± 0.18 µm
2 
(calculated as mean value on 180 measures). All samples, except for HA/βTCP 
scaffold, show a percentage of area covered by bacteria around 5 % of total area at time zero 
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(without release step). However, the results show that the area covered by bacteria on 
HA/βTCP_PEC/VCA_CHIT biomaterials is almost 10 fold lower at each time point compared to 
HA/βTCP scaffold. HA/βTCP_PEC/VCA scaffold shows a low value at time zero, then an increase 
is observed at 24 h and a value around 10 % is reached at 1 week of release. At 24 h, 
HA/βTCP_PEC/VCA scaffold is characterized by a great standard deviation that is mainly due to 
the non-homogeneity of the degraded pectin coating, which allows an accumulation of bacteria in 
some areas. HA/βTCP_VCA scaffold shows a trend demonstrated with serial bacterial dilution 
tests; the percentage of area covered by bacteria amounts to 10 % of total area at 24 h and rises to 
the value of 30 % at 1 week, which means that any kind of antibacterial effect is still present at this 
time point.  
 
Figure 26. SEM images of HA/βTCP, HA/βTCP_VCA, HA/βTCP_PEC/VCA, HA/βTCP_PEC/VCA_CHIT 
scaffolds in as prepared condition (T 0 h, no release), after 24 h of releasing and after 1 week of releasing .  
Images were taken at 30000x, scale bar 1 µm. After 1 week SEM images show a cell-cell interaction and an initial 
deposition of extracellular polysaccharides matrix, in particular on the surface of HA/βTCP and 
HA/βTCP_VCA scaffolds. 
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These results show that a bilayer PEI between pectin and chitosan is necessary to encapsulate drugs 
for a long term release and to inhibit bacterial adhesion, since after 1 week of release less than 2 % 
of total area analyzed is covered by bacteria and, furthermore, most of the bacteria found on the 
surface are poor adhered, only blocked by the folding of the coating. 
 
 
Figure 27. The percentage of surface area covered by bacteria was calculated respect the total area represented 
on 10000x images (a). The area of Staphylococcus epidermidis was calculated as mean value of 180 bacteria, and 
is equal to 0.71 ± 0.18 µm
2
 (diameter of 0.95 ± 0.12 µm (b). The total area analyzed for each images is equal to 
660 µm
2
. Five points for each scaffold (n=2) were analyzed, as it is represented by the schematic diagram (c). 
HA/βTCP scaffold was covered by bacteria for 30% of total area, at each time point. The addition of 
Vancomycin and Vancomycin-Pectin, inhibits bacterial adhesion until 24 h and 1 week, respectively. Only 
engineered HA/βTCP_PEC/VCA_CHIT scaffold allows antiadhesive properties against Staphylococcus 
epidermidis, up to 1 week. The data are represented as mean ± standard deviation (n=5).  
 
In vitro study 
Developing a new composite bone filler using ceramic and polysaccharides material is important to 
check if some inflammatory responses are generated. Furthermore, prevention strategies of 
periprosthetic infection should involve bacterial growth inhibition as well as osteoblast proliferation 
promotion, with the aim to reach new bone formation. Specific ceramic scaffold’s microarchitecture 
could allow cell infiltration and bone growth inside the scaffold, in particular HA and βTCP 
components have already shown a great potential in bone regeneration, since they are the principle 
inorganic component of bone. Ideally, PEI coating would guide soft tissue regeneration in the first 
times after surgery, avoiding connective tissue infiltration inside the bone substitute, since it has a 
faster growth and through ceramic interaction with osteoblast cells promoting bone formation, 
meanwhile controlling bacterial infection. 
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Inflammatory response 
We performed an RT-PCR gene expression on HA/βTCP, HA/βTCP_VCA, HA/βTCP_PEC/VCA 
and HA/βTCP_PEC/VCA_CHIT scaffolds after 4 h of macrophage cells culture. Gene expression 
analysis on IL-1β, IL-10 and MCP1 were conducted by real time RT-PCR (Figure 28). The target 
of this test was to understand if the different steps of functionalization could stir up an inflammatory 
response, compared to HA/βTCP ceramic scaffold, which were set as a control. As it is reported, no 
material elicits a pro-inflammatory response, IL-1β and MCP1 gene fold expressions are 
comparable to the HA/βTCP ceramic control, which means that neither HA/βTCP_VCA nor 
HA/βTCP_PEC/VCA and HA/βTCP_PEC/VCA_CHIT stimulate an inflammatory response. 
HA/βTCP_PEC/VCA_CHIT shows a 3-fold expression higher compared to other samples tested for 
IL-10 gene.   
 
Figure 28. Gene expression of macrophages after 4 h of cell culture. a) Fold expression of cytokines IL-1β, Il-10 
and chemokines MCP1 for HA/βTCP_VCA, HA/βTCP_PEC/VCA and HA/βTCP_PEC/VCA_CHIT scaffolds 
respect the ceramic control HA/βTCP scaffold. Results demonstrated that any material stimulates a pro-
inflammatory response, and that PEC_VCA_CHIT coating elicits anti-inflammatory response, with a higher 
expression of IL-10. The data are represented as mean ± standard deviation (n=3). (*p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, Two-way ANOVA with Tukey’s multiple comparison test). 
If implanted materials rose a local inflammatory response, the immune system would be activated
74
. 
Propagation of this local inflammation would activate the release of a set of cytokines and, if not 
controlled, could promote bone resorption and, consequently, implant’s failure. Bone resorption 
occurs when inflammatory mediators reach a critical concentration, which depends on the 
expression of pro-inflammatory cytokines, such as the Interleukin (IL) family, of which IL-1β is the 
most studied member due to its role in acute and chronic inflammatory and autoimmune disorders, 
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and chemokines, a family of chemoattractant cytokines which major role is the selective recruiting 
of monocytes, neutrophils and lymphocytes. Besides IL-1β primary action, monocyte 
chemoattractant protein-1 (MCP-1), the first discovered human CC chemokine, regulates migration 
and infiltration of monocytes/macrophages, thus contributing to raise a response aimed at 
eliminating invading pathogens through phagocytosis. On the opposite site, the inflammatory level 
is controlled by the expression of anti-inflammatory cytokines, such as IL-10. In normal 
physiological conditions, there is a balance between bone formation and bone resorption, and as it 
happens in certain inflammatory conditions, this balance can be altered. This equilibrium is 
regulated by the relative expression of proteins such as receptor activator of nuclear factor kappa-B 
(RANKL) and the soluble decoy receptor osteoprotegerin (OPG). During an inflammation response, 
RANKL/OPG ratio is altered by the action of pro-inflammatory cytokines, such as IL-1β that 
induces osteoclastogenesis, increasing the expression of RANKL, while counteraction by anti-
inflammatory mediators, such as IL-10, decreases RANKL or increases OPG, in order to inhibit 
osteoclastogenesis. The results elucidate that PEI coating stimulates the expression of an anti-
inflammatory mediator; in vivo, this stimulation could help in controlling inflammation and in 
promoting bone formation.  
Osteoblast-like cell culture 
Adhesion and proliferation of osteoblastic SAOS-2 cells are demonstrated through SEM 
investigations (Figure 29). An excellent colonization could be observed on HA/βTCP scaffold after 
1 week of cell culture, on which substrate cells appeared well adherent with many filipodia 
protrusions. HA/βTCP_PEC/VCA_CHIT scaffold shows a good osteoblast colonization, in 
particular where HA/βTCP phase is directly available for cell adhesion, cells appear well spread and 
strong philipodia protrusions were observed. Polyelectrolyte coating did not interfere with 
osteoblast proliferation
38
, instead as it is possible to observe from SEM images, only pectin coating 
avoids cell adhesion, on the calcium phosphate surface, too.  
HA/βTCP_PEC/VCA_CHIT scaffold provides an excellent substrate for osteoblast adhesion, 
spreading and proliferation, and it is confirmed that the vancomycin released is not cytotoxic 
against osteoblast growing cells. HA and βTCP have been widely used as bone filler materials, 
since they are similar to the inorganic phase of natural bone. Many studies show the 
biocompatibility and the attitude to promote bone formation in vivo, furthermore highly porous 
calcium phosphate scaffolds have been demonstrated to enhance osteoprogenitor cell proliferation 
and infiltration
16–18
. However, the major concern against antibiotic release in situ is related to the 
biocompatibility with the surrounding tissues, research work showing that, along all tested 
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antibiotic, vancomycin shows excellent antibacterial activity against germs and the lowest 
osteoblasts cytotoxicity
75
 . 
 
Figure 29. SAOS-2 osteoblast adhesion and proliferation after 1 week were investigated by SEM, after 
glutaraldehyde fixation. An excellent adhesion and spreading was observed on HA/βTCP scaffold. A very low 
cell adhesion was present on the surface of HA/βTCP_PEC/VCA scaffold, as well on the ceramic exposed part. A 
good cell adhesion and philipodia protrusion was observed on HA/βTCP_PEC/VCA_CHIT scaffold, in 
particular on the ceramic exposed part.  
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4.4.3 Conclusion 
Dental infections caused by infected orthopedic implants may cause devastating consequences, 
since they involve the removal of foreign body and damage tissue from a wound.  A multitude of 
surgical procedures are necessary, coupled to an intensive systemic antibiotic therapy, furthermore 
the poor antibiotic penetration inside the infected bone and the specific interaction of the bacteria 
with the foreign body could result in a re-infection of the site. However, leaving the bone defect 
untreated could allow connective tissue infiltration and a loss in the mechanical stability. Bone 
defects have to be filled with a scaffold that could provide a local administration of antibiotic drug, 
could control the infection and could address bone regeneration before a new implant could be 
inserted. In this study, we developed a new-engineered biphasic calcium phosphate scaffold 
functionalized with a pectin and chitosan polyelectrolyte, loaded with vancomycin, 
HA/βTCP_PEC/VCA_CHIT. Performed tests show good mechanical properties and stability during 
degradation in different pH test solutions, coupled with an excellent antibacterial property along 1 
week. Release studies demonstrated that the developed coating allows a long-term release, 
confirmed by SEM investigation on biofilm formation on the surface of scaffolds. Anti-
inflammatory responses have been stimulated in in vitro studies with macrophages and 
polyelectrolyte functionalization does not interfere with osteoblasts growing. 
HA/βTCP_PEC/VCA_CHIT scaffold could be used as new and effective tools to prevent or treat 
periprosthetic infection in bone and dental procedures. 
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4.5 NOVEL BIOCERAMIC-REINFORCED HYDROGEL FOR 
ALVEOLAR BONE REGENERATION 
 
 
Figure 30. Graphical abstract of the bioceramic-reinforced hydrogel. 
 
4.5.1 Introduction 
The restoration of teeth by using titanium dental implants is nowadays a quite common procedure
1
. 
The American Association of Oral and Maxillofacial Surgeons reported that 69% of adults aged 35 
to 44 have lost at least one permanent tooth and, by age 74, almost 26% of adults have lost all of 
their permanent teeth. More than 300,000 dental implants are placed per year worldwide and, until 
2020, this number is expected to increase
1,2
. Tooth loss is a possible consequence of traumas or 
periodontal diseases, such as gingivitis, periodontitis or tissue decay. The rate of success of dental 
implants is around 98%, but it should be taken into account that the positive fate of a surgical 
procedure involving the insertion of a titanium screw still depends on the quality and quantity of 
alveolar bone which is present in the extraction site. In order to get a successful implant insertion, 
the alveolar ridge should have a minimum dimension, which is of 5 mm of width in the maxilla and 
of 10 mm of bone height
3
. If these dimensions are not available, an augmentation strategy will be 
necessary using grafting procedures. A huge alveolar bone loss of around 2 mm in vertical and 
almost 50% in horizontal occurs in the first 6 months after surgery; a continuous bone resorption 
occurs if no treatment is provided during the next years after the extraction procedure, and an 
average of 60% of bone loss could be reached in 3 years
4–9
. These results show the importance of 
the implementation of a strategy aimed at augmenting the alveolar bone volume to provide a stable 
support for the implant and the future crown. The common use of autografts or allografts is affected 
by the morbidity and the risk of disease transmission associated with the donor site, thus the use of 
man-made bone graft biomaterials is more and more attractive
10–12
. A bone graft material should be 
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biocompatible, degradable, osteoconductive, osteoinductive and should mimic the ECM of bone, in 
order to allow cell infiltration, proliferation and new bone formation. Hydroxyapatite (HA) and β-
tricalcium phosphate (βTCP) are well-known ceramic materials, widely used in bone tissue 
engineering as bone grafts in the form of particles or three-dimensional scaffolds
13–15
. HA 
(Ca10(PO4)6(OH)2) is the most abundant component in native bone, around 65% of inorganic phase, 
but despite many studies show osteoconduction stimulation and excellent mechanical properties, the 
slow degradation rate of HA limits its use as a bone filler only
16–18
. Combination of HA with βTCP 
allows the degradation properties to be managed, since βTCP materials have a degradation rate 3 – 
12 times faster than HA, and mechanical properties to be maintained good
19
. The balance between 
HA and βTCP is a key point to obtain mechanical strength, degradation and, ultimately, to stimulate 
osteointegration. Animal studies demonstrated that HA/βTCP biphasic materials in the rate of 25/75 
allow new bone formation
15
. In the irregular post-extractive site, it is important to use materials 
which can fill the void, be shaped in an easy manner and be not prone to migration, hence particles 
and three-dimensional rigid scaffolds are not the best choice. To overcome this issue, we developed 
a pectin/chitosan-based polyelectrolyte hydrogel reinforced with biphasic calcium phosphate 
particles. Chitosan is a natural polycationic material derived from chitin extracted from crustaceous 
exoskeleton, composed of β – (1,4) – glucosamine and N-acetyl-D-glucosamine and, due to its 
biocompatibility, its intrinsic antibacterial nature, its ability to not stimulate a foreign body reaction, 
and its promotion of cell adhesion, proliferation and differentiation, it has aroused great interest in 
finding many applications in bone tissue engineering
20,21
. Furthermore, chitosan has a backbone 
similar to glycosaminoglycan, the major component of bone ECM
22,23
. In order to stabilize the 
structure, we coupled chitosan with a natural polyanionic polysaccharide, pectin, which is a major 
component of cell walls of citrus or apple peel by-products. Pectin consists in a poly(D-galacturonic 
acid) chain, with a carboxyl group, in part methoxylated
24
. In the last decades, pectin has found 
promising application in bone tissue engineering as a drug carrier and, in this work, the ionic 
interactions that occur between chitosan and pectin were used to develop a novel hydrogel which 
could mimic an ECM-like environment for osteoblast cells
25–27
. Combining ceramics with natural 
materials provides many advantages, in particular for dental practice: shape control, optimization of 
adhesion between implant and surrounding bone tissue, easy adaptation of the extraction site, 
promotion of clot formation and avoiding ceramic particles migration
16,23,28–30
.  
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4.5.2 Results and Discussion 
In this work, we designed, developed and characterized a composite hydrogel sponge, which 
combines the advantages of calcium phosphate materials with those of natural materials, and we 
compared it with base hydrogel materials.  
 
4.5.2.1 Chemical characterization 
ATR-IR analysis 
ATR-IR spectra reported in Figure 31 a show the spectra of pectin, chitosan, pectin/chitosan 
polyelectrolyte complex (PC), HA/βTCP particles and pectin/chitosan_HA/βTCP composite 
hydrogel (PCC). The analysis confirms that all peaks belong to inorganic material; in particular, 
triply degenerated asymmetric stretching mode (ν3) of the P-O bond of the phosphate group  is 
associated to the peaks at 1125 cm
-1
 for tricalcium phosphate and at 1025 cm
-1
-1010 cm
-1 
for 
hydroxyapatite
15,31
. Typical spectra of polysaccharides were shown by pectin and chitosan powder. 
The region between 3700 cm
-1
 and 3000 cm
-1
 for pectin and chitosan is assigned to the O–H 
stretching vibration (νOH), while the region between 3000–2800 cm-1 belongs to C-H stretching 
vibration (νCH)  (Figure 31 a). Deeper analysis on pectin spectra shows two bands associated with 
the stretching vibration at 1740 cm
-1
 of carbonyl group, corresponding to the methyl ester group 
(COOCH3) and carboxyl acid (COOH), while the band at 1606 cm
-1
 belongs to the stretching 
vibration of the carbonyl group of the carboxylate ion (COO
-
) (Figure 31 b). Concerning chitosan 
spectra, the band at 1647 cm
-1
 is due to the C=O stretching vibration of amide I, whilst the band at 
1580 cm
-1
 is due to the NH bending amide II, maybe overlapped to the N-H vibration of the amine 
groups (Figure 31 b). Band assignment is consistent with available literature
32,33
. PC spectra show 
the formation of PEI complex; a shift of amine band to 1557 cm
-1
 due to the interaction between the 
positive charge of chitosan, NH3
+
, and the negative charge of pectin, COO
- 
, was detected (Figure 
31 b). As expected, the spectra of PCC sample show bands associated with both the PEI complex 
and the inorganic phase; in particular, the band at 1557 cm
-1
 and those between 950 cm
-1
 and 1140 
cm
-1
, respectively (Figure 31 b) 
34
. 
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Figure 31. (a) ATR-IR spectra of pectin and chitosan powder, HA/βTCP ceramic particles, PC hydrogels, PCC 
composite scaffolds. (b) ATR-IR spectra focus between 2000 cm
-1
 and 500 cm
-1
 of materials, show the shift of the 
amine band to 1557 cm
-1
, and the bands belonging inorganic phase, at 950 cm
-1 
and 1140 cm
-1
. 
 
4.5.2.2 Structural characterization 
µCT and SEM analysis 
Three-dimensional scaffolds should allow cell-infiltration and facilitate vascular invasion. 
Furthermore, it is necessary that the ceramic particles are homogenous dispersed in the natural 
matrix, in order to promote uniform osteogenesis. Both, micro-porosity and macro-porosity, are 
important morphological properties
35,36
. Micro-porosity promotes blood vessel infiltration, nutrients 
transportation and allows the clot formation that is important to promote the healing process. On the 
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other side, macro-porosity allows cell infiltration and new bone growth
37,38
. Capillary test using red 
ink, qualitatively shows the porosity interconnection of the PCC material, which could adsorb the 
solution in around 5 seconds (Figure 32). Furthermore, after hydration, if a compressive stress is 
applied on the samples, the solution is expulsed from the matrix, but after removal of the stress the 
PCC material is able to re-adsorb all the solution, without any permanent deformation. The material 
works as a bearing, which is an important characteristic in order to avoid inflammatory response on 
the surrounding tissue due to the stiffness of the material, in particular in application at the interface 
between hard and soft tissues. Furthermore, the ability to adsorb water and retain it into the matrix 
allows formation of a clot in the wound site, which is the first step to stimulate the migration of 
bone cells into the scaffold, and to promote regeneration of alveolar bone. In alveolar bone 
regeneration, the use of sponges is desirable, since they could easily fit into the irregular alveolar 
bone defect, be simply cut with scissors or a lancet, and easily molded in the periodontal cavity  
(Figure 32)
16,38,39
.  
 
 
Figure 32. Easy mouldability of composite scaffold, highly hydration properties (water colored with few drops of 
red ink was used for this qualitative hydration test) and capacity to recover the initial shape after a compressive 
stress. 
A µCT study  (Figure 33 a) confirmed the results of SEM analysis. Pore size distribution for PCC 
sample is in the range around 100 - 250 µm, while the PC scaffold has a pore size distribution 
which goes until 600 µm, with most pores located between 250 and 300 µm (Figure 33 b). Direct 
comparison of mean pore sizes (St.Sp) further confirms the decrease of pore dimension due to the 
introduction of ceramic particles (250 vs. 120 µm). The total porosity decreases by adding ceramic 
particles, too, from around 74% for PC sample to 55 % in the case of PCC scaffold.  
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Figure 33. (a) μCT images confirm SEM investigation and reveal uniform distribution of ceramic particles in the 
pectin_chitosan PEI matrix. (b) Pore size distribution of PC and PCC scaffold, the addition of ceramic particles 
reduces the pore size. (c) 2-D development of PC and PCC scaffold, obtained by placing the analysis planes [xy] 
and [yz] in the mid-length, and moving the [xz] plane from the bottom to the middle and until the top of the 
length of the scaffold; and 3-D reconstruction of the central (approximately mid-length) cross-section along the 
[xy], [xz] and  [yz] orthogonal planes.  
In Figure 34, SEM analysis at different magnifications for PC and PCC samples are reported. The 
addition of ceramic particles reduces the pore size and the total porosity, but reinforces the 
trabeculae and the structure of the materials. Furthermore, the dispersed particles are well 
distributed in the PEI matrix. In vitro and in vivo studies show that a porosity up to 50 %, and pore 
size in the range between 100 to 400 µm are the optimum for bone healing and show higher alkaline 
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phosphatase activity and new bone formation compared with materials with a porosity lower than 
100 µm and higher than 400 µm
40
.  
 
 
Figure 34. (a) SEM investigation of PC and PCC scaffolds, highly interconnected pores are shown for PC 
scaffold; the incorporation of ceramic particles reduces the porosity and pore size of the material. 
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4.5.2.3 Mechanical characterization 
Compression test 
The incorporation of ceramic particles into soft hydrogel scaffolds is a valuable strategy to improve 
the mechanical properties of the base material
41,42
. A compressive test was performed on PC and 
PCC scaffolds, and the results are show in Table 3 and in Figure 35. The addition of HA/βTCP 
particles increases the compressive strength, the stress strain and the toughness of the material, both 
in as prepared and hydrated condition. Compressive elastic modulus for PC scaffolds was 1005.3 ± 
250.0 kPa in as prepared condition, instead was two-fold higher for PCC scaffold, 2559.33 ± 595.6 
kPa. Hydration kinetics data show that the water uptake at pH 7.4 was higher in both case and, 
therefore, the compressive elastic modulus decreases to 33.3 ± 7.6 kPa for PC material and until 
65.4 ± 8.97 kPa for PCC scaffolds. Alveolar bone regeneration is a low-bearing application, where 
providing stability and three-dimensional shape for functional and aesthetic reasons is more 
important than mechanical strength
16,43
. PC materials show a soft structure, and the incorporation of 
ceramic particles inside the PEI matrix makes the material tougher (Table 3). For example, the 
toughness was 34.28 ± 4.02 kJ/m
3 
and 222.86 ± 1.94 kJ/m
3
 for PC and PCC scaffold respectively, in 
as prepared conditions. There is a relative paucity of literature dealing with the toughness of bone 
tissue engineering scaffolds and, thus, comparison with previous works is difficult; however, it is 
interesting to point out that the toughness of PCC scaffold is ten times higher than that assessed for 
single-phase glass-ceramic porous scaffolds
44
. After 24 h at 37 °C in a solution with pH 7.4, both 
hydrated samples show a decrease of toughness (2.38 ± 0.46 kJ/m
3
 for PC scaffold and 12.04 ± 2.05 
kJ/m
3
 for PCC scaffold) compared to as prepared materials. A similar behavior was also found by 
Liu et al. on bioglass scaffold
45
. The toughness of PCC material in hydrate conditions is 
comparable, as order of magnitude, to the value found by other authors for hydroxyapatite 
scaffolds
46
. Ceramic particles, as expected, reduce the porosity but mechanically reinforce the 
scaffolds, maintaining a range and a degree of porosity that should still allow cell infiltration and 
proliferation
35
.  
 
Table 3. Table reporting compressive modulus, stress and toughness parameters.  
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Figure 35. Stress – strain curves for PC and PCC scaffolds in as prepared and hydrated conditions. 
Cyclic stress is a common situation under which the scaffolds used for alveolar bone regeneration 
are subjected. The stability and integrity of the scaffolds are the most important properties that they 
should have, since material fragmentation could provoke an inflammatory response and a huge 
deformation could cause the collapse of the defect. Hydrogel PC scaffolds show a stable energy 
adsorbed (and recovery network) from the 5
th
 to the 100
th
 cycle, the addition of 90% of ceramic 
particles does not affect too much the trend, the energy adsorbed was slightly higher for the PCC 
composite due to the reduced mobility of the PEI network. The results are affected by the 
deformation of swollen surface of the samples, that does not return instantaneously to the original 
shape after cessation of compression stress. After 100 cycles, no fragmentation was detected for 
both samples, furthermore the sample left without load to recover the shape for 5 minutes, showed a 
variation of the final diameter with respect to the initial diameter of 1.4 ± 0.59 % and 7.52 ± 1.32 % 
respectively for PC and PCC materials (more than 90 % of recovery for both samples). This means 
that, in vivo, the PCC scaffold is able to maintain the shape and to avoid the collapsing of the site 
(Figure 36). Furthermore, tooth extraction site has a non-regular shape, hence ensuring the 
possibility to customize the dimension of the material in order to fit the socket is an important 
characteristic for dental practitioner. In alveolar bone regeneration, the use of sponges is desirable, 
since they could easily fit in to the alveolar bone defect, and could be simply cut with scissors or a 
bistoury, and easily molded in the periodontal cavity
16,38,39
. The addition of calcium phosphate 
particles, doesn’t influence the mouldability of the PC hydrogel base material. 
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Figure 36. PC and PCC samples were subjected to cyclic strain, in fully hydrated condition and the loading and 
unloading curves were monitored for hundred cycles. Energy adsorbed and recovery percentage were monitored 
for PC and PCC samples every 10 cycle. The incorporation of calcium phosphate particles increases the strength 
of the scaffold, but does not reduce the recovery ability of the PCC scaffold, which is similar to the PC material.  
The data are represented as mean ± standard deviation (n=3). 
 
4.5.2.4 Physical characterization  
Hydration studies at different pH 
A high degree of swelling allows cell infiltration into the scaffolds and maximizes the probability of 
cells growth in a three-dimensional structure
29
. Furthermore, high swelling behavior improves the 
ability of the scaffold to adsorb nutrients from the culture media; chitosan/pectin complexes are 
formed by a ionic interaction between positive charges of chitosan and negative charges of pectin, 
hence, the PEI network exhibits a pH-sensitive swelling
47,48
. We tested the swelling behavior in 
three different solutions with three different pH 2.5, 5.5 and 7.4, and the results are shown in Figure 
37. PC based hydrogels showed a significant different behavior depending on the pH of the 
solution. Changing the pH of the solution, the degree of interaction between pectin and chitosan 
changes and the swelling increases or decreases, depending on the degree of dissociation of the 
complex (Figure 37 a). At low pH values (2.5), pectin is neutralized and free positive charges 
(NH
3+
) appear in the network; COOH from pectin chain allows the swelling of the material until the 
value of 1460.42 ± 81.33 % of the initial mass, after 6 h. After 24 h PC, hydrogels soaked in a 
solution of pH 2.5 showed a huge increase in the water uptake; this behavior could be associated to 
the total degradation of pectin and to the loss of PEI network that allows the highest water 
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adsorption, 2495.34 ± 33.87%. At alkaline pH (7.4), free negative charges appear inside the 
network, since at higher pH chitosan is partially neutralized, and the PEI network will be loosen, 
allowing a percentage of solution uptake equal to 1880.16 ± 218.8 %, after 6 h. At pH 7.4, the 
partial neutralization of NH
3+
 has not caused a total loss of the PEI network, since chitosan has still 
some ionized group bonded with COO
-
 of the pectin chain. However, after 24 h, the swelling ratio 
started to decrease, due to an initial degradation of the network. Since the pKa of pectin is 4.0 and 
that of chitosan is 6.0, at the pH of 5.5 over 99% of pectin is still in its ionized form and chitosan 
exists as both ionized form NH
3+
 and unionized form NH2. The swelling percentage of PC network 
in the solution with a pH of 5.5, was 1443.77 ± 14.4 % after 6 h; then, the ability of the network to 
adsorb the solution reduces. However, due to the presence in the network at pH 5.5 of 
intramolecular H-bonding between COOH3 and OH, which makes more stable the PEI matrix, the 
PC hydrogels after 24 h at pH 5.5 show a lower swelling degree (687.69 %) compared with the PC 
hydrogel at the pH of 7.4 and 2.5. Addition of HA/βTCP particles stabilizes the swelling properties 
of the PC based hydrogel (Figure 37 b). Indeed, no significant differences were measured (two-way 
ANOVA test reveals no significant difference between PCC scaffold at different pH) during the 
hydration kinetics in the three different solutions (pH of 2.5, 5.5, 7.4) (Figure 37 b). Furthermore, 
as expected, the maximum water uptake was lower for PCC scaffold compared with the PC 
hydrogel: for example, the swelling degree for PC scaffold at pH 7.4 was after 6 h about 275.05  ± 
35.45 %, almost 10 folds lower than the value reported for PC hydrogel at the same pH. The 
maximum percentage of solution uptake for PCC material was reached after 2 h and was stable until 
24 h. As already reported for PC hydrogels, also in the case of PCC samples the lowest value of 
water uptake was shown for the sample soaked in the solution at pH 5.5. Providing a stable material 
could allow the dental practitioners to use the scaffold independently of the environment, since it 
will work always at the same manner (Figure 38). Furthermore, the swelling of the PCC scaffold is 
high enough to ensure cell infiltration and nutrient transportation, and a mechanical strength is still 
maintained. The incorporation of ceramic particles into the PC matrix reduces the swelling 
capability of the materials, which is maybe due to the interaction between the particles and the 
network. In particular, pectin carboxylic groups could be ionically crosslinked by calcium ions 
(Ca
2+
), thereby forming the so-called “egg box” structure, where a divalent cation is bonded with 
different carboxylic anions
24
. Furthermore, the high percentage of ceramic particles used in this 
work (90 wt.%) reduces the influence of the PC matrix in the swelling properties (Figure 38).  
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Figure 37. Hydration kinetics, of PC and PCC scaffolds, was tested in different pH conditions, 2.5, 5.5 and 7.4 
within 24 h (a).  PCC material results more stable and less sensible at pH variation than PC scaffold that show 
high water uptake at pH 2.5 and 7.4 due to the neutralization of NH
3+
 at high pH and COO
-
 at low pH, which 
causes the loss of the PEI network (b). The results are reported as mean ± standard deviation (n=3), (*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, two-way ANOVA with Tukey’s multiple comparison test). 
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Figure 38. Optical images show the samples in as-prepared condition (T0) and the swollen sample at different 
pH, after 24 h. 
Degradation properties at different pH  
After implantation, the composite hydrogel should degrade, and new bone should form and replace 
it. Furthermore, during degradation, the osteconductive HA/βTCP ceramic particles come into 
direct contact with the newly formed bone and should further promote osteointegration. The 
degradation behaviors of PC and PCC samples have been tested in three different conditions of pH 
(2.5, 5.5, 7.4) for 1 week and the results are shown in Figure 39.  During the degradation process, 
the mechanisms are similar to those obtained during the hydration kinetics, since the solutions used 
were the same
49
. PC hydrogel shows the highest degradation rate at pH 2.5 with almost 100 % mass 
loss after 1 week; this mass loss was twice compared to that of PC at pH 7.4 and almost three times 
with respect to the base hydrogel at pH 5.5, which lost around 40% of the initial mass (Figure 39 a, 
b). At the pH of 2.5, the PEI network will be loosen due to the neutralization of the pectin. The 
same behavior is reported for the PCC sample, that lost around 40 % of the initial mass after 1 week 
in the solution at the pH of 2.5. These results are partly due to the neutralization of COO
-
 ions, and 
in part to the dissolution of ceramic particles in a highly acidic environment. Furthermore, the ionic 
interaction between the two polymer chains is reversible and non-permanent, so in aqueous solution 
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this association is gradually reduced and then lost with time. PCC scaffolds tested in the solution at 
pH of 5.5 and 7.4 showed a similar percentage of initial mass loss, around 10 %. The addition of 
ceramic particles makes the materials more resistant and less susceptible to pH variation (Figure 38 
c).    
 
Figure 39. Degradation behavior of the PC and PCC materials was studied during 1 week in different pH 
condition. Slow degradation rate was recorded for PCC scaffold at pH 5.5 and 7.4 (around 10 %), while a higher 
degradation percentage with respect to the initial mass was observed at pH 2.5, maybe due to the high solubility 
of calcium phosphate at low pH (a). PCC material showed high degradation rate in particular at low pH 2.5, and 
a pH 7.4; slower degradation rate was calculated at the pH of 5.5 (b). Optical images of PC and PCC scaffold 
during degradation test (c). The results are reported as mean ± standard deviation (n=3), (*p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001, two-way ANOVA with Tukey’s multiple comparison test). 
 
4.5.2.5 Biological characterization 
Osteoblast-like cell culture 
Adhesion, spreading and morphology of osteoblast-like cells cultured for 14 days are shown in 
Figure 40. SEM images show that, after 72 h, SAOS-2 cells seeded on the PC scaffold surface 
exhibit a round shape and low density, followed by high proliferation and formation of a network of 
cells. In particular, SEM images after 2 weeks show the formation of large cords of cells, which 
prefer to stay together rather than adhering and spreading on the surface of the materials (Figure 40 
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a).  The addition of ceramic particles increases the adhesion and proliferation of osteoblast cells at 
72 h, and the SEM images reveal that, after 2 weeks, SAOS-2 cells are completely adhered on the 
surface and infiltrated inside the porosity, forming bridges and creating a strong and consistent layer 
of cells (Figure 40 b). The higher attachment and proliferation of cells on the PCC material are due 
to the presence of the calcium phosphate phase that conducts osteoblast proliferation
50
. 
Furthermore, the addition of micro-particles increases the roughness and the area of the surface, 
which promote the osteoblast proliferation and adhesion
30
. Since PC and PCC materials show 
different cell morphology at two weeks but both demonstrated cytocompatibility and high 
proliferation, we thus performed ALP gene-expression after 7 days of SAOS-2 cell culture. The 
results are reported in the bar graph in Figure 41, demonstrating that the presence of HA/βTCP 
particles in the PCC composite scaffold promotes ALP activity, which is 3-fold higher than that of 
PC-based hydrogel. In vitro studies show a good biocompatibility of PCC scaffold, furthermore the 
addition of ceramic particles could promote alveolar bone formation and infiltration inside the PCC 
composite hydrogel. 
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Figure 40 (a,b). Adhesion and proliferation of osteoblast-like cells were investigated by SEM analysis on PC (a) 
and PCC (b) scaffolds at 72 h and after 2 weeks. HA/βTCP particles promote adhesion and proliferation of 
SAOS-2 cells after 72 h and a confluent layer of cells after 14 days was detected.  
 
Figure 41. ALP gene expression after 1 week of osteoblast-like SaOS-2 cells culture. Gene expression analysis 
reveals that PCC scaffold promotes Alkaline Phosphatase expression, 2 folds more than PC based hydrogel. Both 
materials are cytocompatible and promote cell proliferation, but the presence of ceramic particles enhances the 
formation of new mineral matrix, which means that it could be an excellent tool for alveolar bone regeneration. 
The results are reported as mean ± standard deviation (n=4), (*p<0.05, **p<0.01, Student’s t-test). 
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In order to better analyze the osteogenic response of the cells in contact with the material 
developed, Saos-2 cells were grown in medium culture with insertion of the two different scaffolds 
and, at different time points (24 h and 72 h), were collected in order to perform RT-qPCR (Figure 
42). The RT-qPCR results show, for PCC scaffold, a progressive increment in the expression fold 
values of Collagen I (2.0 at 24h, 3.0 at 72h), Osteopontin (3.0 at 24h and 13.0 at 72h), Runx2 (2.3 at 
24h and 3.0 at 72h), ALP (2.0 at 24 and 4.0 at 72h) and SPARC (2.3 at 24h and 7.0 at 72h) 
compared to controls (polystyrene), and PC scaffold providing the hypothesis that cells in culture 
medium with the presence of ceramic particles produce more elevated levels of early osteogenic 
markers implicated in matrix deposition and differentiation phases, compared to controls. A 
different trend is seen in the expression of osteocalcin, which is downregulated at time point 24h, 
while at 72h a three-fold expression compared to controls can be appreciated. Given that OCN is a 
late osteogenic marker, whose expression is regulated by the transcription factor Runx2, it can be 
hypothesized that the increment in fold expression of Runx2 seen at time point 72h, positively 
regulates OCN after time point 24h.   
 
Figure 42. Gene expression after 24 h and 72 h of osteoblast-like SAOS-2 cells culture on PC and PCC scaffolds. 
The principal osteogenic genes have been analyzed (COLL1A1=Collagen, OPN= Osteopontin; 
OCN=Osteocalcin; RUNX2=Runt-related transcription factor 2; ALP= Alkaline Phosphatase; SPARC= 
Osteonectin), and the results confirm that the presence of ceramic particles in the polysaccharides matrix allow 
the production of more elevated levels of early osteogenic markers, compared to the control. The results are 
reported as mean ± standard deviation (n=4). 
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Inflammatory response of the surrounding cells 
Gene expression analysis on IL-1β, IL-6 and IL-10 is reported in Figure 43. Inflammatory response 
was evaluated on cells grown on the polystyrene in presence of PC, PCC and without the scaffold. 
The test was assessed in order to evaluate the possible inflammation that could be provoked by the 
implanted material on the surrounding tissue. Degradation products, chemical composition and 
swelling behavior could influence the response of the surrounding tissue; if the material does not 
stimulate any cytokines expression, a foreign body reaction is avoided. As shown in Figure 43, no 
material elicits a pro-inflammatory response, the expression of IL-1β and IL-6 are comparable 
between the cells grown in presence of PC and PCC and with the control polystyrene alone. A slight 
increase in the expression of IL-10 was reported for PCC material compared with the polystyrene 
control, conversely no significance was assessed to the increase of IL-10 for PC material. Bone 
resorption occurs when inflammatory mediators reach a critical concentration, which depends on 
the expression of pro-inflammatory cytokines, such as the interleukin (IL) family, of which IL-1β is 
the most studied member due to its role in acute and chronic inflammatory and autoimmune 
disorders. On the opposite site, the inflammatory level is controlled by the expression of anti-
inflammatory cytokines, such as IL-10. In normal physiological conditions, there is a balance 
between bone formation and bone resorption, and as it happens in certain inflammatory conditions, 
this balance can be altered. This equilibrium is altered by the action of pro-inflammatory cytokines, 
such as IL-1β that induces osteoclastogenesis, while counteraction by anti-inflammatory mediators, 
such as IL-10,  inhibits osteoclastogenesis. An anti-inflammatory response seems to occur in both 
PC and PCC scaffold, although a slight increase of IL-10 gene expression was detected in the latter 
compared to the former  (Figure 43). The hypothesis is that this anti-inflammatory could be due to 
the pectin properties, which has shown an anti-inflammatory behavior in many studies
51–53
. Further 
and in-depth studies have to be done in order to fully elucidate this behavior, but this study confirms 
that PCC could be used as a safe bone graft for alveolar bone regeneration, without the risk of 
inducing inflammation in the surrounding tissue.  
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Figure 43. Inflammatory response of the macrophages cells surrounding the material. Gene expression of IL-1β, 
IL-6 and IL-10 of cells grown in contact with PC and PCC scaffold. Both material do not show any pro-
inflammatory response. The results are reported as mean ± standard deviation (n=4), (*p<0.05, two-way 
ANOVA with Tukey’s multiple comparison test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
145 
 
4.5.3 Conclusion  
Alveolar bone regeneration is a procedure that requires a biomaterial with some peculiar 
characteristics such as mouldability in order to fill the irregular void, biodegradability, swelling 
capacity to promote infiltration of nutrients and avoiding inflammatory response on the surrounding 
tissue, osteoconduction and promoting new bone formation. Composite scaffold comprising a 
pectin/chitosan base hydrogel filled with HA/βTCP particles (PCC) were successfully prepared and 
characterized. The results show that PCC material has a good stability in different pH condition, 
with a high swelling degree (up to 200 % of the initial weight). Mechanical characterization 
demonstrated that the addition of ceramic particles increases the mechanical strength compared to 
the base hydrogel (toughness of PCC scaffold was around 220 kJ/m
3
, and compressive elastic 
modulus was 2.5 MPa in dry condition). The scaffold morphology and porosity as well as the 
presence of osteoconductive HA/βTCP micro-particles promote highly osteoblast adhesion and 
proliferation with a 2-fold higher ALP gene expression at 1 week compared to PC scaffold. Gene 
expression results demonstrated that PCC scaffold elicits anti-inflammatory and pro-osteogenic 
responses; this results confirm that PCC biomaterial could be an excellent tool for application in 
alveolar bone regeneration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
REFERENCES 
 
1. Gaviria, L., Salcido, J. P., Guda, T. & Ong, J. L. Current trends in dental implants. J. Korean Assoc. Oral 
Maxillofac. Surg. 40, 50 (2014). 
2. Gupta, A., Dhanraj, M. & Sivagami, G. Status of surface treatment in endosseous implant: a literary overview. 
Indian J. Dent. Res. 21, 433–438 (2010). 
3. Raghoebar, G. M., Batenburg, R. H., Vissink, A. & Reintsema, H. Augmentation of localized defects of the 
anterior maxillary ridge with autogenous bone before insertion of implants. J. Oral Maxillofac. Surg. 54, 1180–
5; discussion 1185–6 (1996). 
4. Liu, J. & Kerns, D. G. Mechanisms of guided bone regeneration: a review. Open Dent. J. 8, 56–65 (2014). 
5. Van Der Weijden, F., Dell’Acqua, F. & Slot, D. E. Alveolar bone dimensional changes of post-extraction 
sockets in humans: A systematic review. J. Clin. Periodontol. 36, 1048–1058 (2009). 
6. Schropp, L., Wenzel, A., Kostopoulos, L. & Karring, T. Bone healing and soft tissue contour changes following 
single-tooth extraction: a clinical and radiographic 12-month prospective study. Int. J. Periodontics Restorative 
Dent. 23, 313–323 (2003). 
7. Tallgren, A. The continuing reduction of the residual alveolar ridges in complete denture wearers: A mixed-
longitudinal study covering 25 years. J. Prosthet. Dent. 89, 427–435 (2003). 
8. Bernstein, S., Cooke, J., Fotek, P. & Wang, H.-L. Vertical bone augmentation: where are we now? Implant 
Dent. 15, 219–228 (2006). 
9. Draenert, F. G., Huetzen, D., Neff,  a. & Mueller, W. E. G. Vertical bone augmentation procedures: Basics and 
techniques in dental implantology. J. Biomed. Mater. Res. - Part A 102, 1605–1613 (2014). 
10. Chen, F.-M. & Jin, Y. Periodontal tissue engineering and regeneration: current approaches and expanding 
opportunities. Tissue Eng. Part B. Rev. 16, 219–255 (2010). 
11. Bashutski, J. D. & Wang, H. L. Periodontal and Endodontic Regeneration. J. Endod. 35, 321–328 (2009). 
12. Elangovan, S., Srinivasan, S. & Ayilavarapu, S. Novel regenerative strategies to enhance periodontal therapy 
outcome. Expert Opin. Biol. Ther. 9, 399–410 (2009). 
13. Tadic, D. & Epple, M. A thorough physicochemical characterisation of 14 calcium phosphate-based bone 
substitution materials in comparison to natural bone. Biomaterials 25, 987–994 (2004). 
14. Yuan, H. et al. A comparison of the osteoinductive potential of two calcium phosphate ceramics implanted 
intramuscularly in goats. J. Mater. Sci. Mater. Med. 13, 1271–1275 (2002). 
15. Morra, M. et al. Surface chemistry and effects on bone regeneration of a novel biomimetic synthetic bone filler. 
J. Mater. Sci. Mater. Med. 26, (2015). 
16. Matsuno, T., Omata, K., Hashimoto, Y., Tabata, Y. & Satoh, T. Alveolar bone tissue engineering using 
composite scaffolds for drug delivery. Jpn. Dent. Sci. Rev. 46, 188–192 (2010). 
17. Zhang, L. et al. Porous hydroxyapatite and biphasic calcium phosphate ceramics promote ectopic osteoblast 
differentiation from mesenchymal stem cells. Sci. Technol. Adv. Mater. 10, 025003 (2009). 
18. Alcaide, M. et al. Biocompatibility markers for the study of interactions between osteoblasts and composite 
biomaterials. Biomaterials 30, 45–51 (2009). 
19. Schaefer, S., Detsch, R., Uhl, F., Deisinger, U. & Ziegler, G. How Degradation of Calcium Phosphate Bone 
Substitute Materials is influenced by Phase Composition and Porosity. Adv. Eng. Mater. 13, 342–350 (2011). 
20. Dutta, P. K., Duta, J. & Tripathi, V. S. Chitin and Chitosan: Chemistry, properties and applications. J. Sci. Ind. 
Res. (India). 63, 20–31 (2004). 
21. Finlay, J., Miller, L. & Poupard, J. a. A review of the antimicrobial activity of chitosan. J. Antimicrob. 
Chemother. 52, 18–23 (2003). 
22. Khor, E. & Lim, L. Y. Implantable applications of chitin and chitosan. Biomaterials 24, 2339–2349 (2003). 
23. Peng, L. Preparation and Evaluation of Porous Chitosan/Collagen Scaffolds for         Periodontal Tissue 
Engineering. J. Bioact. Compat. Polym. 21, 207–220 (2006). 
24. Sriamornsak, P. Chemistry of Pectin and Its Pharmaceutical Uses : A Review. Silpakorn Univ. J. Soc. Sci. 
Humanit. Arts 3, 206–228 (2003). 
25. Mishra, R. K., Banthia,  a. K. & Majeed,  a. B. a. Pectin based formulations for biomedical applications: A 
review. Asian J. Pharm. Clin. Res. 5, 1–7 (2012). 
26. Munarin, F. et al. Pectin-based injectable biomaterials for bone tissue engineering. Biomacromolecules 12, 568–
77 (2011). 
27. Liu, L., Fishman, M. L., Kost, J. & Hicks, K. B. Pectin-based systems for colon-specific drug delivery via oral 
route. Biomaterials 24, 3333–3343 (2003). 
28. Killion, J. a. et al. Hydrogel/bioactive glass composites for bone regeneration applications: Synthesis and 
characterisation. Mater. Sci. Eng. C 33, 4203–4212 (2013). 
29. Peter, M. et al. Novel biodegradable chitosan-gelatin/nano-bioactive glass ceramic composite scaffolds for 
alveolar bone tissue engineering. Chem. Eng. J. 158, 353–361 (2010). 
30. Sowmya, S. et al. Biocompatible β -chitin Hydrogel / Nanobioactive Glass Ceramic Nanocomposite Scaffolds 
for Periodontal Bone Regeneration. Trends Biomater. Artif. Organs 25, 1–11 (2011). 
147 
 
31. Koutsopoulos, S. Synthesis and characterization of hydroxyapatite crystals: a review study on the analytical 
methods. J. Biomed. Mater. Res. 62, 600–12 (2002). 
32. Rashidova, S. S. et al. Characteristics of Interactions in the Pectin?Chitosan System. Chromatographia 59, 
779–782 (2004). 
33. Morris, G., Kök, S., Harding, S. & Adams, G. Polysaccharide drug delivery systems based on pectin and 
chitosan. Biotechnol. Genet. Eng. Rev. 27, 257–284 (2010). 
34. Coimbra, P. et al. Preparation and chemical and biological characterization of a pectin/chitosan polyelectrolyte 
complex scaffold for possible bone tissue engineering applications. Int. J. Biol. Macromol. 48, 112–8 (2011). 
35. Karageorgiou, V. & Kaplan, D. Porosity of 3D biomaterial scaffolds and osteogenesis. Biomaterials 26, 5474–
5491 (2005). 
36. Woodard, J. R. et al. The mechanical properties and osteoconductivity of hydroxyapatite bone scaffolds with 
multi-scale porosity. Biomaterials 28, 45–54 (2007). 
37. Scabbia, A. & Trombelli, L. A comparative study on the use of a HA/collagen/chondroitin sulphate biomaterial 
(Biostite) and a bovine-derived HA xenograft (Bio-Oss) in the treatment of deep intra-osseous defects. J. Clin. 
Periodontol. 31, 348–55 (2004). 
38. Matsuno, T. et al. Development of beta-tricalcium phosphate/collagen sponge composite for bone regeneration. 
Dent. Mater. J. 25, 138–44 (2006). 
39. Sheikh, Z., Sima, C. & Glogauer, M. Bone Replacement Materials and Techniques Used for Achieving Vertical 
Alveolar Bone Augmentation. Materials (Basel). 8, 2953–2993 (2015). 
40. Tsuruga, E., Takita, H., Itoh, H., Wakisaka, Y. & Kuboki, Y. Pore size of porous hydroxyapatite as the cell-
substratum controls BMP-induced osteogenesis. J. Biochem. 121, 317–324 (1997). 
41. Xu, H. H. K. & Simon, C. G. Fast setting calcium phosphate-chitosan scaffold: Mechanical properties and 
biocompatibility. Biomaterials 26, 1337–1348 (2005). 
42. Gaharwar, A. K., Rivera, C., Wu, C. J., Chan, B. K. & Schmidt, G. Photocrosslinked nanocomposite hydrogels 
from PEG and silica nanospheres: Structural, mechanical and cell adhesion characteristics. Mater. Sci. Eng. C 
33, 1800–1807 (2013). 
43. Wahl, D. a. & Czernuszka, J. T. Collagen-hydroxyapatite composites for hard tissue repair. Eur. Cells Mater. 
11, 43–56 (2006). 
44. Vitale-Brovarone, C. et al. Resorbable glass-ceramic phosphate-based scaffolds for bone tissue engineering: 
synthesis, properties, and in vitro effects on human marrow stromal cells. J. Biomater. Appl. 26, 465–89 (2011). 
45. Liu, X., Rahaman, M. N., Hilmas, G. E. & Bal, B. S. Mechanical properties of bioactive glass (13-93) scaffolds 
fabricated by robotic deposition for structural bone repair. Acta Biomater. 9, 7025–34 (2013). 
46. Kim, H.-W., Knowles, J. C. & Kim, H.-E. Hydroxyapatite porous scaffold engineered with biological polymer 
hybrid coating for antibiotic Vancomycin release. J. Mater. Sci. Mater. Med. 16, 189–95 (2005). 
47. Bigucci, F. et al. Chitosan/pectin polyelectrolyte complexes: Selection of suitable preparative conditions for 
colon-specific delivery of vancomycin. Eur. J. Pharm. Sci. 35, 435–441 (2008). 
48. Ghaffari, A., Navaee, K., Oskoui, M., Bayati, K. & Rafiee-Tehrani, M. Preparation and characterization of free 
mixed-film of pectin/chitosan/Eudragit RS intended for sigmoidal drug delivery. Eur. J. Pharm. Biopharm. 67, 
175–86 (2007). 
49. Chen, P.-H. et al. Novel chitosan–pectin composite membranes with enhanced strength, hydrophilicity and 
controllable disintegration. Carbohydr. Polym. 82, 1236–1242 (2010). 
50. Dorozhkin, S. V. Biphasic, triphasic and multiphasic calcium orthophosphates. Acta Biomater. 8, 963–977 
(2012). 
51. Wang, N. L. et al. Polyclonal antibody against a complement-activating pectin from the roots of Angelica 
acutiloba. Planta Med. 60, 425–429 (1994). 
52. Sakurai, M. H., Matsumoto, T., Kiyohara, H. & Yamada, H. B-cell proliferation activity of pectic 
polysaccharide from a medicinal herb, the roots of Bupleurum falcatum L. and its structural requirement. 
Immunology 97, 540–547 (1999). 
53. Salman, H., Bergman, M., Djaldetti, M., Orlin, J. & Bessler, H. Citrus pectin affects cytokine production by 
human peripheral blood mononuclear cells. Biomed. Pharmacother. = Biomédecine pharmacothérapie 62, 579–
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4.6 NOVEL PECTIN/CHITOSAN GUIDED TISSUE REGENERATION 
MEMBRANE COATED WITH HYALURONIC ACID 
 
 
Figure 44. Schematic diagram of the function of guided tissue regeneration membrane. 
4.6.1 Introduction 
Traditional periodontal surgery techniques include gingivectomy, open flap debridement, and 
osseous surgery
1–4
. These techniques allow gaining access to diseased tissues and removing local 
factors, such as plaque, calculus, and endotoxins
5–7
. Chronic periodontitis is a disease caused by an 
untreated bacterial infection, which causes the loss of soft and hard tissue of the periodontal site 
and, in many cases results in the tooth loss
6,8–10
. Whenever the tooth is lost or extracted, surgical 
procedures involve the replacement of it, using titanium dental implants
11,12
. In many cases, bone 
resorption due to the activation of specific cytokines by an inflammation process, does not allow the 
insertion of dental implants. In these cases, it is necessary to promote the regeneration of new 
alveolar bone using the so called bone grafting material, which is usually made of ceramic materials 
in form of particles, porous scaffolds or paste
13,14
. However, the regeneration following these 
techniques usually results in a formation of long junctional epithelium, and the formation of new 
connective tissue in the periodontal wound
15
. The predictability of dental implants to be integrated 
with the surrounding bone is essential to restore functions in patients. According to the hypothesis 
formulated by Melcher, in order to achieve an excellent bone regeneration which could support the 
implant insertion, it is necessary the use of a guided tissue membrane
16
. Epithelial tissue and 
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fibroblasts from the gingiva could grow faster than osteoblast cells and, if not excluded from the 
root socket, they could inhibit formation of new bone tissue
15,17
. Membranes are used to create a 
space and to protect the blood clot in order to preferentially allow bone growth into the space. 
Karring et al. was the first who experimentally and histologically demonstrated the Melcher’s 
hypothesis
16,18
. They showed that periodontal regeneration is achieved when epithelial cells and 
fibroblasts are excluded from the wound space and the pre-osteoblast cells are allowed to migrate in 
the bone graft and to produce mineralized matrix, in order to regenerate bone tissue. The first 
material used for GTR was a cellulose acetate laboratory filter, and it was the first time when 
periodontal regeneration was achieved using GTR technique
19
. From that moment, many studies 
have been done in order to develop membranes with several important properties, such as 
biocompatible, cell exclusion properties, space maintenance, tissue integration, and easy to use
20–22
. 
Many types of materials have been used for GTR membranes, both non-resorbable and resorbable. 
Non-resorbable membranes have the disadvantage that they need a second surgery procedure to be 
removed, the most used non-resorbable membrane is made of ePTFE material, which has the 
advantage that does not generate antigenicity
23
. On the other side, resorbable materials, in particular 
from natural sources, have the advantages that do not require an additional surgery and are 
biocompatible and degradable during tissue formation. The most used material for resorbable 
membranes is collagen from bovine or porcine sources
24,25
. The main disadvantage of xenografts is 
the antigenicity and, for this reason, tissues are previously processed to remove all organic 
constituents, but this process generates high costs that reflect on the final product
26
. Furthermore, 
collagen degradation involves an enzymatic process, due to the collagenase enzymes, and during 
periodontitis bacteria stimulate the production of collagenases which could increase the degradation 
of the membranes, thus making the regeneration unpredictable
27–29
. In order to avoid an un-
controlled degradation rate, the collagen fibers are crosslinked using chemical compounds such as 
glutaraldehyde, which could cause cytotoxicity and inflammation response in the surrounding 
tissue
30,31
. In this work, we developed and functionalized, on its surface, a novel GTR membrane 
made of pectin and chitosan polysaccharides, with hyaluronic acid which gives antiadhesive 
properties to the materials without compromising the membrane’s cytocompatibility.  
Plant-derived biomaterials have aroused great interest in the last years, since they could mimic the 
extracellular environment and avoid a foreign body reaction, promoting cell proliferation and tissue 
formation
32
. Thus, pectin are nowadays under enthusiastic investigation in the biomaterial field as 
novel candidates for soft and hard tissue engineering. Pectin, in plants, creates a wall matrix which 
plays several roles, such as mechanical support, physical barrier against pathogens, and acts as 
bearing for vegetable cells
33
. Furthermore, pectin showed anti-inflammatory properties in vitro, and 
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in some cases, has been shown to be immunologically inert
34,35
. Another great advantage of pectin 
chain is its polyanionic nature, which allows such a polymer to be ionically crosslinked with 
polycationic polysaccharides such as chitosan
36
. Chitosan is a widely used material in tissue 
engineering, due to its biocompatibility, its intrinsic antibacterial nature, its ability to not induce a 
foreign body reaction and to promote cell adhesion, proliferation and differentiation
37–39
. 
Polyelectrolyte complex (PEI) could be generated coupling pectin and chitosan materials, in order 
to create a stable and non-toxic crosslinked membrane with a predictable degradation rate
36,40–42
. 
Furthermore, the non-immunologically and antimicrobial properties of the complex allow reducing 
the inflammation response. PEI membranes could mimic the natural extracellular environment 
promoting cell proliferation. In order to avoid infiltration, we coated the membrane with hyaluronic 
acid, a well-known molecule, which has antiadhesive properties
43,44
. Hyaluronic acid is a 
polyanionic polysaccharide with excellent lubricity, non-adhesive and anti-bacterial nature
45–47
. 
Among all different surface modification techniques, the layer-by-layer deposition has attracted 
much attention since it is versatile and any type of chemical crosslinker is needed
48,49
. Since 
chitosan is a polycationic material, it is able to form a polyelectrolyte with a polyanionic hyaluronic 
acid, and to form a stable surface layer on the membrane surface. In this work, we developed a 
membrane following the concept of layer-by-layer technique, in order to modify the surface of the 
bulk; a single layer of hyaluronic acid was deposed on the surface using ionic interaction with 
chitosan polysaccharides.    
In this way, it is possible to promote proliferation of the fibroblasts avoiding the infiltration and 
maintaining the root space available for osteoblast proliferation and new bone formation. We 
designed and characterized a GTR membrane, made with pectin and chitosan polysaccharides, 
which are bonded together with a ionic crosslinking (PCm). We coated the PCm membrane with 
hyaluronic acid, in order to obtain an antiadhesive surface, to guide fibroblast regeneration without 
infiltration in the membrane matrix (PCmHyA). Chemical, mechanical and biological 
characterizations have been analyzed, and we demonstrated that the novel PCmHyA membrane 
could be used in GTR procedures. 
 
 
 
 
 
 
 
151 
 
4.6.2 Results and Discussion 
 
4.6.2.1 Chemical characterization 
ATR-IR and XPS analysis 
ATR-IR spectra in Figure 45 a show spectra of pectin powder, chitosan powder, hyaluronic acid 
powder, pectin/chitosan polyelectrolyte complex membrane (PCm) and pectin/chitosan membrane 
functionalized with hyaluronic acid (PCmHyA). The analysis confirms that all peaks belong to  
polysaccharide, the region between 3700 cm
-1
 and 3000 cm
-1
 for pectin and chitosan is assigned to 
the O–H stretching vibration (νOH), while the region between 3000–2800 cm-1 belongs to C-H 
stretching vibration (νCH) (Figure 45 b). Deeper analysis on pectin spectra show two bands 
associated with the stretching vibration at 1740 cm
-1
 of carbonyl group, corresponding to the methyl 
ester group (COOCH3) and carboxyl acid (COOH), while the band at 1606 cm
-1
 belongs to the 
stretching vibration of the carbonyl group of the carboxylate ion (COO
-
) (Figure 45 c). Concerning 
chitosan spectra, the band at 1647 cm
-1
 is due to the C=O stretching vibration of amide I, whilst the 
band at 1580 cm
-1
 is due to the NH bending amide II, maybe overlapped to the N-H vibration of the 
amine groups. Band assignment is consistent with available literature (Figure 45 c)
36,40,50
.  
Hyaluronic acid showed a peak around 1040 cm
-1
 and one around 1200 cm
-1
, which are probably 
due to the stretching of C-O-C, C-O and C-O-H, furthermore the weak band around 1650 cm
-1 
could 
be associated at C=O of the amide I (Figure 45 c)
51
. 
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Figure 45. (a) ATR-IR spectra of pectin and chitosan powder, PCm and PCmHyA between 4000 – 525 cm-1. (b) 
ATR-IR of all spectra overlapped between 4000 cm
-1
 and 500 cm
-1
 show the shift of the amine band to 1557 cm
-1
, 
and the bands belonging inorganic phase, at 950 cm
-1 
and 1140 cm
-1
. (c) ATR-IR spectra focus between 2000 cm
-1
 
and 500 cm
-1
 of materials. The presence of HyA on the surface could be associated to the presence of a specific 
peak at 1200 cm
-1
, usually attributed to the C-O stretch.  
PCm spectra show the formation of PEI complex; a shift of amine band to 1557 cm
-1
 due to the 
interaction between the positive charge of chitosan, NH3
+
, and the negative charge of pectin, COO
- 
, 
was detected. As expected, the spectra of PCmHyA membrane sample show bands associated with 
both the PEI complex and the hyaluronic acid polymer. In particular, the peak at 1200 cm
-1 
which is 
present in both HyA and PCmHyA spectra but does not appear in the spectra of PCm material; this 
could be due to the carboxylic acid of hyaluronic acid. Furthermore, between 900 cm
-1
 and 1100 
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cm
-1
 the PCmHyA spectra show a different shape, probably due to the presence of hyaluronic acid, 
a slight difference was also observed in the shape of the curve around 1500 cm
-1 
. In order to 
confirm the success of the coating process, we also performed XPS analysis on the PCm and 
PCmHyA membrane (Figure 46). 
 
 
Figure 46. Wide scans of XPS for PCm and PCmHyA substrates. The chemical composition (at.%) indicates that 
the substrate surface is nearly fully covered with the hyaluronic acid layer. 
As expected for both samples, the main peaks are associated to oxygen, nitrogen and carbon. The 
presence of hyaluronic acid on the surface, changes the ratio between O and C, in particular the 
atomic concentration associated to the peak of O1s increases and that associated to the peak of C1s 
decreases, and the ratio O/C increases of two fold, as compared with the PCm material
52
. These 
results confirm the presence of hyaluronic acid on the PCm surface, and assess the success of the 
coating process.  
4.6.2.2 Structural characterization 
SEM Analysis  
The structure of the developed membranes has been evaluated through SEM analysis. PCm and 
PCmHyA were analyzed in section and in flat direction, in order to investigate if the surface coating 
by hyaluronic acid influences the structure of the PCm material. In Figure 47, three different 
magnification (100x, 200x and 500x) of the section for both PCm and PCmHyA are reported. 
Membranes have a highly porous inner structure, and the hyaluronic acid coating does not affect the 
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pore size and shape. It seems that the coating process does not infiltrate inside the membrane, and 
does not fill the pore but remains, as expected, on the surface of the membrane.  
 
Figure 47. SEM images of porous section for PCm (thickness of 855.5 µm)  and PCmHyA (thickness of 726.6 µm) 
materials. The coating with hyaluronic acid, does not affect the inner structure of the membrane.  
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Porosity is necessary, because it allows nutrients transportation and blood vessels infiltration, which 
is mandatory to achieve a correct periodontal regeneration
53
. The porosity is due to the production 
process, which involves a freeze drying step where the water embedded in the PEI matrix leaves 
and generates the interconnected pores
53–55
. PCmHyA involves two steps of freeze dry, one to 
generate PCm and the second after the coating with HyA. The presence of HyA coating is clear in 
the SEM images reported in Figure 48. HyA layer is present on the membrane surface, forming a 
dense network. HyA is a widely studied polymer for applications requiring minimal cellular 
adhesion
46,48,56
. Barriers made from cross-linked HyA have been effectively used to prevent 
adhesion between adjacent tissue layers in postoperative surgery
57,58
. Furthermore, since HyA is 
naturally present in high concentrations in the soft connective tissues, it is an appropriate choice for 
supporting fibroblast and epithelial regeneration and augmentation. It was demonstrated that cross-
linked HyA films accelerate tissue healing in full-thickness wounds
59
. Highly hydration and non-
immunogenicity of HyA, provide a conductive environment for tissue repair. Keratinocytes and 
fibroblast in vitro, generate soft tissue layers, on the surface of HyA coated materials
59
. The 
presence of ionic cross-linked HyA layers on the surface of the PCmHyA material, could allow 
fibroblast and epithelial proliferation avoiding the infiltration into the defect socket. Furthermore, 
there are many studies which demonstrated the effectiveness of HyA layers to prevent bacterial 
adhesion to dental implants
44,47,49
. These properties might be a further useful characteristic in such 
application as periodontal tissue engineering, where the presence of bacteria in the oral cavity could 
inhibit the correct regeneration. The porous structure of the membrane could be used as a carrier to 
delivery drugs or growth factors in situ in a controlled manner
53
.  
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Figure 48. SEM images on the flat direction for PCm and PCmHyA materials. The presence of hyaluronic acid is 
clear visible on the surface, as a dense network. 
4.6.2.3 Mechanical characterization 
Tensile test 
Tensile test was conducted on PCm and PCmHyA samples. Five samples for each type were tested, 
using a tensile machine Bose Electroforce 5500 equipped with a load cell of 100 N. The testing 
conditions are reported in the paragraph 4.2.4 of the section 4.2 Methods. Both conditions, dry and 
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hydrate, have been tested, and as expected the behavior of the membranes changes from stiff to soft 
and elastic.  
In Figure 49 the Ultimate Tensile strength (UTS) and Elongation (εr ) of the membrane in dry and 
hydrated conditions are reported. PCm is made of two natural polysaccharides, which are 
crosslinked with a low ionic interaction, hence the resulting material has a softener characteristics, 
in particular during hydration. In as prepared conditions, the material results indeed rigid and strong 
enough to reach 2 MPa of Ultimate Tensile Stress, which is a comparable result of gold standard 
GTR membranes produced by Geistlich, Biogide® made of non-crosslinked porcine collagen (data 
not shown). A slight increase was detected for the PCmHyA membrane. However, the differences 
has no significant relevance, and this behavior is not confirmed in hydrate conditions. As well as 
elongation follows the trend of UTS, indeed the elasticity of the dry material is slight lower for the 
PCmHyA material compared with PCm material. Dry conditions are not the working conditions of 
the material, which in clinical applications is usually hydrated, hence we tested the mechanical 
tensile properties in this condition. If in dry condition the crosslinking factor allows a higher 
resistance, in hydrated condition the presence of hydrophilic hyaluronic acid on the surface allows a 
higher amount of water uptake, and this results in a decrease in the mechanical properties compared 
with PCm material. For both materials, there is a shift from stiffness to elasticity, indeed the 
maximum elongation is similar for both materials, and reaches value around 50 % of the initial 
length, 5 times more than in as prepared condition (dry) and a value comparable with the 
commercially available membrane. As expected, for a highly natural porous material, the water 
uptake drastically decreases the ultimate tensile stress, that was 0.05 MPa for PCm and 0.03 MPa 
for PCmHyA, two order of magnitude lower than in dry condition. GTR application is usually a low 
load application, furthermore the stress under which the material undergoes is different from a 
classical tensile stress. The main important property that the membrane should have is the capacity 
to sustain the soft tissue avoiding the collapsing of the soft tissue, and from our test analysis the 
PCmHyA material has this properties
60
.   
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Figure 49. Ultimate tensile stress (a and c) and elongation (b and d)  for PCm and PCmHyA membranes in as 
prepared and hydrated conditions. The presence of hyaluronic acid does not significantly affect the mechanical 
properties of the membrane. The higher hydrophilicity of the hyaluronic acid layer compared with the PCm 
material slightly decreases the ultimate tensile stress in hydrated condition. The data are represented as mean ± 
standard deviation (n=5). 
Suture Retention Strength 
GTR application is usually a low bearing application, for which is rarely necessary a suture in order 
to fix the material, but in some cases it could be necessary. Suture retention strength was conducted 
following the ANSI/AAMI/ISO 7198:1998/2001/(R) 2004 “Cardiovascular implants-tubular 
vascular prostheses”61 procedure, and the setup is shown in Figure 50. A classical PLA suture 
thread was used. 
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Figure 50. Stress-strain curve of the suture retention strength test for PCmHyA material, and optical images of 
the sequence test. The PLA suture thread, acts as knife on the soft structure of the membrane.  
The test was performed in hydrated conditions on the PCmHyA membrane. The stress-strain curve 
shows a retention strength of 16 kPa, and a maximum elongation of 20 %. Considering the natural 
source of the material and the absence of any kind of chemical crosslinking, but just ionic 
interactions, this is a promising results, in particular about the elongation which confirms the 
elasticity of the material. The suture thread acts as a knife and cuts the soft structure of the material. 
In the optical images in Figure 50 it is possible to see the sequence of the test. 
 
4.6.2.4 Physical characterization 
Degradation and swelling properties 
A degradation test was performed in a phosphate buffered saline solution ( PBS at pH 7.4), for 1 
month under agitation at 37 °C. PCm and  PCmHyA  have been tested, the initial weight was 
registered and at each time point the membranes were taken out, washed in ultrapure water and 
lyophilized, then the final weight was registered and the percentage of mass loss was calculated. 
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The results are reported in the bar graph in Figure 51.  PCm lost 41.28 % of initial mass, a slight 
increase was calculated for PCmHyA  sample which lost after 1 month 46.55 % of the initial mass. 
As it is possible to note, no differences are detected among the two different samples at each time 
point. We expected to calculate a lower degradation rate for PCmHyA material, since it was more 
stable, indeed an opposite behavior was reported. We hypothesize that the highest hydrophilicity of 
the hyaluronic acid and the second lyophilization step, which allows the formation of bigger pores, 
allow the incorporation of more water inside the matrix, and its presence affects the ionic 
interactions and degrades the molecules faster than in the PCm membrane which takes more time to 
degrade. However, the percentage reached for both samples PCm and PCmHyA, was around 40 % 
of the initial mass (no significant difference), and it is a value comparable with the commercially 
available membranes, that means a total resorption in 2 – 3 months that is the time necessary to 
achieve a good bone regeneration excluding the fibroblast cells from the defect site.  
 
 
Figure 51.  The physiological stability of copolymer network determined by in vitro degradation of PCm and 
PCmHyA polymers under physiological conditions (PBS, 37 C°). The weight loss of membranes was monitored 
over the period of 1 month. The increase in the hydrophilicity due to the addition of hyaluronic acid, results in 
slight increase of water uptake that accelerates in a non-significant manner the hydrolysis of the polyelectrolyte. 
The data are represented as mean ± standard deviation (n=3). 
At pH 7.4, the partial neutralization of NH
3+
 has not caused a total loss of the PEI network, since 
chitosan has still some ionized group bonded with COO
-
 of the pectin chain. Furthermore, in the 
network, there exists the possibility of intramolecular H-bonding between COOH3 and OH, which 
makes more stable the PEI matrix. Other studies reported a higher degradation percentage of 
pectin/chitosan complex at alkaline pH, compared with what we found
41,62
. This is probably due to 
two important factors. Firstly, the porosity of the material influences the water uptake capacity, and 
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more water could infiltrate in the structure, higher is the degradation of the structure. And second, 
the ratio between pectin and chitosan inside the PEI complex. Pectin is a water soluble 
polysaccharide, which has the ability to uptake enormous quantity of water; the addition of chitosan 
reduces this ability and in our material we have a higher amount of chitosan than pectin, 80 % and 
20 % respectively (w/w), so the material properties are closer to the chitosan properties, which is 
more resistant in physiological condition (pH 7.4). The pH of the solution where samples were 
soaked, was monitored after 1 month, and any significant difference was detected (data not show), 
that means that the degradation products of the membranes do not cause a changing in the pH. In 
particular, many materials used for GTR, for example synthetic materials based on lactic acid or 
glycolic acid, tend to decrease the pH creating an acid environment, which could activate the 
immune system response and cause an inflammation, and a foreign body reaction
63
.  
The hydration properties of the biomaterials are important factors in determining their targeted 
application. The hydration properties of PCm and PCmHyA were investigated by evaluation bulk 
hydration characteristics (Figure 52).  The samples (n=3) were subjected to physiological 
conditions (37 °C and PBS) and uptake of water was calculated after 24 h. The swelling study 
reveals the maximum equilibrium of water content within 24 h. The percentages of water uptake for 
PCm and PcmHyA biomaterials, were of 86% of the initial mass and 90% respectively. The 
addition of hyaluronic acid as coating material slight increases the water uptake. As it is possible to 
see in the optical images, in Figure 52 before and after hydration, a change in the dimension of the 
thickness of the materials is visible. Moreover, the network becomes translucent in the swollen 
condition, which is the characteristic of an hydrophilic copolymer network. An increase of 50% of 
the initial thickness, was calculated for both biomaterials. 
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Figure 52. Effect of hyaluronic acid on hydrophilicity of PCm network. The presence of HyA layer slightly 
increases the water uptake, which is for both materials up to 80 % of the initial weight. Optical images, show the 
swollen PCmHyA, which acts as bearing after hydration. The data are represented as mean ± standard deviation 
(n=3). 
 
The membrane works as bearing, since through the application of a compressive stress on the 
hydrate membranes, the water was expulsed from the PEI matrix, but after the release of the stress, 
the material adsorbed again the water expulsed. These properties are useful for applications in 
which the material is in contact with soft tissues, or if the application of the materials is between 
different tissues or organs, since their ability to adapt to the movement of the surrounding tissue 
avoids inflammation and foreign body reaction. In GTR procedure, it is important to hydrate the 
PCmHyA membrane before the implantation in the gingiva, in order to reach a maximum water 
uptake and to avoid a possible stretching of the gingiva layer. The ability to adsorb water allows 
formation of a clot which is the first step to achieve tissue regeneration in periodontal site. 
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4.6.2.5 Biological characterization 
Fibroblast cell culture and adhesion test 
In GTR procedures, the most important property that the membrane should have, is to guide the 
fibroblast cells on its surface, avoiding the infiltration inside the wound site
20,64,65
. It is further 
important that the membrane does not cause cytotoxicity, but does promote the proliferation of the 
cells from the gingiva on its surface. We assume that a possible solution is to develop an 
antiadhesive surface which promotes cells proliferation. Hyaluronic acid is a well-known material, 
widely used in tissue engineering, in particular for its biocompatibility, and to its ability to promote 
cell proliferation
43
. Many studies on the biological properties of hyaluronic acid have been done, 
furthermore it is also known for its antiadhesive properties. PCm membrane was functionalized 
with hyaluronic acid, and then the antiadhesive properties of the PCmHyA material were tested 
using L929 fibroblast cells in comparison with PCm. The results are reported in Figure 53, and 
show cells stained with neutral red on the surface of PCm and PCmHyA. As expected, on both 
materials the cells have a round shape with a low adhesion properties. However, in the case of 
PCmHyA, more cell aggregates are present, which are due to the presence of HyA on the surface. 
Cells prefer to stay together than to adhere on the material surface, but in both cases cells are still 
alive, that means no cytotoxicity is highlighted. In order to confirm the low adhesion of fibroblasts 
on the PCmHyA surface, we spectrophotometrically analyzed the DNA quantity of cells on the 
surface. After a gently wash of the material, the nucleic acid has been extracted from remaining 
cells on the surface, and the absorbance at 260 nm proper of DNA material was detected. As it is 
possible to see in Figure 53, the value in mg/ml, associated to the PCm material are higher than the 
value associated to the PCmHyA material, which means a higher adhesion was present on PCm 
than PCmHyA. This test confirms the initial hypothesis, that considers HyA an antiadhesive 
material, and demonstrated that the functionalization could exclude the fibroblast cells from the 
wound site, allowing an excellent bone regeneration on one side and an excellent soft tissue 
regeneration on the other side. 
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Figure 53. Neutral red staining of fibroblast cells, on the PCm and PCmHyA membranes. DNA quantity, is 
related to the amount of cells that strongly adhered on the surface. HyA layer reduces the amount of cells 
adhered on its surface and avoids the infiltration inside the defect site. No cytotoxicity was detected. The data are 
represented as mean ± standard deviation (n=3), (*p<0.05, **p<0.01, Student’s t-test). 
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4.6.3 Conclusion 
In order to achieve an excellent periodontal regeneration, the combination of bone graft materials 
and guided tissue membranes is mandatory
13,16
. In this work, we designed, developed and 
characterized a pectin/chitosan membrane functionalized with hyaluronic acid. The membrane is 
based on the formation of polyelectrolyte complex between pectin and chitosan, which mimics the 
extracellular matrix, modified on the surface with a second polyelectrolyte complex with hyaluronic 
acid. The antiadhesive properties of the HyA molecules were demonstrated through in vitro studies 
using fibroblast cells. The membrane shows a degradation rate around 3 months, that is the time 
recommended to exclude the cells of soft tissue in order to allow bone cells to populate the bone 
graft and to generate new bone tissue. Considering the nature of the materials and the absence of 
any chemical crosslinker, the mechanical properties of the material could ensure the stability of the 
periodontal site avoiding the collapse of the gingiva. The ability to uptake water, reduces the 
possible inflammatory response due to the contact between the surrounding soft tissue and the 
membrane, because the PCmHyA works like a bearing and could be fitted in irregular shape defect. 
Furthermore, it enhances the formation of a clot, which could promote the tissue regeneration. 
Further in vitro and in vivo studies will be necessary, however these results confirm a possible use 
of this novel membrane in periodontal tissue engineering. 
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CHAPTER V 
FINAL DISCUSSION AND CONCLUSIONS 
 
Periodontium refers to the specialized tissues that both surround and support the teeth, maintaining 
them in the maxillary and mandibular bones
1,2
. Tooth loss is a possible consequence of trauma or 
periodontal disease, such as gingivitis, periodontitis or tissue decay
3
. Periodontal tissue engineering 
scope is to regenerate the tooth’s supporting tissue through a combination of materials, which 
stimulate cells and signaling molecules to produce new healthy tissue
4
. Many advances have been 
made in the last decade in the regeneration of complex periodontal and alveolar bone defects
5
. 
Research efforts in polymeric and ceramic scaffolding systems for cell, protein, drug and gene 
delivery have led to develop complex systems with predictable response. In the research world there 
is still some debate as to the best treatment modality for obtaining periodontal regeneration
6
. Some 
groups advocate the use of bone replacement grafts alone, others suggest that a guided tissue 
membrane (GTR) alone might be sufficient, and still others recommend a combination of both. 
Tobon et al.
7
 conducted a study comparing three different treatment modalities for achieving 
periodontal regeneration and GTR after endodontic surgery: one control group without bone graft 
and membrane, one group treated with bone graft alone, and another group treated with both bone 
graft and membrane. They used as membrane a non-resorbable material, and as bone graft they used 
hydroxyapatite ceramic material. The results showed that the best periodontal regeneration was 
assessed through the combination of both membrane and bone graft. The worst results were 
obtained in the control group, where no membrane nor graft were used. Yoshikawa and co-workers
8
 
compared the histological outcome of different types of membrane, non-resorbable ePTFE, 
resorbable PLGA, and resorbable collagen membrane, and found that the greatest amount of bone 
regenerated was achieved using non-resorbable membranes. Another group, comparing an open flap 
debridement with a bone allograft and a bone allograft with a collagen membrane in an animal 
study, showed similar results in terms of bone formation in all cases
9
. The studies mentioned above 
and many others, showed different results and suggest different approaches in order to achieve an 
excellent periodontal regeneration. However, case selection is very important to the success of 
regenerative technique, which might explain some of the inconsistencies in the literature
6
. Factors 
that affect success could be due to the specific patient, specific disease and healing categories. The 
success of a surgical procedure, which involves the use of bone graft or membrane or else a 
combination of both, depends on many factors such as good plaque control, compliance, non-
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smoking, anti-infective therapy, and systemic health
10–12
. Furthermore, also during the surgical 
procedures, there are many variables which could affect the results of the regeneration process, for 
example, the possible infection of the implanted material, which could cause periprosthetic 
infection.  
The thesis was aimed at the development of biologically active materials, with improved 
osteoconductive and antimicrobial properties, in order to control the re-infection of the defect site 
and, in parallel, promote new bone formation. In this work, we focused on the possible application 
of natural polysaccharides in combination with widely used bi-phasic calcium phosphates. 
Specifically, we developed and characterized three different materials, designed to overcome the 
current drawbacks of available materials, i.e. unpredictable tissue response, re-infection of the 
implant site, difficult mouldability, uncontrolled cell response, and high complexity which reduces 
the possibility to reach the market.  
Common approach to control the periprosthetic infection is to combine an osteoconductive material 
with a systemic antibiotic therapy
4,13–15
. This type of approach could cause side effects, since in 
order to be effective against bacteria with this therapy, the antibiotic should be provided in a very 
high dosage to ensure that a clinical amount can reach the defect site
16
. An in situ release is 
preferable to combat against bacteria and to prevent a re-infection of the defect wound
17–19
. On the 
other hand, it is important to provide a mechanically stable material such as an osteoconductive 
scaffold to promote bone formation. Usually, to reach a drug delivery in situ, hydrogel, micro-
spheres, or injectable gels are used
20–24
. However, this approach makes necessary the use of another 
material, which acts as a scaffold to sustain and promote new tissue formation. An engineered 
scaffold was developed, using a bi-phasic calcium phosphate material for fabricating a three-
dimensional porous scaffold, and a natural polyelectrolyte as coating material to encapsulate 
antibiotic drugs, in order to successfully combine in one biomaterial all the needed characteristics to 
achieve periodontal bone regeneration. 
Effective antibacterial properties have been demonstrated through deep biological analysis. The 
material developed could inhibit bacterial growth by in situ drug release, promote osteoblast 
proliferation and mechanically sustain the defect site. 
To treat orthopedic infection, there are several commercial available products, which claim to be 
antimicrobial bone graft substitutes, for example Osteoset-T ®, Perossal ®, BonAlive®, Herafill® 
beads, Cerament-G®
25
. However, a summary of clinical evidences or evidence-based guidelines for 
the application of these products to assist surgeons is not available. Furthermore, some are just 
impregnated in drugs, others are designed to adsorb liquids such as drugs, or with a burst release 
within the first 72 hours.  
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The biomaterials developed during this doctoral activity were specifically designed to achieve a 
sustained release with predictable responses in different environmental conditions, maintaining the 
mechanical strength and osteoconductive properties typical of calcium phosphate materials
26–28
. 
Furthermore, in vivo studies are needed to ultimately assess the clinical effectiveness of the 
engineered scaffolds and the non-toxicity of the drug released. Depth studies are ongoing in order to 
replace the vancomycin antibiotic with natural molecules with antimicrobial properties, to 
overcome the certification issue arising from the presence of a drug in the system.  
A criticality of a rigid scaffold is the difficult mouldability to fill irregular defect
29–32
. An urgent 
need of professionals working in dentistry is the ability to customize the biomaterial for each 
patient. Furthermore, the osteointegration of dental implants and the consequent long-term success 
is guaranteed by the presence, in the extraction site, of a healthy and sufficient alveolar bone
33,34
. In 
these cases, placement of titanium implants is contraindicated until a vertical bone augmentation is 
obtained. To achieve this goal, in this thesis we developed a bone graft material which should 
simulate the extracellular matrix (ECM), aimed at promoting osteoblast proliferation and filling the 
void, maintaining the space without collapsing until the new bone is formed. For this purpose, a 
novel chitosan-pectin hydrogel reinforced with biphasic calcium phosphate particles within 100-300 
µm has been designed and characterized. The polysaccharide nature of hydrogels simulates the 
ECM of natural bone, and the ceramic particles promote high osteoblast proliferation, assessed by 
in vitro cell studies
31,35–37
. Swelling properties allow water solution adsorption (up to 200 % of 
solution content) and the space to be filled without compromising the mechanical strength, in both 
static and cyclic conditions. The ability to adsorb water is necessary in order to promote the clot 
formation in the defect site
30,38
. Clot formation promotes the migration and proliferation of 
osteoblast cells which regenerate new alveolar bone
39,40
. The incorporation of ceramic particles 
makes the material stable at different pH and increases the compressive elastic modulus, toughness 
and ultimate tensile strength compared to the base polymer. 
A chemical crosslinker is usually employed to obtain a stable polymer; in this work, the stability is 
given by a ionic interaction which makes the material stable and mechanically resistant enough, 
without any cytotoxic effect
41
. Only a few biomaterials like PCC are present on the market, and the 
gold standard could be considered the Geistlich Bio-oss Collagen® material, that consists of 90% 
Geistlich Bio-Oss® granules with the addition of 10% porcine collagen. Compared to Geistlich 
Bio-Oss Collagen®, PCC material possesses enhanced handling characteristics, and is more 
formable and easy to handle. Furthermore, PCC material showed higher swelling behavior, and the 
polymeric network made with pectin and chitosan makes the material more elastic, with a higher 
ability to recover the shape after a cyclic stress, compared to the Bio-Oss Collagen® material. The 
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absence of interactions between the granules and the collagen matrix, makes un-predictable the 
degradation of the Bio-Oss Collagen ® material, with a loss of cohesion in hydrated conditions. The 
interaction between chitosan and pectin and between pectin and calcium phosphate particles reduces 
the migration of the granules in hydrate environment, which could cause an inflammatory 
response
42,43
. The future study will concentrate on the possible anti-inflammatory properties of 
pectin polysaccharides. The preliminary study showed an increase in the expression of IL-10 gene, 
which is correlated with the anti-inflammatory cascade
44,45
. There are some research works that 
hypothesized an anti-inflammatory action of pectin
46
, but few demonstrations are available
46–48
. 
Following the Melcher’s hypothesis49, in the research work we developed a guided tissue 
regeneration membrane, always based on the chemistry of pectin and chitosan, but with an 
antiadhesive coating made by hyaluronic acid on the surface, in order to exclude fibroblast cells 
from the wound defect. Gottlow was the first who founded the name “Guided Tissue Regeneration”, 
in 1986
50
. Ten years later, in 1996 at the World Workshop in Periodontics the first definition of 
GTR was given: “procedures attempting to regenerate lost periodontal structures through 
differential tissue response. Barriers are employed in the hope of excluding epithelium and gingival 
corium from the root surface in the belief that they interfere with regeneration”. The hypothesis 
formulated by Melcher
49
, and histologically proven by Karring et al.
51
, argues that certain cell 
populations in the periodontium have the potential to create new cementum, alveolar bone and 
periodontal ligament, when they have provided the opportunity to populate the periodontal wound. 
This opportunity is achieved if the gingival epithelial cells or fibroblasts are excluded from the 
wound space and periodontal ligament cells are allowed to migrate and populate the wound 
space
52,53
. This need led to the development of periodontal devices known as barriers or membranes 
for guided tissue regeneration. Nowadays, many types of membranes are commercially available, 
both non-resorbable and resorbable. Resorbable membranes are the most used and studied since 
they do not require a second surgery for their removal. Absorbable membranes are usually made 
from natural materials such as collagen, pericardium, dura mater, laminar bone, connective tissue or 
periosteum. These materials are completely biocompatible, but the process to purify them and to 
obtain these membranes is expensive and, in many cases, low repeatable, since it depends to the 
source of the native tissue. In our preliminary study, we assessed the mechanical and degradation in 
vitro of seven different absorbable membranes present on the market, derived from animal tissue, 
and the results showed a great variability in both properties. These results are translated in 
unpredictable outcomes during the periodontal regeneration. On the basis of stability demonstrated 
by the polyelectrolyte formed between pectin and chitosan, a novel guided tissue regeneration 
membrane has been developed, with an inner porous structure which allows nutrients transportation, 
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and an antiadhesive surface obtained through a functionalization with hyaluronic acid, a widely 
used molecule to obtain non-adhesive surface in biomedical field
54
. A cheapest, repeatable, and 
predictable production process was developed, using simple and economic natural material. Our 
concept was to avoid the adhesion of the cells to the membrane, and their infiltration in the structure 
enhancing the proliferation and growth in parallel to the material, guiding the gingiva regeneration. 
The results demonstrated that fibroblast cells do not adhere to the surface of the GTR membrane but 
any cytotoxic effect was detected, the cells tend to form aggregate, grow and proliferate on the 
surface of the material. 
Three different materials were successfully developed and the characterization demonstrated that 
they could be used in periodontal tissue engineering with predictable and excellent outcomes. With 
this set of biomaterials it is possible to control or prevent possible bacterial growth, achieve the 
correct alveolar bone quantity and quality and guide the tissue regeneration.  
Future studies will be conducted in the Research and Development department of Nobil Bio 
Ricerche srl and will focus on the development of biomaterials, which could meet the need of 
professionals, and could enhance the regeneration process. Biomimetic materials, based on natural 
molecules, coupled with synthetic controlled materials are the basis on which will be developed the 
future biomaterials.  
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